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Bone morphogenetic proteins 9 & 10 in pulmonary arterial hypertension 
 
Pulmonary arterial hypertension (PAH) is a rare disease initiated by dysfunction of the 
pulmonary vascular endothelium. Mutations in BMPR, which encodes the type-II bone 
morphogenic protein (BMP) receptor BMPR-II, explain the majority of heritable PAH. BMPR-II 
forms a signalling complex, with ALK and endoglin, specific to endothelial cells which 
maintains vascular quiescence. BMP and BMP are the high affinity ligands for this 
signalling complex. Administering exogenous BMP has been shown to reverse disease in 
animal models of PAH, so the Morrell group is investigating the use of BMP as a therapy for 
PAH. Nonetheless, mutations in GDF, which encodes BMP, or BMP had not been 
conclusively associated with PAH. BMP and BMP are produced as inactive ProBMPs, which 
are processed by proteases to leave an active, non-covalent Pro:BMP complex of the 
prodomains and growth-factor domain. e circulating levels of processed and unprocessed 
BMP and BMP published in current reports are inconsistent. ere is also some evidence 
circulating BMP and BMP may be co-complexed and otherwise coregulated. BMP is 
highly expressed in livers, and high doses can regulate lipogenesis and glucogenesis in vitro 
and in vivo. BMP deficiency is reported to protect against hepatic fibrosis and damage after 
inducement with severe surgical and chemical interventions. In contrast, BMP deficient 
animals do not appear to develop a phenotype reminiscent of PAH.      
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 Recently, the Morrell group discovered loss-of-function mutations in GDF 
were associated with PAH with genome-wide significance in a rare-variant analysis. Most of 
the identified mutations were missense. To validate their effect in vitro, I compared a 
selection of those predicted to be pathogenic in silico to those predicted to be benign. 
Pathogenic variants were poorly secreted due to destabilisation of the interaction between the 
prodomains and growth-factor domain, reducing their activity. Patients carrying loss-of-
function GDF mutations had reduced circulating levels of both BMP and BMP. Data from 
a combination of ELISAs, immunoprecipitations and activity assays suggested that active 
BMP circulates in healthy people, whilst inactive, unprocessed BMP circulates at higher 
levels. Circulating levels of BMP and BMP were tightly correlated, and data from 
immunoprecipitations and size-exclusion chromatography suggests they may circulate in 
macromolecular complexes. Exogenous BMP administered to mice was rapidly cleared from 
the circulation but was able to bind the lungs and activate signalling there, further 
demonstrating its therapeutic utility. Hepatic transcriptomes from Gdf knockout mice 
showed evidence of reduced lipogenesis and oxidative metabolism, confirming a role for 
endogenous BMP in metabolism. We developed a protocol to measure pulmonary vascular 
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Abbreviations 
ActRIIA Activin receptor a: a type-II receptor for BMP & BMP. 
ACVRL1  Gene which encodes ALK 
ALK1  Activin like kinase receptor I. High affinity receptor for BMP & BMP 
ALK1-Fc ALK conjugated to the Fc (constant) region of human IgG. Forms a dimer 
ALP Alkaline phosphatase. A hepatic enzyme released into serum after damage 
ALT Alanine aminotransferase. A hepatic enzyme released into serum after damage 
AMC A fluorophore which is quenched if bound to a peptide 
AST Aspartate aminotransferase. A hepatic enzyme released into serum after damage 
BMP9  Bone morphogenetic protein  – specifically the growth factor domain. 
BMPR2 e gene which encodes BMPR-II 
BMPR-II Bone morphogenetic protein receptor : a type- receptor for BMP & BMP 
BRE BMP response element. Gene regulatory element from ID promoter which 
binds activated SMAD proteins 
BRE-HMEC1 HMEC cells transduced with BRE:luciferase 
BSA Bovine serum albumin 
CADD Combined annotation dependent depletion. A score that increases with 
predictions of deleteriousness. Includes sequence conservation, in silico 
predictions of disrupted protein structure, sequence DNAse hypersensitivity, 
transcription factor binding etc. Higher score = more deleterious 
CHX Cycloheximide. A translation inhibitor 
Col1a1, 4a4 Genes encoding type-I and type-IV collagen respectively 
EBM2  Endothelial cell basal media (Lonza) 
EDTA  Ethylenediaminetetraacetic acid. Chelates multivalent cations 
ELISA  Enzyme linked immunosorbent assay 
ENG Endoglin. A type- receptor for BMP & BMP 
FBS  Foetal bovine serum 
GDF2 
  
Growth and differentiation factor two. e name of the gene encoding BMP in 
mouse, humans, rat, zebrafish etc. GDF is homologous to Dorsalin in birds. 
GFD  Growth factor domain. e active, c-terminal domain of BMP or BMP 
hAEC  Human aortic endothelial cells. A primary, mortal cell line. 
HEK-EBNA Human embryonic kidney cells with the Epstein Barr virus gene EBNA 
HEY Hairy/enhancer of split related, a marker of Notch & BMP signalling 
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HHT Hereditary haemorrhagic telangiectasia 
HMEC1 Human microvascular endothelial cells. An immortalised line (Ades et al. ) 
HPAH Hereditary pulmonary arterial hypertension 
ID1, ID2
  
Inhibitor of DNA binding /. Genes encoding transcription factors ID and 
ID which are directly upregulated by BMP signalling 
IP Immunoprecipitation 
IPAH Idiopathic pulmonary arterial hypertension 
KO  Genetic knockout 
LPS Lipopolysaccharide: derived from E. coli. Triggers inflammatory responses  
ME1 Gene encoding malic enzyme  required for fatty-acid biosynthesis 
PAECs Pulmonary arterial endothelial cells (Lonza) 
PAH  Pulmonary arterial hypertension 
pBMP9 Pro-BMP. May be unprocessed, in which case pBMP is inactive, or processed 
with the prodomain and growth factor domain associated non-covalently 
PBS  (Dulbecco’s) Phosphate buffered saline 
PBST Phosphate buffered saline supplemented with . (v/v) tween- 
PFO Patent foramen ovale 
PreProBMP9 Unprocessed BMP with signal peptide still present 
Pro:BMP9 e non-covalent complex of BMP and its prodomains 
ProBMP9 Unprocessed BMP 
qPCR  Quantitative polymerase chain reaction 
RDW Red cell distribution width. Percentage deviation in mean cell volume 
RIPA Cell lysis buffer with low detergent strength 
SDS Cell lysis buffer with high detergent strength 
SFM  Serum free media 
SMAD Mothers against dpp homologue: downstream intermediates of BMP signalling 
SVC Superior vena cava 
TBST Tris-buffered saline supplemented with . tween- 
v/v Volume of solute in volume of solvent 
w/v Weight of solute in volume of solvent 








.. Basics of pulmonary arterial hypertension 
Pulmonary hypertension refers to conditions where the mean blood pressure of pulmonary 
arteries increases from the normal value of  ±  mmHg at rest. Recent guidelines reduced 
the threshold for diagnosing pulmonary hypertension from  mmHg to  mmHg 
(Simonneau et al. ; Simonneau et al. ). Pulmonary arterial hypertension (PAH) 
specifically refers to conditions caused by obstructions in the arteries and arterioles, leading to 
increased pulmonary vascular resistance (> mmHg per L/min) and excludes pulmonary 
hypertension caused by left-heart dysfunction (pulmonary arterial wedge pressure must be 
< mmHg)(Galiè et al. ; Archer, Weir, and Wilkins ). PAH is known as class  
pulmonary hypertension (table )(Simonneau et al. ). 
 
1. Pulmonary arterial hypertension (PAH)    ~1 % of PH cases 
1.1. Idiopathic PAH (IPAH). No known cause    30-50% of PAH 
1.2. Heritable PAH (HPAH)      ~5% of PAH 
1.2.1. BMPR2 mutations      ~70% of HPAH 
1.2.2. ALK1, ENG, SMAD9, CAV1, or KCNK3 mutations 
1.2.3. Unknown mutation with family history 
1.3. Drug and toxin induced PAH. Anorexigens, amphetamines, SRC/ABL inhibitors, 
interferon therapy       ~ % of PAH 
1.4. Disease associated PAH 
1.4.1. Connective tissue disease     15-30% of PAH 
1.4.2. HIV infection       1- % of PAH 
1.4.3. Portal hypertension. Usually associated with cirrhosis. 5-10% of PAH 
1.4.4. Congenital heart disease     10-23% of PAH 
1.4.5. Schistosomiasis      20% of PAH if prevalent 
1.5. PAH that responds to calcium channel blockers in the long-term ~7% of PAH 
1. . PAH with obvious venous/capillary involvement 
1.7. Persistent PH of the newborn 
Table 1. World Health Organisation classifications of pulmonary hypertension (bold 
numbers = classification). Proportions of patients affected by different forms of the disease 
collated from Sionneau et al. 2019; Örem 2017; Lau et al. 2017; and Porres-Aguilar et al. 2012. 
 
e division between heritable and idiopathic PAH is often unclear without genetic 
testing since they are often clinically and pathologically indistinguishable, and causal 
mutations may be found after screening idiopathic cases. Additionally, BMPR mutations 
have been found in patients with anorexigen and congenital heart disease associated PAH, 
illustrating how multiple factors might contribute to disease (Ma and Chung ). is 
thesis will focus on type . and . PAH. 
PAH is a rare disease (- cases/million)(Peacock et al. ). PAH was most 
commonly diagnosed at - years-of-age, although mean age-of-diagnosis has increased 
recently to - as the number of elderly patients investigated has increased (Örem ; 
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Lau et al. ). Nonetheless, paediatric cases are also reported, albeit at lower frequency (~ 
cases/million). Paediatric PAH often occurs alongside heterogeneous comorbidities and has 
some distinct genetic associations (Peacock et al. ; Ma and Chung ). PAH is 
generally regarded as being much more common in females (. females :  male), although 
the sex difference is variable between cohorts, and may be reduced as the number of elderly 
patients identified increases (Örem ; Lau et al. ). Except for these factors, and those 
listed in table , hypoxia (exposure to high altitude), pollution and obesity are being 
investigated as risk factors for PAH (Sofianopoulou et al. ).  
Preclinical disease may evolve for some time before manifesting clinical symptoms. 
e pulmonary circulation initially compensates for disease effectively and people are not 
routinely screened for PAH. e right ventricle compensates for increasing pulmonary vascular 
resistance by hypertrophy to contract with enough force to maintain cardiac output. is 
leads to progressively worsening pulmonary pressures and increased ventricular strain (figure 
). e peak-cardiac output attainable during exercise falls as the heart becomes dilated and 
pulmonary resistance increases.  
 
Figure 1. MRI angiograms of chest. Left: healthy person. Right: PAH patient showing 
obliterated distal pulmonary arteries, pressure over-loaded proximal pulmonary arteries and 
distended right-heart. PA = pulmonary artery, RA = right atrium. Adapted from Sutendra and 
Michelakis (2013). 
 
Patients typically present with progressive unexplained breathlessness, fainting, chest-
pain, tiredness and reduced ability to exercise (table ). Diagnosis is via right-heart 
catheterisation of patients with suspect echocardiograms, but at this point, patients usually 
have substantial heart and vascular disease. Maximal cardiac output gradually falls as the right 
ventricle fails, until patients are unable to cope with normal activities. Additionally, patients 
may develop oedema as venous pressure increases as a result of volume overload. Patient 
prognosis is best predicted by how quickly their cardiac output deteriorates, but  
mortality occurs ~ years after diagnosis without treatment, and after ~ years with current 
treatments (Lau et al. ; enappan et al. ; Benza et al. ).   
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World Health Organisation functional classes of pulmonary hypertension: 
1. Patients with PH but without any limitation on ordinary physical activity 
2. PH patients comfortable at rest, but with some undue symptoms from ordinary activity 
3. PH patients comfortable at rest, but with undue symptoms from less than ordinary activity 
4. Patients unable to carry out any activity without symptoms. Signs of heart failure. 
Table 2. 
 
PAH patients are primarily prescribed vasodilators which reduce pulmonary arterial 
resistance and increase cardiac output, including nitric oxide potentiators, endothelin-
receptor antagonists and prostacyclin analogues (Lau et al. ; Jasińska-Stroschein and 
Orszulak-Michalak ). Additionally, ~ of PAH patients sustain a long-term 
vasodilatory response to Ca+ channel blockers, which substantially improves their prognosis. 
A potentially curative treatment route is heart-lung transplant. However, due to the demands 
of the operation, only carefully selected patients are suitable. Lung transplants themselves 
have a poor long-term prognosis, so survival ( after  years) is not much improved. 
 
.. Aetiology of pulmonary arterial hypertension 
... Genetic disposition to pulmonary arterial hypertension 
Pulmonary arterial hypertension can afflict several members of sequential generations in some 
families (Dresdale, Michtom, and Schultz ). In , researchers identified that familial 
PAH was associated with loss-of-function mutations in BMPR (International PPH 
Consortium ; Deng et al. ). Subsequent analyses found - of familial PAH 
cases, and - of patients regarded as idiopathic, are explained by > different BMPR 
mutations (Ma and Chung ; Archer, Weir, and Wilkins ; Soubrier et al. ).  
BMPR encodes a type-II receptor for the transforming growth-factor beta (TGFβ) 
superfamily of ligands. PAH-associated mutations are heterozygous loss-of-function and 
include rearrangements, copy number variants, frameshifts, missense and nonsense variants 
throughout the gene (omson et al. ; Cogan et al. , ; Aldred et al. ).  
Truncating mutations (~ of PAH-associated BMPR mutations) lead to haploinsufficiency, 
whilst missense mutations either cause retention within the endoplasmic reticulum or abolish 
activity (Rudarakanchana et al. ; Sobolewski et al. ). BMPR mutation carriers are 
diagnosed younger than idiopathic PAH patients, and have worse haemodynamics, functional 
class and survival, highlighting the importance of BMPR-II signalling in both the initiation 
and progression of PAH (Rosenzweig et al. ; Evans et al. ).  
BMPR mutations are not highly penetrant: approximately - of carriers develop 
disease (Ma and Chung ; Machado et al. ; Aldred et al. ). is indicates 
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additional genetic or environmental factors must influence disease development. For example, 
in a longitudinal study, BMPR mutation penetrance was higher in females (~) than males 
(~)(Larkin et al. ). Patients carrying mutations in multiple PAH-associated genes 
have been reported, but this requires validation with large cohorts (Pousada, Baloira, and 
Valverde ). Intriguingly, BMPR-II protein levels and downstream intermediaries, are 
downregulated in BMPR mutation carriers, idiopathic cases of PAH and inducible animal 
models of PAH (Archer, Weir, and Wilkins ; Ramos et al. ; Long et al. ). 
Hence non-genetic or epigenetic suppression of BMPR-II signalling could play a role in PAH. 
More rarely, heritable PAH is associated with loss-of-function mutations in other 
components of the BMPR-II signalling pathway (see ..)(Ma and Chung ; Miyazono, 
Kamiya, and Morikawa ; Machado et al. ). ese include: ACVRL, which encodes 
activin receptor-like kinase- (ALK)(Harrison et al. ; Gräf et al. ); ENG, which 
encodes endoglin—a co-receptor (Chaouat et al. ); and SAMD, SMAD and SMAD, 
which encode downstream signalling intermediates of BMPR-II (Nasim et al. ; Shintani 
et al. ; Drake et al. ; Gräf et al. ). Most recently, GDF, which encodes the 
ligand BMP, and BMP, which encodes a ligand with a very similar structure to BMP, 
mutations were found to cause PAH (Wang et al. ; Eyries et al. ; Wang et al. ; 
Gräf et al. ). Notably, ACVRL mutation carriers have an even earlier mean age of 
diagnosis, worse haemodynamics and faster disease progression than BMPRR mutation 
carriers (Girerd et al. ). Bmpr, Acvrl and Smad heterozygous knockout mice may 
spontaneously develop PAH-like hypertension and/or vascular remodelling (Long et al. ; 
Huang et al. ; Jerkic et al. ; Beppu et al. ). However, only a minority of mice 
may be affected (Hong et al. ). is may be exacerbated by inflammatory stimuli or 
combined Bmpr/Smad mutation (Long et al. ; Song et al. ). 
Rare, causal mutations in genes without clear links to BMPR-II signalling have also 
been reported in PAH. Examples include: CAV, which encodes caveolin , an architectural 
protein of the plasma membrane that can modulate TGFβ signalling (Austin et al. ); 
KCNK, which encodes a potassium channel facilitating smooth-muscle polarisation and 
vasodilation (Ma et al. ); and TBX, mutations in which are predominately associated 
with paediatric PAH (< children versus ~. of adults), have a milder prognosis than 
IPAH, and may co-present with other conditions like small patella syndrome (Zhu et al. ; 
Navas et al. ; Kerstjens-Frederikse et al. ). 
Recently, whole-genome and exome sequencing studies of large cohorts of PAH 
patients and controls have been undertaken (Gräf et al. ; Wang et al. ; Zhu et al. 
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; Eyries et al. ). ese studies have confirmed the association of BMPR, ACVRL, 
ENG, SMAD, KCNK,TBX, and GDF with PAH. Notably, GDF loss-of-function was highly 
significantly associated with PAH, and this was driven by missense mutations predicted to 
disrupt protein structure in silico (Gräf et al. ; Wang et al. ; Zhu et al. ).  
Novel genes were putatively associated with PAH in one or more of these studies: 
AQP, which encodes aquaporin , the water channel; ATPA, which encodes a 
transmembrane ATPase (also implicated in Barozzi et al. ); SOX, which encodes a 
transcription factor active in endothelial cells during development; KDR, which encodes 
vascular endothelial growth-factor receptor-II; KLK, which encodes kallikrein , and is 
produced by endothelial cells for systemic blood pressure regulation and vascular remodelling; 
GGCX, which encodes an enzyme associated with coagulation disorders; and BMP.  
Gräf et al. and Wang et al. used burden tests to associate genes with disease because 
each individual variant is so rarely found within PAH. erefore, the association of novel 
genes with PAH rests on in silico predictions of variants’ deleteriousness and their rarity in 
control cohorts. To validate these findings, the Morrell group has undertaken to 
experimentally determine the effects of putatively pathogenic variants in ATPAA, SOX, 
AQP and GDF.  
Not all coding variation was reported in these studies due to technical and stochastic 
factors. For example, two patients carrying large deletions including GDF were not reported 
in Gräf et al. because current technologies are not efficient at detecting structural variation. 
Similarly, the frequency of PAH cases associated with mutations in each gene varies between 
cohorts. is could reflect different ethnicities, environments and inclusion criteria, or be due 
to random variation. 
e contribution of rare non-coding variants to PAH has not been explored fully 
because it is difficult to determine their pathogenicity and many previous studies have used 
exome sequencing. Common variants are expected to have small effect-sizes, so it is difficult 
to gather sufficiently large cohorts of PAH patients to identify them. Nonetheless, genome-
wide association studies have been carried out for PAH, identifying risk loci close to a SOX 
enhancer (Rhodes et al. ); HLA-DPA/DPB encoding the MHC-II complex (Rhodes et al. 
); and CBLN, encoding cerebellin , which is highly expressed on pulmonary vascular 
endothelial cells (Germain et al. ). 
In summary, BMPR loss-of-function mutations are by far the largest contributor to 
heritable PAH. Nonetheless, identifying other genes involved in PAH through human genetic 
studies will refine our understanding of disease pathways, aid the identification of druggable 
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targets, and help provide an explanation for patients suffering from unexplained PAH 
(Morrell, Aldred, et al. ). Most PAH-associated genes are in the BMP/ALK/BMPR-II 
signalling pathway, making this a preeminent potential therapeutic target.  
 
... Environmental triggers of pulmonary arterial hypertension 
Environmental triggers of PAH are diverse even though they generally cause histologically 
indistinguishable disease. An inflammatory milieu may be important: infections and 
autoimmune diseases create highly inflammatory environments, disrupt endothelial integrity, 
and can lead to PAH in a high proportion of patients. In genetically predisposed animals and 
cells, lipopolysaccharide, -lipoxygenase and tumour necrosis factor-α induced inflammation 
can exacerbate PAH-like phenotypes (Kiskin et al. ; Soon et al. ; Hurst et al. ; 
Song et al. ; Tian et al. ). 
An initial pressure overload may trigger the development of pulmonary vascular 
lesions that lead to the development of lasting PAH. Congenital heart disease leads to PAH in 
- of patients because blood shunting at high pressure from the left-ventricle to the 
right-ventricle leads to over-loading of the pulmonary vasculature. Correcting the heart 
defect does not necessarily prevent the escalation of PAH, which indicates some positive-
feedbacks or a common cause for both morbidities (Brida and Gatzoulis ). For example, 
BMPR mutations are found in  of combined PAH-CHD cases (Roberts et al. ).  
Similarly, ~ of patients with hepatic portal vein hypertension develop PAH, perhaps 
because blood shunts into the right-heart, over-loading the pulmonary vasculature (Porres-
Aguilar et al. ). In small cohort studies, around three-quarters of portopulmonary 
hypertension resolved after liver transplant (Ashfaq et al. ; Hollatz et al. ). Hepatic 
cirrhosis also releases various inflammatory signals, and inhibits BMP secretion, which could 
contribute to PAH (Nikolic et al. ; Upton unpublished).  
 
... Pathobiology of pulmonary arterial hypertension 
Human samples necessarily come from late-stage disease. Small arteries (< µm) from 
these patients show thickening and fibrosis of the intima (concentric intimal fibrosis). 
Additionally, medial smooth-muscle cell layers become expanded with disorganised cells, 
thickened extracellular matrices and fibrosis (figure ). ese changes lead to greatly 
narrowed vessel lumens (Archer, Weir, and Wilkins ; Hoeper et al. ). Plexiform 
lesions, which are tangles of small channels found adjacent to small arteries, comprised of 
proliferative endothelial, smooth-muscle and fibroblast cells, are found distally to vessel 
branch-points in ~ of PAH patients (Tuder et al. ).   
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ere is compelling evidence that endothelial dysfunction underlies the earliest stages 
of PAH (Budhiraja, Tuder, and Hassoun ; Xu and Erzurum ; Toshner et al. ). 
Endothelial cell-specific knockout of Bmpr is sufficient to predispose mice to a PAH-like 
phenotype including pulmonary hypertension and vascular remodelling (Hong et al. ). 
Intriguingly, a patient with congenital heart disease associated PAH was found to have a 
SMAD deletion in pulmonary artery endothelial cells, but not other pulmonary cell-types 
(Drake et al. ). A wave of endothelial cell apoptosis is believed to be among the earliest 
events in PAH. is may facilitate the expansion of metabolically dysfunctional, angiogenic 
endothelial cells which stain strongly for markers of hyper-proliferation (Cool et al. ; Xu 
and Erzurum ).  
Figure 2. Vessel pathology in pulmonary arterial hypertension. Left: healthy pulmonary artery, 
middle: early stages of intimal dysfunction and wall thickening, right: advanced disease with 
intimal and adventitial proliferation, media thickening and angiogenic plexiform lesions. 
Redrawn from Gaine (2000).  
 
In PAH, endothelial cells over-produce vasoconstrictive paracrines, such as endothelin-
 and serotonin, which drives smooth-muscle cell constriction and proliferation (Budhiraja, 
Tuder, and Hassoun ; Eddahibi et al. ). Endothelial cells also downregulate 
vasodilatory paracrines, such as prostacyclin, vasoactive intestinal peptide and nitric oxide, 
which removes anti-proliferative signals (Budhiraja, Tuder, and Hassoun ). 
Additionally, endothelial cells from PAH patients, or with BMPR mutations, form monolayers 
with reduced integrity which may allow serum factors and inflammatory cells to egress into 
the smooth-muscle and fibroblast layers (Rabinovitch ; Burton et al. ).   
Pulmonary artery smooth-muscle cells and fibroblasts express BMPR, but at lower 
levels than pulmonary artery endothelial cells. In smooth-muscle cells, BMPR-II signalling is 
anti-proliferative, anti-hypertrophic, and pro-apoptotic (Tajsic and Morrell ). Mice 
expressing Bmpr truncating transgenes only in smooth muscle can develop PAH 
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spontaneously (West et al. ). us BMPR-II signalling in smooth-muscle protects against 
PAH, but it is not ALK-mediated and is more responsive to ligands other than BMP (Lagna 
et al. ; Yu et al. ; Morrell et al. ; Long et al. ). Dysfunctional endothelial 
cell signalling is believed to be the preeminent factor driving smooth-muscle and fibroblast 
cells to remodel pulmonary arteries through growth, migration and extracellular matrix 
synthesis (Tajsic and Morrell ).  
In summary, the lesions found in PAH are complex and profoundly dysfunctional. 
However, an initial endothelial dysfunction, in response to impaired BMPR-II signalling, 
inflammation or pressure overload, appears to trigger progressive vessel remodelling. 
Pulmonary arteries become obliterated, constricted and fibrotic. BMP signalling on 
endothelial cells is a key way to study PAH development in vitro. 
 
... Overlap between PAH & HHT 
Several genes involved in BMP signalling are associated with the disease hereditary 
haemorrhagic telangiectasia (HHT). HHT is a dysplasia of the vasculature consisting of poorly 
muscularised, dilated and tortuous arterioles and venules in the mucosa, hands, brain, spine, 
gut, liver and lung (figure )(Abdalla and Letarte ). is is driven by endothelial cell 
dysfunction. Some reports suggest plexiform lesions found in PAH are derived from 
bronchopulmonary anastomoses (Galambos et al. ) which could be compared to the 
arteriovenous anastomoses of HHT. us, there is genetic and phenotypic overlap between 
PAH and HHT (Vorselaars et al. ; Faughnan, Granton, and Young ).  
Loss-of-function mutations in ACVRL (Tørring et al. ); ENG (Tørring et al. 
; Saito et al. ), SMAD (Tørring et al. ; Gallione et al. ); and GDF 
(Wooderchak-Donahue et al. ; Hernandez et al. ) are reported in HHT-like 
syndromes (table ). ACVRL and ENG mutations cause HHT much more often than PAH 
(Shovlin ). However, HHT (- cases/million) is much more common than PAH. 
Some HHT patients (<), including a high proportion (<) of ACVRL mutation 
carriers, also suffer from PAH (McDonald et al. ; Harrison et al. ; Vorselaars et al. 
). e histology and haemodynamics of HHT-PAH is often indistinguishable from 
classical PAH (Harrison et al. ; Prigoda ; Abdalla et al. ; Faughnan, Granton, 
and Young ). Notably, / of ACVRL mutation carrying PAH patients manifested with 
HHT after PAH so longitudinal reassessments are needed to describe the co-incidence of 
disease (Girerd et al. ). Nevertheless, some argue GDF mutations do not cause HHT 
based on the weak evidence mutations are not found in all cohorts (Tørring et al. ). 
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Classification of hereditary haemorrhagic telangiectasia: 
HHT1. ENG mutations. 0% lead to premature STOP codons   <50% of HHT 
HHT2. ACVRL1 (ALK1) mutations. ~50% missense, rest loss-of-function <40% of HHT 
HHT3. Unknown gene linked to 5q31.3-q32 
HHT4. Unknown gene linked to 7p14 
HHT5. GDF2 mutations. Loss-of-function missense    ~1. % of HHT   
JPHHT. SMAD4 mutations. Combined juvenile polyposis-HHT. Loss-of-function 1-2% of HHT 
 
Table 3. Details were collated from Ma and Chung 2017; Abdalla and Letarte 200 ; and 
McDonald et al. 2015. 
 
Figure 3. Arteriovenous malformations in hereditary haemorrhagic telangiectasia. Left: 
normal blood vessel architecture. Right: arteriovenous malformation showing tortuous 
vessels, dilated pre-capillaries and capillary bypass. Redrawn from Crist et al. (2019). 
 
.. BMP, BMP/ALK/BMPR-II/Endoglin signalling 
... Receptor activation 
Endothelial cells are constitutively stimulated by circulating BMP via the ALK/BMPR-
II/endoglin complex (David et al. ). BMPR-II is expressed on numerous cell-types, but its 
expression is strong in pulmonary artery endothelial cells. BMPR-II is a type-II receptor 
serine/threonine kinase with low affinity for BMP,,, and . ALKis a type-I receptor 
serine/threonine kinase with high affinity for BMP and BMP, most highly expressed by 
endothelial cells, especially in arteries proximal to the heart, and is particularly highly 
expressed by pulmonary artery endothelial cells (David et al. ; Mahmoud et al. ; 
Seki, Yun, and Oh ; Corti et al. ; Panchenko et al. ). Endoglin is almost 
exclusively expressed by endothelial cells, highly expressed on pulmonary artery endothelial 
cells, and can bind BMP and BMP with very high affinity (Saito et al. ; Mahmoud et 
al. ). Endoglin does not appear to have catalytic activity, and can be expressed at the cell 
surface, with a small intracellular domain, or cleaved and released into the blood.  
It is difficult to crystallise tertiary BMP signalling complexes and aspects of BMP 
signalling have been inferred from other ligands/receptors which may behave differently. 
Nonetheless, the relative affinities and binding surfaces of each receptor lead to the following 
model of BMP and BMP signalling (figure ): 
. Active BMP and BMP are dimers in non-covalent complexes with their prodomains (Bidart 
et al. ; Jiang et al. ).  
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. At the apical surface of endothelial cells, two molecules of ALK form a high affinity complex 
with one BMP dimer. Two molecules of endoglin are likely present in the receptor complex 
(Alt et al. ; Barbara, Wrana, and Letarte ; Blanco et al. ). is may take place 
near the primary cilium and caveolae (Goetz and Anderson ; Vion et al. ). 
. Two molecules of BMPR-II or ActR-II are then recruited (Upton et al. ). e BMP/ 
prodomains must be displaced to allow BMPR-II binding, and there is some evidence 
prodomains are released from the cell-surface (Kienast et al. ; Jiang et al. ).  
. BMPR-II phosphorylates the cytoplasmic side of itself and ALK. e cytoplasmic tail of 
endoglin may become phosphorylated, and this may facilitate activation of the complex 
(Morris et al. ; Blanco et al. ). e receptor complex then recruits and 
phosphorylates receptor regulated SMADs, predominantly SMAD-// complexes, but 
sometimes SMAD- (Miyazono, Kamiya, and Morikawa ; Upton et al. ). These 
complex with the common partner SMAD- and translocate to the nucleus.  
. e SMADs behave as weak transcriptional activators/repressors, acting in concert with cell-
type specific factors to drive responses characteristic of the ligand, concentration and tissue 
(Miyazono, Kamiya, and Morikawa ; Schmierer and Hill ). 
 
Figure 4. High-affinity BMP9 receptor complex of endothelial cells. Left-to-right: Endoglin 
binds the ligand, followed by ALK1. BMPR-II or ActR-II joins the complex, displacing the 
prodomains. ALK1 phosphorylates the cytoplasmic tail of the type-II receptor, and the 
activated complex phosphorylates R-SMADs. The activated R-SMADs complex with the co-
SMAD and translocate into the nucleus. Based on Tillet and Bailly (2015). 
 
Conclusive evidence shows BMP and BMP primarily act through the ALK/[BMPR-
II/ActR-II]/endoglin complex:  
 BMP and BMP have the closest amino-acid sequence homology of any two BMPs, but are 
most divergent from other BMPs and well conserved across vertebrates (Ducy ) 
 Both have high affinity for ALK in cell-free assays (Brown et al. ; Townson et al. )  
 Both bind ALK, ActR-II and endoglin tightly in crystal structures (Brown et al. ; Saito et 
al. ; Townson et al. ) 
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 Both have activity at pg/ml levels on endothelial cells (David et al. ; Baeyens et al. ) 
 BMP activity is reduced when each of these receptors are silenced (David et al. ; Upton 
et al. ; Lawera et al. ) 
 BMP activity can be mimicked by overexpressing endoglin and ALK (David et al. ) 
 Radiolabelled BMP is co-immunoprecipitated with BMPR-II, ActR-II, ALK and endoglin 
from endothelial cells (Scharpfenecker et al. ) 
Conversely, conclusive evidence shows BMP and BMP are the preeminent ligands 
for the ALK/[BMPR-II/ActR-II]/endoglin complex:  
 BMP and BMP are at active concentrations in blood (David et al. ; Jiang et al. )  
 Soluble ALK and endoglin can neutralise serum activity whereas ALK,,,,, BMPR-B,A, 
and ActR-B cannot (David et al. ; Brown et al. ; Nikolic et al. ) 
 Anti-BMP can neutralise serum activity, whereas anti-BMP,,, anti-TGFβ and noggin (an 
inhibitor of BMP,,,,,,) cannot (David et al. ; Lux, Attisano, and Marchuk 
). In contrast, Herrera and Inman () show anti-BMP and  can neutralise a minor 
proportion of serum activity compared to anti-BMP, but they used a -hour time-course 
which may result in cells being stimulated by any BMP and  they produced themselves. 
 TGFβ and TGFβ can signal through ALK, but unlike BMP and BMP, only in the 
presence of ALK (Goumans et al. ) 
 BMP exerts a strong effect on the transcriptome of pulmonary artery endothelial cells and 
blood outgrowth endothelial cells, whilst BMP,, have negligible effects (Long et al. ) 
 BMP induces stable SMAD/ phosphorylation in endothelial cells over time, whilst other 
members of the TGFβ superfamily do not (David et al. ; Goumans et al. ) 
 BMP and BMP can directly bind endoglin in cell-free assays, but neither BMP,/,, 
b,,/,,,,b,, GDF,,,,b,,, TFGβ,β,β, MIS, nodal, activin-A,B,C,AC,AB, 
artemin, neurturin, persephin, glial cell-derived neurotrophic factor, nor brain-derived 
neurotrophic factor can (Castonguay et al. ) 
 Other members of the TGFβ superfamily adopt different conformations and have different 
receptor binding residues to BMP and BMP (Brown et al. ; Townson et al. ).  
 
... Biases in receptor activation 
It is not straightforward to elucidate exactly what effects ALK/BMPR-II signalling has on 
endothelial cells. is is because cells also express other type-I and type-II receptors, which 
signal through overlapping downstream pathways. ALK is the receptor with highest affinity 
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for BMP and is the most highly expressed type-I receptor on endothelial cells. Nonetheless, 
many experiments use supraphysiological doses of BMP which may activate other type-I 
receptors, or supraphysiological doses of other BMPs which may activate ALK.  
Secondly, a proportion of BMP/ALK complexes recruit an alternative type-II 
receptor, activin type-II receptor (ActR-II), instead of BMPR-II (Townson et al. ; Upton et 
al. ; Kienast et al. ). ALK/BMPR-II and ALK/ActR-II signalling induce many 
overlapping effects to different extents, and this is hypothesised to be why ALK and BMP 
deficiency can lead to both HHT and PAH, whilst BMPR-II deficiency only leads to PAH 
(Upton et al. ). 
Brown et al. () measured the adsorbance of BMP onto BIAcore chips coated with 
different type-I and type-II receptors using surface plasmon resonance. ey found BMP had 
highest affinity for ALK-Fc followed by BMPR-II-Fc. BMPR-II’s affinity for BMP was . fold 
higher than ActR-IIa-Fc, and  fold higher than ActR-IIb-Fc. However, Townson et al. 
() used very similar reagents and reported ActR-IIb’s affinity for BMP was ~ fold 
higher than BMPR-II and ~ fold higher than ActR-IIa, whereas BMP had similar affinity 
for all three receptor complexes. Mi et al. () used an ELISA-based method to show BMP 
does not discriminate between BMPR-II and ActR-IIb, but has ten-fold lower affinity for ActR-
IIa. However, in the presence of its prodomains, Pro:BMP has a ten-fold higher affinity for 
ActR-IIb than BMPR-II, and does not bind ActR-IIa (Mi et al. ). Both BMP and BMP 
bind to endoglin with similarly high affinity in BIAcore experiments (Blanco et al. ). 
erefore, BMP and BMP could have different activities depending on features of 
the receptor complex. For example, BMP may signal in the heart differently to BMP (see 
..), and BMP inhibits myeloma proliferation with high affinity whereas BMP cannot 
(Olsen et al. ). Nonetheless, many different endothelial cell types appear to respond to 
BMP in a similar way, BMP and BMP growth-factor domains have extremely similar 
structures, are believed to interact with receptor complexes in the same way, and endothelial 
cells treated with BMP and BMP have very similar responses (Li et al unpublished). 
In summary, the BMP/ALK/BMPR-II signalling axis is active on endothelial cells, 
especially pulmonary artery endothelial cells. Loss of components of this axis is expected to 
impair the protective functions of this signalling. ere is potentially some redundancy 
between ligands, receptors and intermediates, although there are biases in the responses of 
each. Signal duration and intensity faithfully determines nuclear SMAD activity, so it is 
difficult to predict exactly how each ligand will affect different cell-types and influence disease 
(Schmierer and Hill ).      
19 
 
... Flow & BMP signalling 
Both blood flow and BMP can stimulate endothelial quiescence, vasodilation and reduced 
proliferation (Baeyens et al. ; Laux et al. ). is is partly mediated via ALK 
signalling:  
 ALK loss induces similar transcriptional changes to loss of flow (Laux et al. ) 
 Knocking out flow responsive genes mimics the phenotype of ALK deficiency, including 
formation of arterio-venous malformations (Laux et al. ; Baeyens et al. ) 
 Flow does not stimulate quiescence if BMP is completely absent (Baeyens et al. ) 
 High shear-stress upregulates ALK (Seki, Yun, and Oh ) 
 Flow sensitises cells to BMP (Zhou et al. ; Baeyens et al. ) 
 Smad deficiency disrupts artery size only after the heart begins beating (Poduri et al. ) 
 ALK or Smad deficiency leads to dysfunctional migration of endothelial cells with respect to 
direction of flow (Rochon, Menon, and Roman ; Poduri et al. ) 
 Fish without a heart-beat have reduced ALK signalling (Laux et al. )  
In cell free assays, the EC of ALK for BMP is ~ pg/ml, which is close to the EC 
of endothelial cells (- pg/ml) in vitro (Kienast et al. ; Vion et al. ). Under flow, 
cells’ sensitivity seems to increase to .- pg/ml at high flow, and just ~. pg/ml in gentle 
flow (Baeyens et al. ; Vion et al. ). Laux et al. hypothesised that endothelial cells 
sense flow via rate of BMP delivery—in fish without heartbeats, injecting BMP can restore 
ALK signalling at the site of injection. However, flow may also cause the rearrangement of 
cell-surface receptors, changing their signalling dynamics, which endothelial cells may use to 
sense flow (Franco and Gerhardt ). Interestingly, flow increases the physical association 
of ALK with endoglin, and endoglin is required for the potentiation of BMP signalling by 
flow (Baeyens et al. ). 
In endothelial cells, ALK and SMADs localise to the base of the primary cilium, a 
mechano-chemo sensory organelle which protrudes into the vessel lumen (Goetz and 
Anderson ; Vion et al. ). Endothelial cells unable to form primary cilia do not show 
greater sensitivity for BMP under gentle-flow compared to high-flow (Vion et al. ). 
Conversely, normal endothelial cells show reduced migration compared to cells lacking 
primary cilia only in the presence of BMP. In combination, these effects mean loss of the 
primary cilium primarily disrupts angiogenesis in regions of low-flow in vivo, possibly because 
cells here are less responsive to BMP than normal (Vion et al. ). 
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In summary, endothelial cells seem to respond to flow partly by determining the 
strength of ALK signalling. Similarly, the potency of circulating BMP or BMP is partly 
determined by flow. is modulates the effects of BMP and BMP in vivo.   
 
.. Physiology of BMP & BMP  
.. Sources of BMP & BMP 
BMP is most highly expressed in the livers of zebrafish, mice and humans. However, no two 
reports agree on a particular secretory cell-type (figure ; table ). Miller et al. isolated liver 
sinusoidal cells, hepatic stellate cells, liver endothelial cells, Kupffer cells and hepatocytes, and 
maintained them in culture. ey looked for Gdf mRNA in these cultures with ribonuclease 
protection assays, and BMP protein by Western blotting. e results from cultured cells 
should be treated with scepticism, since hepatic cell cultures are notoriously difficult to purify 
and often represent incorrect cell-types (Elvevold, Smedsrød, and Martinez ). Moreover, 
cultured cells often have a different transcriptional profile to cells in vivo.  
 
Figure 5. Hepatic cell-types. Modified from Frevert et al. (2005). 
 
 
Bidart et al. bought RNA from specific hepatic cell-types, assessed GDF mRNA levels 
by qPCR and validated the qPCR results by immunostaining human and mouse tissue sections. 
Cells which stain strongly for BMP are not necessarily the cells which secrete it, since it is a 
diffusible ligand, and has been shown to bind various hepatic cell-types (Miller et al. ; 
Truksa et al. ). Breitkopf-Heinlein et al. isolated hepatocytes, liver sinusoidal endothelial 
cells, Kupffer cells and hepatic stellate cells from mice, and bought human hepatic stellate 
cells. ey assessed Gdf expression by qPCR. They showed that hepatic stellate cells in 
culture maintain GDF expression over-time and demonstrated they secrete BMP by ELISA. 
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Finally, Tillet et al. used RNA-in situ hybridisation, to show Gdf expression in mouse livers. 
Whilst in situs are the best way to identify which cell-types express BMP in vivo, Tillet et al. 
did not use any counter stains, so relied entirely on cell-shape to define all Gdf positive cells 
as hepatic stellate cells. 
 Miller et al. ( ) 
Breitkopf-Heinlein et al. 
( ) Bidart et al. ( ) 
Tillet et al. 
( ) 
 Rat Mouse Human Mouse Human Mouse 
Hepatic 
stellate cells +++ +++ ++ 
Cannot 





tested + Possibly 
Cannot 



























++ Not tested Not tested Cannot asses Not tested 
Cannot 
asses 
Table 4. GDF2 expressing cell-types identified in different publications. + indicates cell-type 




Miller et al. also assessed whole rat tissues and found Gdf expression in liver, but not 
bone, skin cartilage, intestine, lung, skeletal muscle, spleen, pancreas, brain, kidney, heart nor 
stomach. Bidart et al. assessed twelve types of frozen human tissue by qPCR and found high 
expression in the liver, but also much lower expression in lung, and even lower expression in 
brain and skeletal muscle. Li et al. () and Chen et al. () also report GDF expression 
in lung, at lower levels than liver, in mouse and humans. Inconsistency in organs identified 
compared to Miller et al. could be species specific, or because qPCR is more sensitive. 
BMP is expressed in myocardiocytes forming ventricular trabeculae in embryonic 
hearts (Neuhaus, Rosen, and ies ). As development continues, expression is mostly 
restricted to the right-atrium, although there is some expression in the left atrium (Neuhaus, 
Rosen, and ies ; Jiang et al. ). BMP expression, as measured by qPCR, is much 
higher in the liver of adult mice than all other organs, except the right atrium where 
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expression is much higher still (Tillet et al. ). Tillet et al. used RNA-in situ hybridisation 
to identify hepatic stellate cells as a source of BMP, with the same caveats as before.  
In summary, BMP is secreted from the liver. e strongest evidence suggests that 
hepatic stellate cells produce BMP, but it is very possible other cell-types do also. BMP is 
secreted from the right atrium. However, we cannot know whether all circulating BMP and 
BMP is secreted from the liver and right atrium respectively without generating organ-
specific knockouts. It seems likely that some BMP is produced in the lungs and may act as a 
paracrine here. Some BMP seems to be produced by the liver. Expression localisation could 
be important for how BMP and BMP ligands reach the pulmonary vascular endothelium. 
 
... BMP & BMP secretion and processing 
BMP and BMP are translated as  and  amino-acid PreProProteins, respectively, with 
their N-terminal signal peptide directing them into the secretory pathway (figure )(Chen et 
al. ). e signal peptide is cleaved to leave a ProBMP. e endoplasmic reticulum is 
oxidising and contains enzymes catalysing the formation of four disulphide bonds in the C-
terminal growth-factor domain (Wei et al. ). One of these forms between cysteine- 
of two BMP molecules, or  of two BMP molecules, to produce a ProBMP dimer 
(Schlunegger and Grütter ). is species is latent, since the prodomains prevent 
signalling activity. BMP is also predicted to be glycosylated at residues N and N, and 
BMP at N and N, as they pass through the secretory pathway. ese glycosyl groups 
improve the efficiency of furin processing (Susan-Resiga et al. ). 
       
Figure . BMP9 and BMP10 production and processing. Left: cartoon of BMP9 transcription, 
translation, translocation, glycosylation, secretion and processing. Right: Schematic 




ProBMP can be activated by cleaving the prodomains at RRKR319↓, and ProBMP at 
RIRR316↓, to release a growth-factor domain dimer (Mi et al. ; Susan-Resiga et al. ). 
ese are canonical furin recognition sequences, so a furin-like protease is hypothesised to be 
responsible for processing. Furin is widely expressed, enriched in the trans golgi apparatus, 
and belongs to the subtilisin-like prohormone convertase family (omas ).  
BMP is believed to be constitutively activated—serum and plasma from many species 
contains BMP activity which can be neutralised with anti-BMP antibodies, and BMP is 
secreted predominately in its processed form when overexpressed in vitro (Herrera and Inman 
; Bidart et al. ; Wei et al. ; Wooderchak-Donahue et al. ; David et al. 
). Moreover, David et al. () and Nikolic et al. () were able to purify active 
BMP in a ~ kDa fraction from human serum. 
One report estimated ~ of circulating BMP is unprocessed (Bidart et al. ). 
is is because furin treating EDTA-plasma increased its activity. e experiment was 
conducted at pH  in the presence of EDTA, which is unphysiological for furin which prefers 
neutral-acidic conditions and is strictly calcium dependant (omas ). ey showed the 
activity of BMP containing plasma size-fractions increased after furin treatment, and this 
could be completely neutralised by anti-BMP antibodies (Bidart et al. ). Nonetheless, 
their measured activity was very low, suggesting the sensitivity of this assay was poor. If much 
endogenous activity is not being measured, we cannot tell if BMP really constitutes the bulk 
of it. is means the furin treatment could be activating other ligands, including ProBMP. 
Caperuto et al. () used Western blotting to show the presence of both 
unprocessed and active BMP in rat liver extracts, and the ratio could be changed by fasting 
and other stimuli. However, their blots were heavily cropped and had neither molecular 
weight markers nor positive controls, so the bands could be non-specific. Moreover, the 
unprocessed bands could be intracellular protein. 
ProBMP processing appears to be less efficient than ProBMP processing in 
overexpression systems (David et al. ; Wei Li unpublished). Nonetheless, ProBMP can 
be processed by furin during overexpression in vitro (Jiang et al. ; Susan-Resiga et al. 
). Susan-Resiga et al. also showed prohormone convertases PC/ and paired basic 
amino-acid-cleaving enzyme  can process ProBMP in vitro. Using enzyme 
overexpression/inhibition assays, they found intracellular furin was the most important 
processing factor in vitro, although this depends on the cell-type. Neither furin nor PC/ 
knockout mice are viable, so their role in processing cannot be studied in vivo. erefore, we 
do not know for certain which enzyme(s) processes endogenous BMP and BMP. 
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Circulating BMP was assumed to be processed because ALK-Fc treatment can 
neutralise more plasma activity than anti-BMP antibodies alone (Jiang et al. ). Chen et 
al. () also report that anti-BMP antibodies can neutralise some serum activity, although 
not as much as anti-BMP antibodies. However, Jiang et al. were unable to show this for 
plasma using the same antibody. Moreover, anti-BMP neutralises - of human serum 
activity, and Gdf knockout mice have very little residual plasma BMP activity (Ricard et al. 
; Nikolic et al. ; Jiang et al. ). Mouse right atria extracts contain processed 
BMP and can secrete active BMP ex vivo (Jiang et al. ; Susan-Resiga et al. ). 
Whether right atria also secrete unprocessed ProBMP has never been assessed. 
In summary, there is good evidence that active BMP circulates, but only mixed 
evidence that ProBMP circulates. ere is mixed evidence that active BMP circulates. e 
presence or absence of latent ligands is interesting, because they may be activated in specific 
circumstances, or at specific sites. 
 
... Circulating BMP & BMP 
After processing, the prodomains remain tightly associated with the growth-factor domain 
dimer in vitro, forming a non-covalent complex, Pro:BMP / Pro:BMP (Brown et al. ; 
Jiang et al. ). The predominant circulating forms of BMP and BMP are prodomain 
bound—after affinity purification and size-exclusion chromatography, endogenous BMP and 
BMP have a similar molecular size to Pro:BMP (Bidart et al. ; Jiang et al. ). An 
ELISA using a capture antibody against BMP growth-factor domains, and a detection 
antibody against BMP prodomains, detects reactivity in this fraction (Bidart et al. ). 
ese size-exclusion chromatography experiments were carried out with samples pre-purified 
on affinity columns then eluted, so any higher-order circulating complexes could be disrupted 
and not measured. A small proportion of circulating BMP may have its prodomains displaced 
by circulating endoglin, which could impact its activity in some contexts (Lawera et al. ). 
e prodomains may solubilise and stabilise the hydrophobic growth-factor domain 
(Brown et al. ). Hydrophobic residues on the surface of the prodomains are important 
for the correct dimerisation and folding of other TGFβ family members (Gray and Mason 
; Walton et al. ). e prodomains also extend the half-life of TGFβ and activin-A in 
vivo, and the prodomain bound form of activin-A is active, so this is not due to blocking 
receptor binding (Johnson et al. ; Wakefield et al. ). e prodomains of several 
BMPs bind to the extracellular matrix and other TGFβ binding proteins. is includes BMP 
which has a fibrillin binding site in its prodomain (Sengle et al. ).  
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e prodomains could limit growth-factor domain availability to some receptors, 
especially type-II receptors (Mi et al. ). However, they have no effect on high-affinity 
ALK binding, and do not inhibit BMP or BMP activity on known cells except when at 
huge molar excess (Jiang et al. ; Bidart et al. ; Brown et al. ; Mi et al. ). 
is is likely because the mature complex adopts an open ‘butterfly’ conformation, exposing 
ALK and endoglin binding sites (Mi et al. ). One report suggested crossveinless-, 
which is secreted by endothelial cells, can bind and inhibit BMP (Yao et al. ). However, 
this result could not be replicated by our group (Wood et al. ). us, no BMP or BMP 
inhibitors are known. 
Notably, the intermolecular disulphide bond between BMP monomers is susceptible 
to reduction in physiological conditions, whereas other BMPs are not. However, the non-
covalent dimer retains its overall structure and activity (Wei et al. ). e reduced form 
may only sustain signalling for a shorter time and is more susceptible to degradation in serum 
(Wei et al. ). It is not known if any endogenous BMP is reduced. 
A recent report claimed the predominant circulating form of BMP and BMP was a 
BMP/ heterodimer (Tillet et al. ). ey showed BMP/ heterodimers are produced 
by cells transfected with both. Additionally, ELISAs comprised of capture antibodies against 
BMP and detection antibodies against BMP give immunoreactivity to human and mouse 
plasma. Finally, they showed that BMP from human plasma was captured on affinity 
columns against BMP. Notably, Dr. Paul Upton showed a striking correlation between 
circulating levels of BMP and BMP in human plasma (Hodgson et al. ).   
However, aspects of Tillet et al.’s report are inconclusive. Firstly, the hetero-ELISA 
results could not be replicated in our lab (Upton unpublished). Secondly, Tillet et al. show 
only modest reductions in circulating BMP in Bmp knockout mice and vice versa. ey 
previously reported BMP levels are unchanged in Gdf knockout mice (Ricard et al. ). 
Numerous reports show Gdf knockout and Bmp knockout mice have different phenotypes 
(see ..). Moreover, these results are consistent with BMP and BMP being in another 
kind of complex. Dr. Paul Upton finds the circulating level of pBMP is -fold greater than 
BMP, which suggests the majority cannot be in dimeric complexes. Although Tillet et al. 
showed both Gdf and Bmp are transcribed in hepatic stellate cells, they did not show they 
were transcribed within the same cells by using multi-colour in situs. Indeed, the 




In summary, the prodomains of Pro:BMP and Pro:BMP may modulate their 
function, and this should be considered when recombinant BMP or BMP is used. e 
ligands can exist in different forms and could be in complexes which may affect 
measurements and regulate their activity. 
 
... Levels of circulating BMP & BMP 
ere is no consensus in the literature regarding the circulating concentration of BMP or 
BMP (table ). Reports based on activity assume there is no inhibition or enhancement of 
BMP activity by other factors in serum. High intra- and inter-report variation in measured 
levels suggests ELISA protocols are ineffective. Moreover, the ELISAs have not been validated.  
 
Report Substrate Method 
Levels 
(pg/ml) 























n 2700- 100 
Human serum 400-1200 
Bidart et al. (2012) 
Human plasma 13 
Foetal mice plasma 000 
Adult mouse plasma 2000 
David et al. (200 ) Human plasma & serum 2000-12000 
Bidart et al. (2012) Human plasma ELISA of plasma size fraction 37 

















Tillet et al. (201 ) 400-1 00 
Ntumba et al. (201 ) 75-125 
Ouarné et al. (201 ) 500- 00 
Larriveé et al. (2012) 100 
Larriveé et al. (2012) Foetal mouse plasma 1500 
van Baardewijk et al. (2013) Diluted human plasmas 72-249  
Wang et al. (2019) Human serum -1000 Li et al. (201 ) 0-50 
Ricard et al. (2012) 












Tillet et al. (201 ) 25-175 
Ouarné et al. (201 ) 25-200 
Chen et al. (2013) Adult mouse serum 500-2000 Human serum 1000-3000 
Table 5. Levels of circulating BMP9 (top) and BMP10 (bottom) measured in vivo. 
 
Nikolic et al. and Dr. Paul Upton undertook to optimise and validate a sandwich 
ELISA comprised of capture and detection antibodies against the BMP growth-factor domain. 
Some plasmas give aberrantly high immunoreactivities due to endogenous antibodies 
crosslinking ELISA detection and capture antibodies (Tate and Ward ). is was 
overcome by supplementing samples with goat serum. Samples were mixed with Triton-X 
and diluted  in  to minimise interference from other plasma proteins. is ELISA gives 
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~ recovery of Pro:BMP from EDTA-plasma. Approximately - pg/ml of BMP is 
found in control plasmas using this protocol (Nikolic et al. ; Hodgson et al. ). 
Interestingly, there is significantly more BMP circulating in human females than males, so 
the sex of animal and human samples should be considered (Hodgson et al. ). Dr. Paul 
Upton optimised and validated a sandwich ELISA comprised of capture antibodies against the 
growth-factor domain, and detection antibodies against the prodomain, of pBMP in a 
similar way to the BMP ELISA. Circulating levels of pBMP were about - pg/ml in 
males and - pg/ml in females (Hodgson et al. ). 
In summary, the circulating level of BMP is ~ pg/ml, and pBMP ~ pg/ml 
when using a validated ELISA in large cohorts of people. Many reports generate spurious 
results. ere seems to be a discrepancy between the amount of BMP and BMP activity 
measured in cell-based assays versus ELISAs. However, we do not know whether the ELISAs 
detect latent and/or active BMPs, and the cell-based assays assume serum factors do not 
enhance or inhibit BMP signalling.   
 
.. Function of BMP & BMP 
... BMP in PAH 
BMP was indirectly implicated in PAH because it was the first high-affinity ligand for ALK 
discovered, can stimulate BMPR-II and circulates at active levels in adults. In vitro, BMP 
appears to inhibit cellular phenotypes associated with PAH. BMP treatment also partially 
rescues the apoptotic and leaky monolayer phenotypes of blood outgrowth endothelial cells 
taken from PAH patients carrying BMPR mutations (Long et al. ). Secondly, BMP 
treatment upregulates the expression of BMPR-II; partly a direct effect of SMAD activity on the 
BMPR promoter (Long et al. ; Upton et al. ). 
erefore, the Morrell group used intraperitoneal injections of Pro:BMP to prevent 
and reverse PAH-like disease in mice and rats. BMP reduced pulmonary vascular leak, 
partially restored haemodynamics, and rescued BMPR-II expression and signalling (Long et al. 
). However, this study does not necessarily demonstrate a role for endogenous BMP in 
human PAH, since treatment was administered at supraphysiological doses, through an 
unphysiological route, and induced disease may not reflect spontaneous human disease. 
Tu et al. () report Gdf knockout and anti-BMP treated mice have less severe 
pulmonary hypertension and pulmonary vascular remodelling in chronic hypoxia. However, 
Gdf knockout mice had less muscularised pulmonary arteries at baseline, reminiscent of 
HHT, and anti-BMP treatment appeared to alter the haemodynamics of control mice. Hence 
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vessels may develop and respond to hypoxia abnormally in this model (Morrell et al. ). 
Nikolic et al. () show ALK-Fc treatment of adult mice in hypoxia exacerbates PAH.  
Moreover, human genetic data increasingly shows GDF deficiency contributes to PAH.  
A five-year-old who developed severe PAH with a dilated right-ventricle, without 
evidence of HHT or cardiac defects, was discovered to carry a homozygous truncating 
mutation in GDF, BMP-QX (Wang et al. ). e heterozygous parents showed no 
evidence of disease. Wang et al. found this mutation by targeted sequencing BMPR, ACVRL, 
ENG, SMAD, SMAD, CAV, KCNK, KCNA, EIFAK, TOPBP, NOTCH, NOTCH (all of 
which were mutation-free) and GDF. is child should not produce BMP, but plasma 
samples were not analysed so we cannot be sure there is no escape or compensation.  
Recently, the Morrell group published a rare variant analysis showing GDF mutations 
predicted to be deleterious were over-represented in PAH patients compared to controls with 
genome-wide significance (see .)(Gräf et al. ). GDF mutation carriers in this cohort 
did not have significantly worse haemodynamics, age of diagnosis or prognosis than IPAH 
patients, and so had milder disease than BMPR mutation carriers (Hodgson et al. ). 
ese genetic and phenotypic findings were replicated by whole-exome sequencing Chinese 
PAH and control cohorts (Wang et al. ). Both studies found that putatively pathogenic 
variants in GDF were predominately heterozygous missense, which makes their effects hard 
to predict in silico. erefore, I undertook to assess the secretion, activity and circulating 
levels of BMP variants discovered in the Morrell study, and Wang et al. reported a similar 
analysis in their study.  
Wang et al. found missense BMP variants were poorly secreted in vitro. is was 
mirrored within human carriers which had reduced circulating levels of BMP ( pg/ml) 
compared to healthy controls ( pg/ml) and other PAH patients ( pg/ml). However, these 
BMP levels are well below those recorded in previous reports, and the ELISA protocol was not 
validated (see ..). Additionally, information about the sex and age of control samples was 
not recorded. e Chinese cohort exhibits high rates of pathogenic GDF mutations (. 
versus . of UK cases), and was generally young and with severe disease, compared to the 
British cohort. Patients with liver disease were stringently excluded from the British cohort 
because they can exhibit low plasma BMP levels (Nikolic et al. ; Upton unpublished). 
Moreover, the Chinese cohort only included  patients. 
A targeted analysis of BMPR, TBX, EIFAK, CAV, KCNK, SMAD, ACVRL, ENG, 
BMP and GDF in a European cohort of  IPAH patients was published simultaneously 
(Eyries et al. ). ey found two GDF truncating mutations and a missense variant 
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predicted to be deleterious in silico. Finally, a rare-variant analysis of  exome-sequences 
from an American cohort implicates GDF as causal in PAH (Zhu et al. ).  
Dr. Paul Upton measured circulating BMP levels in  PAH patients and  
controls (Hodgson et al. ). ere was no significant difference in average circulating 
BMP levels between controls and PAH patients. is suggests low BMP levels are not 
generally involved in PAH, in contrast to the claims of Wang et al. (). Nikolic et al. 
() also find normal BMP levels in PAH patients, and rodents with PH, unless they have 
liver disease. However, a disproportionate number (~) of PAH patients not carrying GDF 
mutations had circulating levels of BMP below the lowest control sample, suggesting BMP 
deficiency may contribute to some PAH cases (Hodgson et al. ). Dr. Emilia Swietlik 
assessed the phenotype of PAH patients with low levels of BMP and found no impact on age 
of diagnosis, prognosis or haemodynamics (Hodgson et al. ).  
In summary, multiple cohorts cross-validate a role for GDF mutations in PAH. 
Analysis of these variants demonstrates BMP deficiency contributes to PAH risk. BMPR-
II/ALK signalling is deficient in PAH and BMP can restore this, making BMP-like molecules 
promising treatments for PAH (Ormiston, Upton, et al. ). Further study is needed to 
define how each missense mutation disrupts BMP. 
 
... BMP in PAH 
e role of BMP in PAH and HHT has not attracted as much attention as BMP—it was 
identified as a circulating ALK/BMPR-II ligand later and is generally less well understood. 
erefore, neither Wang et al. () nor Nikolic et al. () measured BMP levels in PAH 
patients compared to controls. 
Moreover, BMP mutations have not been statistically associated with human disease 
in British, American or Chinese cohorts (Gräf et al. ; Zhu et al. ; Wang et al. 
). Interestingly, Eyries et al. () report a truncating mutation (BMP-RX), and a 
missense mutation predicted to be deleterious (BMP-RC), in their cohort. e British 
study re-sequenced and confirmed the patient carrying BMP-RC and discovered a PAH 
patient carrying BMP-AE (Hodgson et al. ). ese variants are expected to 
profoundly disrupt the growth-factor domain of BMP. Unfortunately, in vitro expression of 
Pro:BMP is relatively variable which makes analysis difficult and plasmas were not available 
from these patients. eir age and haemodynamics were not notable (Hodgson et al. ). 
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Dr. Paul Upton found circulating pBMP levels were significantly lower in females 
with PAH, but not males, compared to controls (Hodgson et al. ). Additionally, ~ of 
PAH patients had circulating levels of pBMP below the lowest healthy control. Hence, 
BMP deficiency might contribute to some PAH cases. Circulating pBMP levels were not 
correlated with age at diagnosis, haemodynamics or prognosis (Hodgson et al. ).    
According to the genome aggregation database, BMP is more intolerant of loss-of-
function mutations (observed/expected ratio = . to .) than GDF (observed/expected 
ratio = . to .), which may explain why few pathogenic mutations have been found in 
BMP. e BMP and BMP growth-factor domains have extremely similar structures and 
activity on endothelial cells. erefore, it is conceivable that BMP activity protects against 
PAH or compensates for BMP deficiency. Hence, levels and activity of both ligands should be 
considered within patients.  
 
... BMP & BMP in vascular development 
e ALK signalling complex regulates endothelial cells. In turn, endothelial cells regulate 
blood vessel development, vascular tone, and movement of cells and substances across vessel 
walls. Vasculogenesis is the first stage of vascular development, when endothelial cells form 
uniform tubes under the influence of TGFβ (Li et al. ). During angiogenesis, endothelial 
cells take on distinct identities and remodel vessels to give the vasculature appropriate 
architecture (Li et al. ). Neither Eng nor Acvrl knockout embryos are viable because 
they have profoundly disturbed angiogenesis, including hyperdilation of larger vessels, 
formation of shunts between arteries and veins due to loss of arterial/venous identity, and 
failure to recruit vascular smooth muscle (Li et al. ; Urness, Sorensen, and Li ; Oh 
et al. ; Larrivée et al. ; Lamouille et al. ; Rochon, Menon, and Roman ).  
[BMP/BMP]/ALK signalling cross-talks with Notch signalling and other regulators 
of endothelial development (Larrivée et al. ; Ricard et al. ). us, when neonatal 
mice are given ALK-Fc, or DAPT to inhibit Notch signalling, their developing retinas and ears 
hypervascularise due to increased endothelial cell sprouting (Larrivée et al. ). BMP 
administration can rescue the effect of DAPT by directly inducing the expression of Notch 
target genes such as HEY and HEY (Larrivée et al. ; Ricard et al. ). 
Bmp knockout embryos show defective blood-vessel development (Chen et al. 
). In contrast, Gdf knockout mice are viable and do not show an obvious blood-vessel 
phenotype (Hao Chen et al. ; Ricard et al. ). In mice, BMP and ALK expression 
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begins at embryonic day ., whereas BMP is not produced until embryonic day . (Chen 
et al. ; Seki, Yun, and Oh ). In mice with the coding sequence of Bmp  replaced 
with that of Gdf, blood vessel development is normal (Chen et al. ). is suggests the 
presence of either ligand is sufficient during early vessel development. 
Later, neonatal mice given anti-BMP do not show any blood-vessel phenotypes 
(Chen et al. ). However, Gdf heterozygous and knockout mice given anti-BMP, and 
wild-type mice given ALK-Fc or both anti-BMP and anti-BMP, show hypervascularisation, 
dilation, haemorrhaging and impaired vessel muscularisation (Chen et al. ; Ricard et al. 
; Baeyens et al. ). is indicates redundancy between the ALK ligands in neonatal 
mice. Notably, anti-BMP alone had a similar effect to ALK-Fc in wildtype mice, suggesting 
that it disrupts BMP signalling (possible if they are in complex) or chronic germline loss of 
BMP leads to better compensation by BMP (Ricard et al. ). Combined depletion of 
BMP and BMP is lethal after ~ days, similar to ALK depletion (Levet et al. ). 
A consistent result was reported for embryonic zebrafish. BMP deficient embryos do 
not have an early vascular phenotype, but later fish develop a venous remodelling defect in the 
tail (Laux et al. ). In contrast, BMP deficient embryos have an early arterial phenotype 
reminiscent of ALK deficiency and lose early endothelial SMAD signalling (Laux et al. ).  
In adulthood, BMP is reported to either promote vascularisation or inhibit it. In a 
mouse model of macular degeneration, adenovirus expressing BMP, which leads to increased 
circulating BMP, reduces the formation of invasive vessels, whereas ALK-Fc expression 
increases it (Ntumba et al. ). In mice given ischemic hind-limb injuries, injection of 
BMP enhances vascularisation (Kim et al. ). However, this effect was only seen in the 
presence of exogenous foetal endothelial progenitor cells. ALK blockade has been 
investigated extensively as a tumour vascularisation inhibitor. Conflicting reports show Gdf, 
but not Bmp, knockout mice have more neovascularisation and faster growth of 
spontaneous tumours (Ouarné et al. ; de Vinuesa et al. ). 
BMP and BMP seem to cooperate during ductus arteriosus closure and remodelling. 
e ductus arteriosus closes normally at birth in Gdf knockout mice, but tends to re-open 
again after  days because intimal and medial remodelling is reduced (Levet et al. ). 
Anti-BMP antibodies exacerbate this (Levet et al. ). In humans, BMP deletions have 
been associated with having a patent ductus arteriosus (Levet et al. ).    
Lymphatic vessels develop after embryonic day  in mice, when either ligand could 
have a role. Mice treated with ALK-Fc, inducible Acvrl knockout, and Gdf knockout mice 
given anti-BMP, have improperly developed lymphatic systems (Niessen et al. ; Chen 
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et al. ; Yoshimatsu et al. ). However, later reports also argue Gdf knockout alone 
leads to the development of dysfunctional lymphatic vessels and a loss of lymphatic valves 
(Levet et al. ; Yoshimatsu et al. ; Derynck and Akhurst ). 
In summary, BMP and BMP are semi-redundant in angiogenesis in adults. ere is 
some evidence that BMP deficiency can induce subtle phenotypes alone, but also some 
evidence chronic deficiency is compensated by BMP. BMP deficiency seems to promote 
vascularisation in some situations and inhibit it in others. is may reflect the nuanced 
purpose of angiogenesis, which is to prune some vessels, enlarge others, maintain some 
redundancy but increase the efficiency of perfusion. These features are consistent with BMP 
or BMP deficiency being a rare, poorly penetrant trigger for PAH. 
 
... BMP & BMP in vascular quiescence 
ALK signalling is necessary for blood vessel homeostasis in adulthood, since inducible Acvrl 
knockout mice develop arterio-venous malformations, and die of internal haemorrhaging 
(Park et al. ; ). BMP signalling elicits many effects on adult endothelial cells, but is 
generally a quiescence factor (David et al. ). It alters the secretion of various chemokines 
and selectins from endothelial cells, some with auto/paracrine roles stabilising the 
endothelium and recruiting accessory cells, but others that may promote vascular tone and 
angiogenesis (Young et al. ; Upton et al. ). is is likely context dependent in vivo. 
Endothelial cells stimulated with BMP are less apoptotic, proliferative and migratory, form 
tighter cell-junctions, and have a different metabolic profile (Bidart et al. ; David et al. 
; Suzuki et al. ; Long et al. ; Burton et al. ; Lamouille et al. ; Akla et 
al. ). ALK mediates endothelial transcytosis of low-density lipoproteins, but this is not 
associated with SMAD signalling (Kraehling et al. ).  
e mechanism leading to quiescence has not been thoroughly explored. SMAD-
regulated genes include inhibitor of DNA-binding proteins ID and ID (Miyazono, Kamiya, 
and Morikawa ; Upton et al. ; Long et al. ). As in development, BMP and 
Notch signalling are synergistic for quiescence, and there is some evidence BMP is 
upregulated to compensate loss of Notch activity in vivo (Rostama et al. ). BMP also 
upregulates components of its own signalling pathway, including BMPR-II, endoglin and 
SMAD which further stabilises and quiesces the endothelium, even in BMPR deficient cells 
(Long et al. ; Young et al. ).  
In summary, BMP is a quiescence factor in many settings. Sustained signalling is 
needed for endothelial cells to maintain proper vessel architecture through adulthood. BMP 
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promotes normal migration, proliferation, apoptosis and chemokine secretion, and 
upregulates its own signalling. ese features are consistent with BMP deficiency 
contributing to PAH. 
 
.. BMP in the heart 
Bmp knockout mice are not viable since cardiomyocyte numbers are dramatically reduced 
(Chen et al. ;  ). Interestingly, a heterozygous, very rare missense-variant, BMP-
VI, was found in a mother and daughter suffering from left-ventricular non-compaction 
(Hirono et al. ). is variant is predicted to be highly deleterious in silico, and was less 
able to bind BMPR-II in vitro (Hirono et al. ). 
Replacing the coding sequence of Bmp with that of Gdf leads to profound cardiac 
defects, which indicates BMP may signal differently to BMP in the heart (Chen et al. 
). Chen et al. checked BMP was expressed in place of BMP in this model, but it is 
possible there are nuanced regulatory functions contained within the coding sequences that 
could be influencing this result. ese embryos were not compared side-by-side with Bmp 
knockouts to see if BMP compensated for BMP loss to any extent.  
One report suggests circulating BMP levels are inversely correlated with coronary 
heart disease and systemic essential hypertension (Liu et al. ). However, these data were 
generated using an ELISA protocol which is unsuitable in our hands. Circulating pBMP 
levels are significantly inversely associated with systemic hypertension in the cohort of PAH 
patients measured by us (Hodgson et al. ). BMP levels are not significantly associated 
with hypertension in this cohort, but a correlation is evident, and BMP is very tightly 
correlated with pBMP suggesting both ligands are associated. 
 
... BMP in the liver 
e first investigations into BMP identified it as a hepatic paracrine, where it binds specific, 
high-affinity receptors (Song et al. ; Miller et al. ). Liver tissue expresses ALK, 
ALK, BMPR-II, ActR-II, and endoglin, with ALK the main receptor on hepatic stellate, 
Kupffer and bile-duct endothelial cells (Bi and Ge ). BMP treatment leads to SMAD 
signalling and ID induction in many hepatic cell-types in vitro, although it is not completely 
clear which cell-types are able to respond to BMP, or at what concentrations.  
e first functional study of GDF explored glucose homeostasis (Chen et al. ). 
Of all secreted factors except insulin, BMP was found to be the most potent driver of insulin-
like effects on hepatoma, myoblast and adipocyte cell lines. Secondly, exogenous BMP was 
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found to be a potent anti-glycaemic in mice (Chen et al. ). However, the EC of cells 
was supraphysiological (~ ng/ml), and high BMP doses ( mg/kg) were administered 
which may have caused severe morbidity.  
Circulating BMP levels are negatively correlated with insulin resistance in type-II 
diabetes (Luo et al. ). Feeding or injecting glucose leads to GDF upregulation in rat 
livers, whilst anti-BMP injection leads to glucose intolerance (Caperuto et al. ). BMP 
overexpression inhibits glucogenesis and lipogenesis in mice and improves insulin resistance 
(Yang et al. ). Circulating pBMP levels are significantly inversely associated with type-
II diabetes in the cohort of PAH patients we measured (Hodgson et al. ). BMP levels 
were not significantly associated with diabetes, but a correlation is evident and BMP is tightly 
correlated with pBMP suggesting both ligands are associated. BMP mRNA and protein may 
be decreased in livers of type-II diabetes patients (Yang et al. ). BMP upregulates the 
expression of browning genes in mouse fat-tissue and human adipose stem cells (Kuo et al. 
). is reduces weight gain in mice treated with exogenous BMP (Kuo et al. ). 
Evidence also supports a role for BMP in hepatic non-glucose metabolism. BMP 
appears to be a constitutive quiescence factor of hepatocytes, facilitating the expression of 
metabolic enzymes such as cytochrome P and hepcidin (Truksa et al. ; Breitkopf-
Heinlein et al. ). Additionally, BMP may have a developmental role in the liver—Gdf 
knockout mice have sinusoidal endothelial cells which fail to differentiate fully, leading to 
improper fenestrations and perivascular fibrosis (Desroches‐Castan et al. ). Gdf 
knockout livers also have an increased mesenchymal component, which could reflect 
destabilisation of epithelial hepatocytes (Breitkopf-Heinlein et al. ; Addante et al. ).  
Numerous reports demonstrate Gdf expression is immediately and transiently 
downregulated upon liver injury, including after lipopolysaccharide, carbon tetrachloride, 
bile-duct ligation and cholestatic injury (Li et al. ; Breitkopf-Heinlein et al. ; 
Addante et al. ; Nikolic et al. ). Gdf knockout, ALK-Fc or anti-BMP treated 
mice suffer less liver damage, and show better liver regeneration after such injuries, suggesting 
this fall in BMP levels is adaptive (Breitkopf-Heinlein et al. ; Li et al. ; Wiercinska 
et al. ; Addante et al. ). Conversely, forced GDF overexpression, or BMP 
administration, leads to impaired proliferation, increased apoptosis and reduced regeneration 
of hepatocytes in vivo and in vitro (Li et al. ; Breitkopf-Heinlein et al. ).  
Excess BMP activity is accompanied by increased liver fibrosis because 
endoglin/ALK/SMAD/ID signalling drives hepatic stellate cells to transdifferentiate into 
fibroblasts; drives SNAIL expression in hepatocytes which triggers epithelial to mesenchymal 
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transition; and drives the expression of components of the extracellular matrix (Li et al. ; 
Meurer et al. ; Wiercinska et al. ; Li et al. ; Addante et al. ). Anti-BMP 
treatment has even been used to partially reverse liver fibrosis in animals (Li et al. ). 
Importantly, BMP may also have protective effects in the liver. For example, in 
sinusoidal endothelial cells, ID expression drives the secretion of paracrines which are pro-
regenerative, and anti-fibrotic for the liver (Ding et al. ). Hence, in the absence of 
insults, Gdf deficiency may increase fibrosis (Addante et al. ; Desroches‐Castan et al. 
). Secondly, although BMP deficient livers are less damaged by insults, they may become 
more inflamed, and secrete inflammatory cytokines (Desroches‐Castan et al. ). is 
could precipitate liver dysfunction or induce problems in other organs.  
Notably, these animal models of liver damage are severe. In patients with hepatitis B, 
GDF expression was not correlated with fibrosis (Breitkopf-Heinlein et al. ). Similarly, 
in people with different stages of liver disease, only the most severe cases have reduced 
circulating levels of BMP (Upton unpublished). Circulating BMP levels are markedly reduced 
in patients with portopulmonary hypertension, which likely have cirrhosis, compared to 
pulmonary hypertension without liver involvement (Nikolic et al. ).  
In contrast, another report suggested circulating BMP levels are increased in fibrotic 
patients, although they measured serum by an ELISA protocol that is not suitable in our hands 
(Li et al. ). A brief analysis of publicly available datasets from various liver diseases 
showed that GDF, ACVRL, ACVRB and BMP mRNA is upregulated in some cirrhotic 
cohorts, and downregulated in others (John et al. ). However, mRNA level may not 
correlate well with secretion level in senescent cells.     
In summary, BMP is likely to have important roles in liver development and 
quiescence. BMP may also have short-term metabolic regulatory roles. ere has not been a 
comprehensive assessment of the baseline phenotype of BMP deficient livers. erefore, 
metabolic markers and enzyme expression should be assessed as comprehensively as possible 
in BMP deficient animals to give an unbiased view of the roles of BMP in the liver. 
 
... BMP in osteogenesis 
BMP,,, and  are known to be potent osteogenic factors (Luu et al. ; Cheng et al. 
; Peng et al. , ). In vitro, BMP can drive the expression of alkaline 
phosphatase, an early marker of osteogenesis, in myoblasts, stromal marrow stem cells and 
mesenchymal stem cells (Luu et al. ; Wang et al. ; Zhu et al. ; Fujioka-
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Kobayashi et al. ; Luo et al. ; Li et al. ). Prolonged BMP treatment stimulates 
matrix mineralisation, a late marker of osteogenesis.  
Osteogenic effects seem to require ~ ng/ml of BMP, a supraphysiological dose 
(Fujioka-Kobayashi et al. ; Morrell unpublished). BMP mediated osteogenesis is 
dependant non-redundantly on both ALK and ALK in complex with BMPR-II and ActR-II 
(Luo et al. ; Wu et al. ). e EC of ALK for BMP is about  ng/ml. Hence, these 
studies suggest the osteogenic effects of endogenous BMP are limited to special 
circumstances where concentrations are elevated.  
Mice and rats injected with cells transfected with adenoviral vectors expressing BMP 
show enhanced bone formation compared to other BMPs (Luo et al. ; Luu et al. ; 
Kang et al. ). ese animal models use exogenous cells, an unknown dose of BMP, and 
are likely to be inflammatory, so it is unclear if they reflect a normal role of BMP. Notably, 
Gdf knockout mice do not show any osteogenesis defects (Ricard et al. ; Yoshimatsu et 
al. ). Humans with delayed fracture healing do not have lower circulating BMP levels 
(van Baardewijk et al. ). Nevertheless, several studies have assessed using BMP to aid 
bone growth and healing (Fu et al. ; Nie et al. ; Fujioka-Kobayashi et al. ). 
In adenoviral models, BMP did not appear to have osteogenic activity (Luu et al. 
; Cheng et al. ). However, it is unclear how much processed or unprocessed BMP 
the virus produced: it would be useful to reassess this in vitro and in vivo with purified BMP 
where the dose can be controlled.   
 
.. Hypotheses & approaches 
... Rare GDF variants associated with PAH 
Gräf et al. () identified several rare missense-variants in GDF which were associated 
with PAH. These variants are predicted to damage the protein stucture in silico. e variants 
are spread across the prodomain and growth-factor domains of BMP, so they could disrupt 
BMP function in several ways. We hypothesised they reduce protein secretion, processing or 
stability, which are known to depend on the prodomain. Additionally, they could lead to 
missfolding, and reduce receptor binding and activity on endothelial cells, or bias signalling. 
To assess this, we over-expressed BMP variants in vitro. I assessed their secretion 
level in conditioned media by ELISA and processing defects by Western blotting. Secondly, I 
assessed the ability of BMP variants to activate ALK signalling in a heterologous cell-system. 
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Finally, I judged the function of BMP variants on endothelial cells by measuring the 
transcription of BMP signalling target genes and anti-apoptotic activity. 
We hypothesised patients carrying PAH-associated BMP variants have reduced 
circulating BMP activity and levels. To assess this, I incubated endothelial cells with patient 
plasmas to measure transcriptional acitivty, and measured circulating BMP levels by ELISA. 
ere are mixed reports over whether BMP levels are generally low in PAH patients, so I 
included samples from PAH patients carrying GDF variants shown to be both loss-of-
function and benign in vitro, as well as age and sex matched healthy controls. We 
hypothesised that chronic BMP deficiency in these patients is compensated by BMP. To 
assess this, I measured pBMP levels in these samples by ELISA. 
e homozygous variant BMP-QX has been found in pediatric PAH (Wang et al. 
). We hypothesised that this variant is partially rescued by re-initiation of translation at 
Met. I expressed this variant in vitro to assess expression and secretion by ELISA and 
Western blotting. Additionally, the homozygous variant BMP-DX has been found in a 
pedriatric case of HHT. Samples from the patients and parents were available, so I measured 
activity on endothelial cells and circulating levels by ELISA to confirm the in vitro findings.   
 
... Circulating species of BMP & BMP 
ere is mixed evidence over the amount of BMP and BMP circulating in their active 
versus latent forms. ere seems to be a discrepancy between the amount of circulating 
BMP recoverable by ELISA, and the amount of circulating activity attributable to it. 
erefore, we hypotheised that more circulating BMP is unprocessed than BMP.  
To assess this, I investigated the immunoreactivity of processed and unprocessed 
species in growth-factor domain only and prodomain/growth-factor domain ELISAs for BMP 
and BMP. I then investigated the immunoreactivity of human plasmas with the same 
ELISAs. I assessed the residual activity of serum which had been cleared of BMP and/or 
BMP on endothelial cells. Secondly, I incubated serum with furin and a flourometric 
positive control, to measure whether circulating BMP or BMP can be processed. Finally, I 
assessed circulating BMP by Western blotting. 
Circulating BMP and BMP levels are tightly correlated, and there is some evidence 
that they are in complex. erefore, I hypothesised that immunopreciptating BMP from 
plasma reduced recovery of BMP by ELISA, and vice versa. I also analysed plasma and serum 
by size-exclusion chromotography to assess the size of circulating BMP and BMP.  
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... Pharmacokinetics of BMP 
Intraperitoneal injections of BMP have been used in various studies to induce long-lasting 
changes. However, Dr. Claudia-Gabriela Mitrofan was able to recover excess BMP from 
plasma  hour after administration, but not at later time-points (unpublished). erefore, we 
hypothesised that the circulating half-life of BMP is short, and it may be sequestered to the 
pulmonary endothelium which highly expresses high-affinity receptors.  
To assess this, we administered Pro:BMP intravenously to knockout and wildtype 
mice, and withdrew samples at different times for up to an hour. I measured plasma BMP 
levels by ELISA and activity assays, lung and liver levels by ELISA and transcriptional activity 
by qPCR. To assess whether endogenous BMP and BMP behaved similarly, I measured 
levels by ELISA and activity assays in human plasmas from the superior vena cava, pulmonary 
artery and brachial artery, to look for trans-vascular gradients. 
 
... Phenotype of Gdf knockout mice 
BMP and BMP deficient people are predisposed to PAH, and there is limited evidence they 
are metabolically dysfunctional. In animals, BMP has a potent effect on liver metabolism.  
erefore, we hypothesised that Gdf knockout mice would have disrupted levels of 
fat and glucose metabolism markers in their serum and elevated levels of markers of liver 
damage. We hypothesised that Gdf knockout liver transcriptomes would have significantly 
disrupted expression of metabolic enzymes and proliferation markers. 
 
Materials & Methods 
. Production of conditioned media containing BMP 
.. Site-directed mutagenesis of the BMP expression vector 
Dr. Rick Salmon prepared the BMP missense variant overexpression plasmids, with my 
assistance in some cases. e template plasmid comprised wildtype GDF cDNA cloned into a 
pCEP plasmid (Wei et al. ). Mutagenesis was carried out with a QuickChange kit 
(Agilent technologies ) using primers designed with Amplifx (https://inp.univ-
amu.fr/en/amplifx-manage-test-and-design-your-primers-for-pcr)(table ). 
 e PCR reaction mix comprised  µl Pfu turbo polymerase,  µl ddHO,  µl  
(v/v) DMSO,  µl turbo buffer,  µl dNTPs ( mM stock) and  µl each of forward and 
reverse mutagenesis primers ( µM stocks). A range of - ng of template plasmid was 
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included, which was varied until mutagenesis was successful. e PCR mix was incubated in a 
thermocycler at  oC for  seconds, followed by  cycles of  oC for  seconds,  oC for 
 minute, and  oC for  minutes, and a final annealing step of  oC for  minutes. e 
PCR products were digested with Dpn (NEB RO) to remove template DNA which is 
methylated:  µl of the products were mixed with  µl cut smart buffer,  µl ddHO, and  
µl enzyme and incubated at  oC for  hours, then denatured by  minutes at  oC.  
 
Mutation Primer Sequences 
p.Gly18Val For: 5’-CTGCTGGCTgtcTCCCTACAGGGGAAG-3’ 
Rev: 5’-CCCTGTAGGGAgacAGCCAGCAGGGAC-3’ 
p.Gly74Glu For: 5’-AGCCTTAACCTGAGTgagGTCCCTTCGCA-3’ 
Rev: 5’-TGCGAAGGGACctcACTCAGGTTAAGGC-3’ 
p.Met89Val For: 5’-CCGCCGCAGTACgtgATTGACCTGTACAAC-3’ 
Rev: 5’-GTACAGGTCAATcacGTACTGCGGCGGCT-3’ 
p.Prol104Leu For: 5’-AAGTCGACTACGctaGCGTCCAACATTGTG-3’ 
Rev: 5’-GCACAATGTTGGACGCtagCGTAGTCGACTTA-3’ 
p.Arg110Trp For: 5’-CGTCCAACATTGTGtggAGCTTCAGCAT-3’ 
Rev: 5’-ATGCTGAAGCTccaCACAATGTTGGAC-3’ 
p.Ile118Phe For: 5’-TGGAAGATGCCttcTCCATAACTGCCACA-3’ 
Rev: 5’-GCAGTTATGGAgaaGGCATCTTCCATGCT-3’ 
p.Glu143Lys For: 5’-CCATTCCTAGGCATaagCAGATCACCAGA-3’ 
Rev: 5’-GCTCTGGTGATCTGcttATGCCTAGGAATG-3’ 
p.Val154Ile For: 5’-TGAGCTCCGACTCTATatcTCCTGTCAAAATCACG-3’ 
Rev: 5’-TTTTGACAGGAgatATAGAGTCGGAGCTCAG-3’ 
p.Asp218Asn For: 5’-GGGTCCGGTCCaacTCCACCAAGAGCA-3’ 
Rev: 5’-TTTGCTCTTGGTGGAgttGGACCGGACCC-3’ 
p.Glu297Lys For: 5’-TCCACAGAGGCAGGTaagAGCAGTCACGA-3’ 
Rev: 5’-CTCGTGACTGCTcttACCTGCCTCTGTGGA-3’ 
p.Glu302Val For: 5’-GAGCAGTCACGAGgtgGACACGGATGGC-3’ 
Rev: 5’-CCATCCGTGTCcacCTCGTGACTGCTCT-3’ 
p.Ser320Cys For: 5’-GGAAAAGGtgcGCCGGGGCTGGCAGCCACT-3’ 
Rev: 5’-TGCCAGCCCCGGCgcaCCTTTTCCGCCT-3’ 
p.Ala347Val For: 5’-AGCTGGATCATTgtaCCCAAGGAGTATGAA-3’ 
Rev: 5’- GCTTCATACTCCTTGGGtacAATGATCCAG-3’ 
p.Tyr351His For: 5’-ATTGCACCCAAGGAGcatGAAGCCTACGAGT-3’ 
Rev: 5’-CTCGTAGGCTTCatgCTCCTTGGGTGCAAT-3’ 
p.Lys397Arg For: 5’-CTGTGTGCCCACCagaCTGAGCCCCAT-3’ 
Rev: 5’-AGATGGGGCTCAGtctGGTGGGCACACA-3’ 
p.Thr413Asn For: 5’-ATGGGGGTGCCCaacCTCAAGTACCATTA-3’ 
Rev: 5’-TGGTACTTGAGgttGGGCACCCCCATGTC-3’ 
Table . Site-directed mutagenesis primers for introducing BMP9 mutations. 
 
 e digestion products were amplified in E. coli. Fifty µl of DH-α bacteria (Bioline 
BIO-) were thawed on ice with  µl of DNA for  minutes, followed by a -second 
heat-shock at  oC, then a final -minute incubation on ice. Transformed bacteria were 
transferred into  µl of SOC outgrowth medium (CIMR) and incubated for  hour at  oC 
with shaking. Bacteria were pelleted by centrifugation, resuspended in  µl of SOC medium 
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and spread onto lysogeny broth agar plates containing ampicillin (CIMR). Plates were 
incubated overnight at  oC. Individual colonies were transferred into  ml of lysogeny 
broth supplemented with ampicillin (CIMR). ese were cultured overnight at  oC with 
shaking. Plasmids were recovered by miniprep (Merck PLN) according to the 
manufacturer’s protocol. e concentration of DNA was measured by NanoDrop (ermo ND-
LITE). Sanger sequencing (Source Bioscience) was used to check to plasmids were correct.   
 
.. BMP over-expression system 
Dr. Rick Salmon used the plasmids to produce variant BMP protein with my assistance. 
Human embryonic kidney  EBNA (HEK-EBNA) cells constitutively express the Epstein-
Barr virus EBNA protein, which stabilises pCEP as a nuclear episome. HEK-EBNA cells 
(American Type Culture Collection) were seeded in  cm dishes and grown in Dulbecco’s 
modified Eagle’s medium (DMEM)(Gibco ) supplemented with  (v/v) foetal bovine 
serum (FBS)(Invitrogen A) and antimicrobials (Invitrogen ) until confluent.  
Two µg of plasmid was mixed with  µl of mg/ml polyethyleneimine (Polysciences 
-), incubated at room-temperature for  hours then added to  ml of DMEM with  
(v/v) FBS without antibiotics. Cells were washed twice with PBS, then the transfection mix 
was added overnight. Transfected cells were washed twice with PBS and placed in  ml of 
chemically defined Chinese hamster ovary cell over-expression medium (Gibco ).  
After  days, conditioned media were collected and centrifuged at   g for  
minutes to remove debris. Clarified conditioned media were aliquoted into PCR tubes and 
stored at - oC. ree independent transfections were carried out on different days for each 
BMP variant and used as biological replicates in subsequent analyses. Each batch of 
transfections included pCEP-BMP-wildtype and pCEP without GDF cDNA inserted 
(empty vector), as positive and negative controls respectively.  
 
.. Nonsense variant 
Dr. Lydia Ruiz Llorente produced expression vectors for wildtype PreProBMP-QX and 
ORF variants using pcDNA./V-His-TOPO/BMP (Wooderchak-Donahue et al. ) as 
the template. ese were shipped dried on filter paper. Plasmid was reconstituted in  µl 
ddHO and the amount of DNA was quantified by NanoDrop. Plasmids were transformed into 
E. coli, purified and sequenced as in section ...  
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pcDNA is not stabilised by EBNA, so I transfected it into HEK-T cells for over-
expression. HEK-T cells were cultured in the same way as HEK-EBNA cells. Fifteen µl of 
lipofectamine  (Life Technologies) was mixed with  µl of optiMEM (Gibco 
). Two µg of DNA was mixed with  µl of optiMEM, then added to the 
lipofectamine mix and incubated for  minutes at room-temperature. Cells were washed with 
optiMEM, then placed in . ml of optiMEM with the transfection mix swirled in gently. After 
 hours, transfected cells were placed in expression media, which were collected after  days, 
as described in section ...   
 
. Enzyme-linked immunosorbent assays 
.. BMP growth-factor domain in conditioned media 
High-binding -well ELISA plates (Greiner ) were coated with . µg/well (in  µl 
volume) of monoclonal anti-BMP (R&D Systems mAb, stock  µg/ml in PBS stored 
at - oC ) in PBS overnight at  oC in a humidified chamber. Unadsorbed antibody was 
removed by thrice washing with PBS supplemented with . (v/v) Tween- (PBST). e 
plate was blocked with  µl/well of PBS supplemented with  (w/v) of bovine serum 
albumin (BSA)(Fisher BioReagents ) at room-temperature for two hours.  
 e standard curve comprised recombinant BMP (R&D Systems -BP, stock  
ng/µl in PBS supplemented with  (w/v) BSA and  (v/v) HCl stored at - oC ) serially 
diluted two-fold in PBS supplemented with  (w/v) BSA to give concentrations spanning 
 pg/ml to . pg/ml). Samples of conditioned media were also serially diluted in PBS 
supplemented with  (w/v) BSA. One hundred µl of each sample/standard was added to 
duplicate wells and the plate was incubated at room-temperature for two hours. 
 e plate was thrice washed with PBST and incubated with  µg/well (in  µl 
volume) of biotinylated anti-BMP (R&D Systems BAF, stock  ng/µl in PBS 
supplemented with  (w/v) BSA stored at - oC) in PBS supplemented with  (w/v) BSA 
for two hours at room-temperature. Unadsorbed detection antibody was removed by thrice 
washing with PBST, and  µl/well of a : dilution of ExtrAvidin-alkaline phosphatase 
conjugate (Sigma E) in PBS supplemented with  (w/v) BSA was added for  minutes 
at room-temperature.  For detection, -nitrophenylphosphate disodium hexahydrate (Sigma 
N) was dissolved to  mg/ml in diethanolamine buffer ( M diethanolamine, . mM 
MgCl, pH .). e plate was washed thrice with PBST and then ddHO,  µl/well of 
detection reagent was added, and the plate was incubated in the dark.  
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Periodically, the absorbance of each well at  nm was measured with a plate reader 
(BioRad model ). e mean absorbance of each duplicate standard/sample was calculated. 
e mean absorbance of the blank (a sample comprised of PBS supplemented with  (w/v) 
BSA alone) was subtracted from each measurement. A standard curve was fitted using four 
parameter logistic regression and the BMP concentration in samples was imputed from this.    
.. BMP growth-factor domain ELISA for plasma & serum 
Like section .., except plates were coated with  µg/well of mAb to maximise 
sensitivity. Additionally, standards and samples were diluted to give final concentrations of 
 (v/v) plasma/serum, . (v/v) goat serum (Abcam ab), . (v/v) Triton-X and 
 (w/v) BSA in PBS. Where indicated, the PBS and BSA in this diluent was replaced with 
BioRad ELISA diluent (BUFA). Where indicated,  mM EDTA was added. BAF was 
diluted in PBS supplemented with  (w/v) BSA and . (v/v) goat serum. For quantifying 
endogenous BMP in mouse plasma, recombinant mouse BMP (R&D systems -BP) was 
used in the standard. 
.. BMP growth-factor domain ELISA for tissue 
Tissue was stored at - oC. Eppendorf tubes containing a stainless-steel bead (Qiagen 
) were weighed then, along with tweezers, razorblades and the benchtop, chilled with 
dry ice. Pieces of frozen tissue were cut with razorblades and transferred to the tubes, which 
were re-weighed. Tubes were transferred to chilled TissueLyser II racks (Qiagen) and  µl 
RIPA buffer ( mM tris-base pH ,  mM NaCl,  (v/v) igepal, . (v/v) deoxycholate, 
. (w/v) SDS) per mg of tissue was added. Tissue was homogenised by shaking at  Hz in 
a TissueLyser for ~ minutes for lung, or ~ minutes for liver, until there were no visible 
lumps. Homogenised samples were incubated at  oC with rotation for  hour, then freeze-
thawed. awed lysates were sonicated at an amplitude of  µm for  seconds on ice, then 
clarified by centrifugation at  g for  minutes at  oC. The ELISA was carried out as in 
section .. except tissue lysates were diluted to a final concentration of  or  (v/v) and 
the standard curve diluent was supplemented with  or  (v/v) RIPA buffer. 
.. pBMP ELISA 
Like section .. except BAF was replaced by anti-prodomain antibody (BAF). 
.. pBMP ELISA 
Like section .., except plasma/serum was diluted t a final concentration of  (v/v) and 
additionally supplemented with . mM EDTA. The antibodies were different—mAb for 
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capture and BAF for detection. e standard comprised of Pro:BMP purified by Dr. 
Aleksandra Lawera diluted to give concentrations spanning   pg/ml to  pg/ml. 
.. BMP growth-factor domain ELISA 
Like section .., except the antibodies were from a R&D Systems kit (DY). e 
capture antibody was diluted : and the detection antibody was diluted :. 
.. Column fractions ELISA 
Column fractions were spiked with  µl concentrated supplements to give final volumes of  
µl sample, . (v/v) goat serum, . (v/v) triton-x, and  mM EDTA per well. 
Otherwise, ELISAs were carried out as in section .. for BMP and .. for pBMP.  
 
. Western blotting 
.. Cell lysate preparation 
After media were aspirated, adherent cells were snap-frozen on dry ice. Cells were 
homogenised in  µl SDS lysis buffer ( mM Tris pH .,  glycerol,  SDS) 
supplemented with EDTA-free protease inhibitor cocktail (Roche). Homogenised samples 
were processed as in section ... I used a modified Lowry assay to quantify the amount of 
protein present in clarified lysates following the manufacturer’s instructions (BioRad DC- 
protein assay ). Since lysates were very concentrated, I diluted them  in  and 
assayed this in triplicate. Concentration was determined by colourimetry compared to a 
standard of bovine serum albumin (BSA) fitted with a four-parameter logistic regression.   
.. Gel electrophoresis and semi-dry transfer 
I made SDS-polyacrylamide gels by mixing the resolving gel reagents in table  (National 
Diagnostics Protogel reagents), pouring this mix between glass plates, flattening the top by 
pipetting on isopropanol and allowing to set for  minutes at room-temperature. After 
pouring off the isopropanol, I added the stacking gel mix, inserted a comb and allowed to set. 
Figure  was produced using WedgeWell gradient gels (Invitrogen XPOOBOX) to 
maximise sample volume and resolution of small proteins. 
 12 % resolving gel (15 ml) Stacking gel (7.5 ml) 
Protogel 6.0 ml 1.0 ml 
Gel buffer 3.9 ml 1.95 ml 
dH2O 4.94 ml 4.47 ml 
10% APS 150 l 75 l 
TEMED 15 l 8 l 
Table . SDS-PAGE gel recipe. 
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Samples were diluted : with SDS-loading buffer (. mM Tris-HCl, pH .,  
(w/v) SDS,  (v/v) glycerol and . (w/v) bromophenol blue). To reduce samples, the 
SDS-loading buffer additionally contained . (v/v) β-mercaptoethanol. Samples in buffer 
were heated at  oC for  minutes then centrifuged at  g for  minute. Gels were 
submerged in SDS-running buffer (Geneflow EC-) and denatured samples were loaded 
into wells. Page-ruler plus (ermo ) was used as a pre-stained ladder and spare wells 
were filled with diluted loading buffer. A potential difference of  V was applied to drive 
samples into the stacking gel, then proteins were separated by electrophoresis at  V.  
 PVDF membranes with . µm pores (GE healthcare -) were activated by 
submersion in methanol, then equilibrated along with filter paper in transfer buffer ( ml/l 
methanol,  g/l glycine,  g/l Tris-base, . (w/v) SDS). SDS was not included in the 
transfer buffer for blots in section .. to improve transfer of small proteins. e paper, gel 
and membrane were layered between electrodes, bubbles were removed with gentle pressure, 
and  mA was applied for ~. hours. Post-transfer, membranes were re-wet with methanol 
and transfer buffer prior to blocking.  
.. Probing 
Membranes were blocked with tris-buffered saline (TBS)(. g/l Tris-base,  g/l NaCl, pH 
.) with the supplements indicated in table  for  hour at room-temperature with rocking. 
Blocked membranes were probed as indicated overnight at  oC with rocking. Membranes 
were washed six times over an hour with TBS supplemented with . (v/v) Tween- 
(TBST). Horseradish-peroxidase (HRP) conjugated antibodies were used to probe blots for  
hour at room-temperature with rocking.  
Antibody  Block Dilution Species Target 
mAb3209 TBS with 5% (w/v) 
BSA 




TBS with 5% (w/v) 
BSA 
1:1000 Mouse BMP9 growth-factor domain 
(reduced) 
AF3 79 (R&D 
Systems) 
TBS with 5% (w/v) 
Marvel milk 
1:2500 Goat BMP9 prodomain (reduced & 
non-reduced) 
A5441 (Sigma) TBS with 5% (w/v) 
Marvel milk 
1:5000 Mouse β-actin 
P0447 (Dako) TBST with 5% (w/v) 
Marvel milk 
1:2000 Goat-HRP Mouse IgG 
ab 742 
(AbCam) 
TBST with 5% (w/v) 
Marvel milk 
1:2000 Rabbit-HRP Goat IgG 
Table . Western blot antibodies & conditions. 
 
 Membranes were again washed with TBST, and additionally washed twice with PBS. 
Membranes were coated in ECL reagent (GE healthcare), sealed in plastic film and exposed 
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to chemiluminescence film (GE healthcare Amersham hyperfilm) in a dark room. After 
varying amounts of time, films were developed by an automatic machine. Developed films 
were scanned into a computer. I used the ‘gels’ tool of ‘FIJI (is just image J)’ to measure the 
intensity of bands, being careful to use films which were not saturated. 
 
. Quantitative real-time PCR 
.. Human aortic endothelial cell culture 
Human aortic endothelial cells (AECs)(Lonza) were grown in endothelial growth medium 
(EGM)(Lonza CC-) supplemented with  (v/v) FBS. AECs between passages  and  
were seeded at   cells/well into -well plates and grown to confluence. Prior to 
treatment, they were washed for  hour in endothelial cell basal medium (EBM)(Lonza CC-
) supplemented with . (v/v) FBS, then quiesced in this medium overnight. In the 
morning, media was refreshed to give . ml/well. EDTA-plasma samples were thawed on ice, 
and the indicated volumes were swirled into each well and incubated for  hour. 
.. Human pulmonary artery endothelial cell culture 
Human pulmonary artery endothelial cells (PAECs)(Lonza) were grown in EGM. PAECs 
between passages  and  were seeded, quiesced and treated as in section ...  
.. Human microvascular endothelial cell culture 
Human microvascular endothelial cells (HMEC)(LGC standards)(Ades et al. ) were 
grown in MDCB- media (Gibco ) supplemented with  (v/v) FBS,  mM L-
Glutamine (Invitrogen -),  mg/ml hydrocortisone (Sigma HO),  ng/ml 
endothelial growth factor (Sigma E) and antimicrobials. hMECs were seeded, quiesced 
and treated as in section .., except MDCB- media was used to quiesce cells.  
.. Blood outgrowth endothelial cell culture 
Human blood outgrowth endothelial cells (BOECs) were grown in grown in EGM without 
heparin supplemented with  FBS (Ormiston, Toshner, et al. ). BOECs were seeded 
and quiesced as in section ... Serial dilutions of HEK-EBNA cell conditioned media were 
prepared in . ml of prewarmed EBM supplemented with . (v/v) FBS, and cells were 
treated with this mix for  hours. 
.. RNA extraction & cDNA preparation 
After treatment, media were aspirated and cells were lysed with  µl RLT buffer 
supplemented with  (v/v) β-mercaptoethanol. RNA was extracted using an RNeasy kit 
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according to the manufacturer’s instructions (Qiagen ). An on-column DNA digestion 
was carried out according to the manufacturer’s instructions (Qiagen ). e quality and 
concentration of RNA was assessed by NanoDrop.  
 For tissues, flushed samples were dissected out of mice and snap frozen. Tissue was 
stored at - oC. Eppendorf tubes containing a stainless-steel bead, tweezers, razorblades and 
the benchtop were chilled with dry ice. Pieces of frozen tissue ( lung lobe, or ~ mm of 
liver) were cut with razorblades and transferred to the tubes. Tubes were placed in chilled 
TissueLyser racks and  ml of Trizol reagent (Gibco ) was added to each. Tissue was 
homogenised by shaking at  Hz for ~ minutes for lung and ~  minutes for liver until 
there were no visible lumps. Homogenised samples were freeze-thawed. Lysates were 
transferred to phase-lock tubes (prime ) and left to reach room-temperature for  
minutes. en  µl of chloroform was added to each tube and they were shaken until an 
emulsion formed. Tubes were centrifuged at  g for  minutes at  oC and the aqueous 
layer was transferred to a fresh tube. To precipitate RNA,  µl of cold isopropanol was 
added and tubes were incubated at - oC for  minutes, followed by centrifugation at  
g for  minutes at  oC. e pellet was washed with  (v/v) ethanol in water by vortexing 
followed by centrifugation at  g for  minutes at  oC. RNA was dissolved in RNase-free 
water by trituration and incubation at  oC. e concentration and quality of RNA was 
assessed by NanoDrop: samples were re-extracted if the ratio of absorbances at  nm and 
 nm was not ~. Secondly, RNA was assessed by gel electrophoresis, using  (w/v) 
agarose gels in TBE buffer (BioRad -) stained with . (v/v) GelRed. Samples were 
re-extracted if two clean bands corresponding to rRNA were not visible. 
 A high capacity reverse-transcriptase kit (ermo ) was used to produce 
cDNA with random primers from  µg of RNA per sample according to the manufacturer’s 
instructions. Both RNA and cDNA were stored at - oC.  
.. qPCR 
Quantitative real-time polymerase chain reaction analysis was carried out in -well plates 
(Applied Biosystems). Two µl/well of a  in  dilution of cDNA was added. Additionally, . 
µl ROX reference dye (Invitrogen ),  µl SYBR green jumpstart Taq polymerase ready 
mix (Merck), forward and reverse primers each to a final concentration of  nM (table ), 
and water to a final volume of  µl was mixed into each well.   
e cycling profile of the PCR reaction was  oC for  minutes, followed by  cycles 
of  oC for  seconds,  oC for  seconds and  oC for  seconds. e reaction was 
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carried out in a QuantStudio system (Applied Biosystems) which determined cycle threshold 
(Ct) values for each well automatically. Each sample was measured in triplicate wells. Any Ct 
values ≥ those obtained from water in the absence of cDNA were discarded. e mean of 
triplicate Ct values was calculated. Where multiple housekeeping genes were measured, the 
geometric mean of all Ct values was used so all had equal weight. Gene expression was 
normalised to the housekeeping genes and presented as relative fold change compared to a 
control (as indicated) using the  Ct method (Livak and Schmittgen ). 
 
Gene Primer Sequences Source 
Human B2M Proprietary Cat.№ QT00088935 Qiagen 
Human ID1 For: 5’- CGAAGTTGGAACCCCGGGG-3’ Rev: 5’- CAGGAACGCATGCCGCCTCG-3’ Sigma 
Human ID2 For: 5’- GACCCGATGAGCCTGCTATAC-3’ Rev: 5’- GGTGCTGCAGGATTTCCATCT-3’ Sigma 
Human HEY1 For: 5’- GGCTCTAGGTTCCATGTCCC-3’ Rev: 5’- AGCAGATCCCTGCTTCTCAA-3’ Sigma 
Human HEY2 For: 5’- GCCATACAGATGCCGACAGA-3’ Rev: 5’- CAGTTACCGAGCTGCCTTGA-3’ Sigma 
Human BMPR2 For: 5’- CAAATCTGTGAGCCCAACAGTCAA-3’ Rev: 5’- GAGGAAGAATAATCTGGATAAGGACCAAT-3’ Sigma 
Human SMAD9 For: 5’- TACTGTCGCGTGTGGCGCTG-3’ Rev: 5’- AGCACAGGAGGCAGTACTGGAG-3’ Sigma 
Human SMAD9 vA For: 5’- CACCCCTGCCTTATCATGCCAC-3’ Rev: 5’- AGTAGGCGACCGAGCACCAGT-3’ Sigma 
Mouse B2M For: 5’- GTATACTCACGCCACCCACC-3’ Rev: 5’- TGGGGGTGAATTCAGTGTGAG-3’ Sigma 
Mouse Id1 For: 5’- GCTCACTTTGCGGTTCTGG-3’ Rev: 5’- ACGACATGAACGGCTGCTACT-3’ Sigma 
Mouse Id2 For: 5’- CGATAGTGGGATGCGAGTCC-3’ Rev: 5’- CCTGCAGCACGTCATCGAT-3’ Sigma 
Mouse Hprt For: 5’- CTTCCTCCTCAGACCGCTTT-3’ Rev: 5’- ATCGCTAATCACGACGCTGG-3’ Sigma 
Mouse Actb For: 5’- GGGAAATCGTGCGTGACAT-3’ Rev: 5’- GTGATGACCTGGCCGTCAG-3’ Sigma 
Mouse Pck1 For: 5’-TTGAACTGACAGACTCGCCC-3’ Rev: 5’- GGCACTTGATGAACTCCCCA-3’ Sigma 
Mouse Fasn For: 5’-GGCCCCTCTGTTAATTGGCT-3’ Rev: 5’-GGATCTCAGGGTTGGGGTTG-3’ Sigma 
Mouse Srebf1 For: 5’-CTTTTCCTTAACGTGGGCCT-3’ Rev: 5’-TCAAAACCGCTGTGTCCAGT-3’ Sigma 
Mouse Me1 For: 5’-GGACCCGCATCTCAACAAGG-3’ Rev: 5’-CAGGGCGGCAACAATCCAT-3’ Sigma 
Mouse Cola For: 5’-CGATGGATTCCCGTTCGAGT-3’ Rev: 5’-CATTAGGCGCAGGAAGGTCA-3’ Sigma 
Table . qPCR primers. Dr Paul Upton designed all primers except mouse Id  and Id , 
and tested all primers except Pck , Fasn, Srebp , Me  and Cola, which I tested. SMAD  has 
two splice variants, with the first primer detecting both, and the second only variant a. 
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Prior to analysing experimental samples, primers were tested using serially diluted 
control cDNA. The primer efficiencies were automatically calculated, with - deemed 
acceptable. e slopes of amplification curves, and the melt curves were also inspected, with 
steep curves and a single peak respectively, required. 
 
. Deglycosylation of BMP 
To deglycosylate BMP I mixed  µl of PNGase F (New England biolabs p), a volume 
HEK-EBNA cell conditioned media containing  ng of BMP according to ELISA,  µl 
glycobuffer-, and water to a total volume of  µl. is was incubated for  hours at  oC. I 
denatured a second set of samples by mixing them with glyco-denaturing buffer and heating 
at  oC for  minutes. ese were deglycosylated as before, except  µl of  (v/v) NP- 
was present in the mix, and the reaction only took  hour.  
 
. Luciferase-based ALK signalling assay 
Variations of this assay are published (Wooderchak-Donahue et al. ; Wei et al. ). 
.. Plasmids 
Plasmid containing a palindromic SMAD/ binding element that drives firefly luciferase 
expression (pBRE:Luciferase) was courtesy of Prof. Peter ten Dijke (pGL-(BRE)-luciferase 
from Korchynskyi and ten Dijke ). Plasmid constitutively expressing human ALK 
(pcDNA-ALK) was courtesy of Prof. Richard Trembath. Plasmid containing thymidine 
kinase promoter driven sea pansy luciferase (pTK:Renilla) was from Promega (E). 
Plasmids were expanded in bacteria as in section ... I used a Hi-Pure maxiprep kit to 
purify plasmid, using high-speed centrifugation, according to the manufacturer’s instructions 
(Invitrogen K). I checked the quality and concentration of DNA by NanoDrop. 
.. Cell culture 
Mouse myoblast CC cells were grown in DMEM supplemented with  (v/v) FBS and 
antimicrobials. To prevent differentiation, cells were passaged before reaching confluence. 
Cells were seeded at   cells/well in -well plates and grown overnight. Transfections 
were performed as in section .. using  ng of pTK:Renilla,  ng of pBRE:Luciferase, 
and  ng of pcDNA-ALK. Cells were returned to growth medium overnight. Transfected 
cells were washed in serum-free DMEM for  hour, then incubated in fresh DMEM overnight. 
Quiescent cells were treated with a  µl mix of DMEM and HEK-EBNA cell conditioned 
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media for six hours. Each treatment was performed in triplicate (in addition to three 
biological repeats performed on separate days).  
.. Luciferase activity measurement 
I measured luciferase activity using a modified version of Promega’s DualGlo system (E). 
Treatment solutions were replaced with  µl/well of a : mix of luciferase reagent and 
DMEM. After  minutes, this was transferred to a white -well white plate and firefly 
luciferase activity was measured in a luminometer (Promega GloMax multi+) with a  second 
integration time. To measure Renilla luciferase,  µl/well of Stop&Glo reagent was added 
and luminescence was remeasured. Firefly luciferase activity was normalised by Renilla 
luciferase. e mean of each triplicate was calculated. Normalised means were linearly 
transformed so, for each plate,  pg/ml of wildtype Pro:BMP had  activity and DMEM 
had  activity. 
 
. Caspase / Glo apoptosis assay 
PAECs were grown as in section .. and seeded at   cells/well into -well plates. 
Once confluent, cells were washed with EBM supplemented with . (v/v) FBS, and 
quiesced in  µl/well of this overnight. Treatment wells were additionally supplemented 
with HEK-EBNA cell conditioned media. e following morning, CaspaseGlo reagent 
(Promega G) was equilibrated to room-temperature, then  µl was spiked into each 
well. e plate was incubated for  minutes at room-temperature with shaking, then the 
contents were transferred to a white -well plate and measured in a luminometer with a . 
second integration time. Luminescence was brightest ~ minutes after lysis.  
 
. Annexin-V flow cytometry 
.. Apoptosis induction 
BOECs were seeded and grown as in section ... Once confluent, they were quiesced in  
ml of EBM supplemented with  (v/v) FBS overnight. Additionally, treatment wells were 
supplemented with HEK-EBNA cell conditioned media. e next morning, cycloheximide 
(Sigma C-G) was dissolved to  mg/ml in EBM by vortexing, and tumour necrosis 
factor (TNFα)(R&D systems -TA) was thawed on ice. Concentrated mixes of both were 
prepared, and wells of cells were spiked with  µl so they were exposed to a final 
concentration of  µg/ml cycloheximide and  ng/ml TNFα.  
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.. Staining & measurement 
After ~. hours, when cell morphology began changing but they were still adherent, cells 
were briefly washed with PBS, trypsinised and suspended in ice-cold PBS. Cells were stained 
with the Annexin-V / propidium iodide (PI) apoptosis detection kit (BD biosciences ) 
according to the manufacturer’s instructions. Unstained and singly stained cells were prepared 
to facilitate compensation against overlap in the emissions of each dye. Staining of at least 
 cells/treatment was measured with an accuri flow-cytometer (BD biosciences) using 
filter  to measure PI and filter  to measure FITC.  
.. Data analysis 
Data were exported to FlowJo (version ) and channels were compensated using the wizard 
tool. Samples were gated based on forward and side-scatter such that debris were excluded, 
but both healthy and apoptotic cells were captured. I applied the same gate to all samples and 
checked it was appropriate for each. Staining intensity plots were gated such that no 
unstained cells, and very few cells not exposed to TNFα, were annexin V or PI positive. I 
applied the same gate to all samples and noted the proportion of cells in each quadrant. 
 
. BRE-HMEC activity measurements 
Dr. Paul Upton generated a HMEC line stably expressing the BRE:luciferase vector by 
transfecting cells with linearized pGL-(BRE)-luciferase and pSelect-puro (Invivogen) 
followed by selection with puromycin for  days. Transduced cells were grown as in section 
... ese were seeded into -well plates at  cells/well and grown until confluent. 
Cells were quiesced in MCDB- medium overnight. In the morning, cells were placed in 
 µl/well fresh MCDB-. is was supplemented with plasma or other treatments where 
indicated. After  hours,  µl/well ONE-Glo was added (Promega E). Well contents 
were transferred to a white -well white plate and luminescence was measured with a . 
second integration time. 
 
. Immunoprecipitations 
.. Immunoprecipitation with anti-BMP for Western blotting 
Protein-G conjugated sepharose beads (Sigma P) were washed thrice by resuspending in 
PBS supplemented with  (w/v) BSA and centrifugation at  g for  minutes, using 
wide-bore pipette tips to reduce loss. One ml plasma samples were precleared of endogenous 
antibodies by incubating them with  µl of washed beads for  hour at  oC with rotation.  
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 Two µg of either human ALK-Fc conjugate, mAb or AF were incubated 
with  µl of washed beads for  hour at  oC with rotation. Coated beads were again washed 
thrice. Samples were cleared by centrifugation at  g for  min and transferred to the 
coated beads. is mix was incubated overnight at  oC with rotation. Beads were pelleted 
and washed thrice with ice-cold PBS. Beads were heated at  oC in reducing SDS-loading 
buffer for  minutes to elute BMP.   
.. Immunoprecipitation with anti-BMP/ for ELISA & activity 
Fifteen µl of protein-G conjugated metal beads (ermo D) were washed thrice by 
resuspending in PBS followed by magnetic separation. Beads were incubated with . µg of 
mAb (anti-BMP),  µg Ab-C (non-specific IgG),  µg mAb (anti-BMP) or 
AF (anti-BMP-prodomain) for  minutes at room-temperature with rotation. Beads 
were again washed thrice and added to  µl plasma samples. Samples were incubated for  
minutes (BMP) or overnight (BMP) at room-temperature with rotating, then samples were 
cleared by magnetic separation.  
.. Immunoprecipitation with ALK-Fc 
Like section .., except mAb was replaced with  µg ALK-Fc (R&D systems -
AL). For Western blotting, amounts were scaled up to use  ml of plasma and protein was 
eluted from the beads as in section ... To covalently link ALK-Fc to beads, they were 
incubated with  mM or  mM of BS reagent (ermo ) for  minutes at room-
temperature, then the reaction was quenched with . M tris-HCl (Sigma T), and beads 
were washed thrice. For Coomassie staining gels washed thrice in water, incubated with  
ml SimplyBlue (Invitrogen LC) for  hour at room-temperature with rocking, then  
ml water for  hour, then  (w/v) NaCl in water overnight. Gels were briefly washed in 
water, sandwiched in plastic and scanned. 
 
. Size exclusion chromatography 
.. Evans blue 
For determining whether Evans blue was bound to albumin,  g of sephadex G- powder 
(Sigma) was added to  ml of boiling water and left to cool overnight. e beads were 
poured into a  cm column (GE healthcare C /) and left to settle under gravity. Evans 
blue treatment solutions were prepared as in section .., and  µl was added to the top of 
the gel bed. Sequentially,  µl volumes of PBS were added to the top of the column, and 
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 µl fractions were collected from the bottom, as it flowed through under gravity. e 
absorbance of  µl aliquots of each fraction was measured at  nm in a plate reader. 
 
.. Plasma & serum  
Sephacryl S- gel beads in  ethanol (GE healthcare --) were sedimented by 
gravity and the liquid was poured off. e beads were resuspended in two volumes of water 
supplemented with . (v/v) tween-. is was repeated to produce a final volume of 
beads plus . tween that was approximately twice the volume of settled beads. is was 
gently stirred to produce a homogenous slurry, which was poured into a  cm column (GE 
healthcare C /) that was fitted with a packing reservoir (GE healthcare --) at 
the top. A plumb line was used to ensure the column was vertical. 
 A peristaltic pump (Gilson miniplus ) was attached and ~ ml/min (speed .) water 
supplemented with . (v/v) tween- was pumped through the column until the gel bed 
stabilised. e packing reservoir was removed, and the column was equilibrated with  ml 
of running buffer at . ml/min (speed .). Running buffer comprised PBS without calcium 
or magnesium supplemented with  mM EDTA, or PBS with . mM calcium and . mM 
magnesium (Sigma D) as indicated. When not in use, the column was stored in  
(v/v) ethanol. Every five uses, the column was washed with  ml of . M NaOH. 
 Samples were prepared by mixing . ml of EDTA-plasma, serum or running buffer 
with coloured markers— µl dextran blue (stock  mg/ml),  µl equine myoglobin (stock 
 mg/ml),  µl vitamin B (stock . mg/ml) and  µl phenol red (stock  mg/ml)—and 
recombinant BMP ( ng) and Pro:BMP ( ng) as indicated. Samples were centrifuged 
at  g for  minutes at  oC to sediment particles. Samples were taken into a  ml 
syringe fitted with column tubing. e pump was disconnected and the syringe tubing was 
threaded through the column lid so sample could be gently expelled under the running buffer 
at the surface of the gel bed. e pump was then reconnected and running buffer was applied 
at ~. ml/minute (speed .). 
 When the blue dye front reached the end of the column, -drop (~. ml) fractions 
were collected by an automated collector (BioRad model ). At this time during the first 
run, the positions of all the markers was labelled on the column, so fraction collecting could 
begin at a similar point in subsequent runs. e intensity of marker in each fraction was 




. Furin treatment of serum 
Serum was incubated overnight at  oC with  U/ml furin (NEB P). e reaction was 
quenched by adding EDTA to a final concentration of  mM. As a negative control, serum 
supplemented with  mM EDTA was incubated in parallel. Samples were stored at - oC. For 
a positive control, fluorometric furin substrate (Calbiochem ) was reconstituted to  
mg/ml in water. Serum samples prepared as previously were supplemented with  µM 
substrate and protected from light during incubation. Periodically,  µl samples, were 
withdrawn, diluted to  µl with water, put in a -well black plate and fluorescence was 
measured with a plate reader (PerkinElmer victor) using  nm excitation and  nm 
emission wavelength filters.     
 
. Ex vivo culture of mouse organs 
C/BL mice were killed by CO inhalation. Organs were dissected, chopped into ~ mm 
pieces and placed in ice-cold PBS. ese were transferred into -well plates with  µl/well 
DMEM supplemented with antimicrobials. Additionally, this was supplemented with  ng/ml 
recombinant BMP,  (v/v) FBS or  µg/ml LPS (Enzo ALX--) as indicated. Plates 
were incubated in a cell culture incubator. Periodically,  µl samples of conditioned media 
were taken, centrifuged at  g for  minutes at  oC to clear debris, and stored at - oC.   
 
. Gdf knockout mouse phenotyping 
Gdf knockout mice were c-terminal deletants on a C/BL/J background, courtesy of Prof. 
Se-Jin Lee (unpublished). Mice had access to food and water ad libertum. I genotyped mice 
using a protocol from Dr. Claudia Mitrofan. I confirmed genotyping via ELISA measurement 
of plasma BMP levels or qPCR of hepatic Gdf transcripts. Gdf knockout, heterozygous and 
wildtype littermates of both sexes aged - months are being collected. Blood from live mice 
was placed in EDTA-tubes as in section ... Blood cell counts and morphology was 
measured using a Wooley ABC (mouse) analyser. Mice were killed by injecting sodium 
pentobarbital and exsanguinated via the inferior vena cava. To collect serum, blood was 
placed in Eppendorf tubes, clotted for  minutes at room-temperature and centrifuged at 
 g. Serum was analysed by Adenbrooke’s Core Biochemical Assay Laboratory.  
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. Pharmacokinetic studies 
.. Pro:BMP administration 
Wildtypes were male C/BL mice purchased from Charles River and used at ~ weeks old. 
Gdf knockout mice were males aged ~ weeks. Mice were weighed at the start of the 
experiment. To make intravenous injection and saphenous vein bleeding easier, mice were 
warmed in a  oC chamber for  minutes prior to either.  
Dr. Aleksandra Lawera purified human Pro:BMP at a total protein concentration of 
 ng/µl. One µl aliquots were placed into siliconized Eppendorf tubes (Fisher ). 
Separate aliquots of vehicle—PBS supplemented with . (w/v) mouse serum albumin 
(Sigma A) filtered through a . µm filter—were prepared and both were stored at - 
oC. On the day of administration, I thawed each on ice and added  µl vehicle to the 
Pro:BMP. For Gdf knockout mice, Pro:BMP was administered at this concentration (. 
ng/µl), but for wildtype mice, I transferred this solution serially through  more tubes to 
reach a concentration of . ng/µl. I drew  µl of these solutions per gram of bodyweight into 
a  ml syringe and Stephen Moore administered them by tail-vein injection.  
.. Tissue collection 
Dr. Alexi Crosby withdrew  µl of blood by pricking the saphenous vein and collected it 
into EDTA-tubes (Microvette CB  KE). Mice were killed by pentobarbitone injection, and 
Stephen Moore collected blood into EDTA-tubes by cardiac puncture. I centrifuged EDTA-
tubes at  g for  minutes at  oC, aliquoted plasma and stored it at -oC. I exposed and 
snipped the inferior vena cava, and flushed the circulation by injecting ~ ml of  U/ml 
heparin in PBS through the right ventricle. I dissected organs, snap froze them and stored at -
 oC. For Gdf knockout mice, I left the right lung in place and tied of the right trachea. I 
then inflated the left lung to twice its collapsed size with  formalin (Cellstore pot BAF-
-A) by intratracheal injection, tied it to maintain its volume, and placed it in  
formalin for  hours. I transferred fixed lung to  (v/v) ethanol in water and sent them for 
processing into paraffin blocks (Pathology department, Addenbrooke’s Hospital). 
. Evans blue 
.. Preparation of Evans blue & LPS solutions 
Several serotypes of LPS were trialled: E. coli O:B (B)(Sigma L), E. coli O:B (B) 
(Enzo ALX--) and E. coli O:B (B)(Sigma L). ese were diluted to  mg/ml. 
Doses, timings and routes of administration are indicated. For intranasal administration, 
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Stephen Moore and I lightly anesthetised mice with isoflurane, held them upright and put 
LPS solution on their nostrils with a pipette. PBS (Sigma D) was supplemented with  
or . (w/v) Evans blue dye (Sigma E) with or without  (w/v) low-endotoxin bovine 
serum albumin (Sigma A) as indicated. e solution was passed through a . µm filter 
and stored at - oC. Stephen Moore administered  µl of Evans blue solution per gram of 
mouse bodyweight (~ mg/kg) intravenously or intraperitoneally as indicated. 
.. Extraction & quantification of Evans blue 
One hour after Evans blue administration, mice were killed by sodium pentobarbital 
injection. e inferior vena cava was snipped and ~ ml of heparinised saline was flushed via 
the right ventricle. Tissues were dissected and snap frozen. Pieces of lungs were weighed, 
finely diced with a razor blade and added to  µl formamide (Sigma ) per milligram of 
tissue. is was incubated overnight at  oC with shaking. Samples were centrifuged at 
 g for  minutes to clarify the supernatant, and  µl was transferred to a clear -
well plate. Absorbance was measured in a plate reader at the indicated absorbance (due to 
equipment breakdowns, different readers and absorbance wavelengths were used between 
experiments as indicated). 
 
. Ethics & human samples 
All animal studies followed University of Cambridge guidelines and the Animal Scientific 
Procedures Act as amended . All regulated procedures were approved under project 
licences / and /. Human patient plasma samples were from the National 
Cohort of Idiopathic and Heritable PAH (NCT) approved by the ethics review 
committee (/EE/). Control comparisons for these are previously published (Rhodes et 
al. ). Vascular gradient samples were collected for the Royal Papworth Hospital Tissue 
Bank. Plasma and serum for characterising ELISAs and circulating species of BMP and 
BMP were from volunteers in the Morrell group. 
 
. Statistics 
Except where indicated, statistical analyses were carried out using GraphPad Prism . 
Experiments comprising multiple groups were analysed with one-way ANOVAs. Dose 
responses of ≤  doses, or experiments comprising multiple variables e.g. sex and genotype, 
were analysed with two-way ANOVAs. Where only two factors were compared (indicated in 
the text), Student’s t-tests were used. Where dose responses of > doses were carried out e.g. 
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ELISA recovery testing, ECs were calculated using Prism’s normalised log(dose)-response 
function. Matched analyses were used for assays performed in batches e.g. comparison of 
BMP variants generated in vitro, or when samples from the same source were exposed to 
treatments e.g. plasmas treated with IgG versus anti-BMP. Unmatched analyses were used for 
assays performed on samples from different sources and measured simultaneously e.g. control 
versus patient ELISAs. Significant differences between columns, as indicated in figures, were 
calculated by post-hoc testing. For two-way ANOVAs, Bonferroni testing was used. For one-
way ANOVAs, comparisons to a control column (e.g. variant BMP versus wildtype BMP) 
were made with Dunnett’s tests, whilst comparisons between other columns were made with 
Bonferroni tests. 
ere were insufficient data to assess for normality. Nonetheless, in the first instance 
data were analysed with the tests described above, since these are relatively robust against 
deviations from normality and maximise statistical power. Non-parametric tests are less 
robust to deviations from unideal distributions and give lower power. However, to affirm 
conclusions drawn in section  and ., one-way matched analyses were repeated with 
Friedman tests followed by Dunn’s post-hoc analyses. On the advice of Dr. James Liley, two-
way analyses were repeated using stratified Van Elteren tests using R. Secondly, the results 
were confirmed by simulation using R. Briefly, data from each experiment were randomly 
redistributed between conditions multiple times. e rate at which the data produced 
differences as extreme as those observed was calculated. Each of these tests gave results 
consistent with the parametric tests at a significance level of .. Reanalyses were not 
undertaken for other sections, since either there were sufficient data to suggest data were not 
highly non-normal by eye, or data were used for optimisations and observational discussion 
where statistical inferences did not determine conclusions.  
  
Results 
. e impact of GDF mutations on BMP proteins 
.. Introduction 
A large majority of heritable PAH and a minority of idiopathic PAH is associated with 
mutations in genes encoding components of the BMPR-II signalling complex (Ma and Chung 
; Miyazono, Kamiya, and Morikawa ; Machado et al. ). Excepting BMPR, 
these genes are also associated with HHT (Vorselaars et al. ; Faughnan, Granton, and 
Young ). e known cognate ligands for this receptor complex are BMP and BMP.  
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e National Institutes of Health Research bio-resource for rare-diseases (NIHR-
BRIDGE) study, a pilot study for Genomics England, recruited patients diagnosed with several 
rare diseases, including PAH, for whole-genome sequencing. Stefan Gräf’s group was 
responsible for genetic analysis of these patients, as briefly described here. After quality 
control,  whole genome sequences from unrelated people diagnosed with type . PAH 
were compared to  from unrelated control patients with other rare diseases. Since this is 
a relatively small sample, a rare-variant analysis was undertaken to find highly deleterious 
causal variants associated with PAH (Gräf et al. ). Qualifying variants were in protein 
coding sequences, had a minor allele frequency of < in  , a combined annotation 
dependent depletion (CADD)(Rentzsch et al. ) score > , and were predicted to be 
deleterious/damaging by either SIFT (Vaser et al. ) or PolyPhen (Adzhubei et al. ).  
Several versions of burden analysis show that GDF is associated with PAH with 
genome-wide significance. Unusually, most of the PAH associated variants in GDF are 
missense-mutations, and so their functional effect is difficult to predict without further 
analyses (table ). Moreover, SIFT and PolyPhen predictions do not take context into 
account, and CADD scores depend on the quality of annotation, so these in silico predictors of 
deleteriousness require validation. erefore, we undertook to express and analyse some of 
the BMP missense variants found in people in vitro. 
e Morrell group has an expression vector for PreProBMP in HEK-EBNA cells, which 
uses genes from the Epstein-Barr virus to stabilise the vector as an episome in the nucleus 
and a cytomegalovirus promoter to drive transcription. is produces conditioned media rich 
in Pro:BMP. HEK-EBNA cells can be grown in chemically defined media without serum 
which makes the conditioned media amenable to downstream analysis. Dr. Rick Salmon 
helped me carry out site-directed mutagenesis of the PreProBMP expression vector, transfect 
mutagenized vectors into HEK-EBNA cells, and collect conditioned media. Sixteen expression 
vectors were created in total—a mix of PreProBMP variant proteins expected to be 
pathogenic and benign (table  top).  
Putatively pathogenic variants were classified as such by the rare-variant analysis 
described above, except for BMP-YH. is variant, was sufficiently rare and predicted to 
disrupt protein structure by CADD, SIFT and PolyPhen scores, but a single allele was found in a 
paediatric case of primary immune deficiency which prevented statistical association with 
PAH. Nonetheless, residue  is found within the core of the growth factor domain 
interacting with distant residues, so Dr. Wei Li predicted the substitution would prevent 
proper folding. Moreover, the patient harbouring this variant had a family history of PAH 
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suggesting a genetic cause. erefore, BMP-YH was reclassified as putatively pathogenic. 
Putatively benign variants include some which were common in the population, not 
associated with PAH, and/or not predicted to disrupt protein structure.  
Each vector was transfected into three independent batches of HEK-EBNA cells, so all 
the following data is based on three separate measurements. Figure  shows the species of 
BMP that can result from expression of PreProBMP. 
 
 
Figure 7. Schematic of BMP9 species. PreProBMP9 missense variants were expressed in 
vitro. BMP9 dimerises and is processed during secretion, forming a non-covalent 
prodomain:growth-factor domain complex. This may be dissociated during Western blotting, 
or spontaneously dissociate when disrupted by deleterious variants. Reduction of the inter-
chain disulphide bond can occur spontaneously but the complex remains associated (Wei et 
al. 2014). The numbers are used to label bands on subsequent Western blots. Species (9) and 
(10) refer to BMP9-Q2 X expressed in section 3. .  
  
Table 10 (overleaf). Protein coding GDF2 variants found in the NIHR-BRIDGE study at a minor 
allele frequency <1/250. Top: variants assessed in vitro or measured in patient plasma 
samples. Bottom: other variants analysed in silico. HGVSc = human genome variation society 
sequence change; csq = consequence type; HGVSp = protein change (bold = acronym used 
herein); Freq = frequency in exome aggregation consortium database; CADD = combined 
annotation dependent depletion (includes sequence conservation, in silico predictions of 
disrupted protein structure, sequence DNAse hypersensitivity, transcription factor binding etc. 
Higher score = more deleterious); SIFT = sorting intolerant from tolerant (a score of 
deleteriousness based on empirical measurements of how well generic proteins tolerate one 
amino-acid being substituted for another); PolyPhen = polymorphism phenotyping version 2 
(similar to SIFT); Disease found in = which cohort of the NIHR-BRIDGE study the variants were 
found in (PAH = pulmonary arterial hypertension, a = Specialist pathology: evaluating exomes 
in diagnostics, b = Genomics England 100,000 genomes pilot study, c = primary immune 
disorders, d = bleeding and platelet disorders, e = hypertrophic cardiomyopathy, f = paediatric 
neurodevelopmental disorders, g = multiple primary malignant tumours, h = steroid resistant 
nephrotic syndrome, i = intrahepatic choliosis of pregnancy, j = stem cell and myeloid 
disorders, k = cerebral small vessel disease); Other genes = mutations in other genes which 
could be relevant in PAH that were found alongside the GDF2 variant reported in the PAH 
patient. The NIHR-BRIDGE study comprised of 1048 PAH patients, and 7979 genomes from 
other groups. Shading: lightest = lowest value, darkest = highest value. Note that 
classifications of benign and pathogenic are made with regard to PAH specifically. 
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c.244A>G missense p.Arg82Gly R82G +   9.07E-05 24.2 deleterious PossDam 2 0 0 3 0 0 0 0 0 0 0 0   
c.871G>A missense p.Gly291Ser G291S +  3.30E-05 0 tolerated Benign 1 0 2 0 0 1 0 0 0 0 0 0   
c.911C>T missense p.Thr304Met T304M +  1.61E-03 0.01 tolerated Benign 1 3 2 0 2 0 3 1 2 0 0 0   
c.997C>T missense p.Arg333Trp R333W +  1.65E-05 6.43 tolerated Benign 1 0 0 2 0 0 0 0 0 0 0 0   
c.53G>T missense p.Gly18Val G18V + + 0 18.5 tolerated Benign 1 0 0 0 0 0 0 0 0 0 0 0   
c.221G>A missense p.Gly74Glu G74E + + 2.72E-04 15.9 deleterious Benign 1 0 3 0 1 0 0 0 0 0 1 1   
c.311C>T missense p.Pro104Leu P104L + + 3.35E-05 28.8 deleterious Damaging 1 1 0 0 0 0 0 0 0 0 0 0   
c.352A>T missense p.Ile118Phe I118F + + 1.06E-03 0.01 tolerated Benign 2 0 0 0 0 0 0 0 1 1 0 0   
c.460G>A missense p.Val154Ile V154I + + 0 8.37 tolerated Benign 1 0 0 0 0 0 0 0 0 0 0 0   
c.652G>A missense p.Asp218Asn D218N + + 3.18E-03 24.4 deleterious Damaging 3 7 8 0 4 0 0 0 2 4 7 2   
c.889G>A missense p.Glu297Lys E297K + + 0 5.91 tolerated Benign 1 0 0 0 0 0 0 0 0 0 0 0   
c.905A>T missense p.Glu302Val E302V  + 0 5.97 tolerated PossDam 2 0 0 0 0 0 0 0 0 0 0 0   











 c.265A>G missense p.Met89Val M89V + + 0 24.8 deleterious Damaging 1 0 0 0 0 0 0 0 0 0 0 0 KLF2 
c.328C>T missense p.Arg110Trp R110W  + 0 35 deleterious Damaging 1 0 0 0 0 0 0 0 0 0 0 0   
c.427G>A missense p.Glu143Lys E143K  + 0 28 deleterious Damaging 1 0 0 0 0 0 0 0 0 0 0 0   
c.958A>T missense p.Ser320Cys S320C  + 0 23.3 deleterious Damaging 1 0 0 0 0 0 0 0 0 0 0 0   
c.1040C>T missense p.Ala347Val A347V + + 8.25E-06 23.9 deleterious Damaging 1 0 0 0 0 0 0 0 0 0 0 0   
c.1051T>C missense p.Tyr351His Y351H + + 0 23.8 deleterious Damaging 2 0 0 1 0 0 0 0 0 0 0 0 BMPR1a 
c.1238C>A missense p.Thr413Asn T413N + + 1.98E-05 26.3 deleterious Damaging 1 0 0 0 0 0 0 0 0 0 0 0   
  c.347-1G>A Splice acceptor/truncating +     23.6 NA NA 1 0 0 0 0 0 0 0 0 0 0 0 BMPR2 
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p.Ser14_Leu16dup 1.87E-04 NA NA NA 0 2 0 0 0 0 0 0 0 0 0 0 
 
c.52G>C missense p.Gly18Arg 0 13.9 tolerated PossDam 0 0 0 0 1 0 0 0 0 0 0 0  
c.69G>T missense p.Lys23Asn 2.01E-04 27.8 deleterious Damaging 0 1 0 0 0 0 0 0 0 0 0 0  
c.89G>C missense p.Arg30Pro 9.12E-06 11.5 deleterious PossDam 0 0 2 0 0 0 0 0 0 0 0 0  
c.89G>A missense p.Arg30Gln 4.56E-05 2.88 tolerated Benign 0 0 1 0 0 0 0 0 0 0 0 0  
c.314C>T missense p.Ala105Val 2.52E-05 20.3 tolerated PossDam 0 0 1 0 0 0 0 0 0 0 0 0  
c.338G>A missense p.Ser113Asn 3.51E-05 14.8 tolerated Benign 0 1 0 0 0 0 0 0 0 0 0 0  
c.378C>A missense p.Phe126Leu 5.19E-04 0.73 tolerated Benign 0 1 0 0 0 0 0 0 1 0 0 0  
c.432G>T missense p.Gln144His 0 9.93 tolerated Benign 0 0 0 1 0 0 0 0 0 0 0 0  
c.463T>A missense p.Ser155Thr 0 21.7 tolerated PossDam 0 0 0 1 0 0 0 0 0 0 0 0  
c.508G>A missense p.Val170Met 3.30E-05 2.41 tolerated Benign 1 0 0 0 0 0 0 0 1 0 0 0  
c.548A>G missense p.Asp183Gly 0 11.2 tolerated PossDam 0 0 0 0 1 0 0 0 0 0 0 0  
c.619G>T missense p.Val207Leu 4.95E-05 23.5 tolerated Damaging 0 2 1 0 0 0 0 0 0 0 0 0  
c.712G>A missense p.Asp238Asn 5.77E-05 11.4 tolerated Damaging 0 2 0 0 0 0 0 0 0 0 0 0  
c.740G>T missense p.Gly247Val 0 17.8 tolerated PossDam 0 0 1 0 1 0 0 0 0 0 0 0  
c.776A>G missense p.Asn259Ser 3.71E-04 23.8 deleterious Damaging 0 0 4 0 0 0 0 2 0 0 0 0  
c.806G>A missense p.Arg269Lys 8.24E-06 7.58 tolerated Benign 0 0 1 0 0 0 0 0 0 0 0 0  
c.833A>G missense p.His278Arg 0 13.7 deleterious Benign 0 1 0 0 0 0 0 0 0 0 0 0  
c.835G>T Nonsense p.Glu279Ter 0 37 NA NA 0 0 0 0 0 0 0 0 0 0 1 0  
c.847G>A missense p.Val283Met 5.77E-05 1.39 tolerated Benign 0 1 2 0 1 0 0 0 0 0 0 0  
c.884C>A missense p.Ala295Glu 0 0 tolerated Benign 0 1 0 0 0 0 0 0 0 0 0 0  
c.883G>T missense p.Ala295Ser 0 0.22 tolerated Benign 0 1 0 0 0 0 0 0 0 0 0 0  
c.917G>A missense p.Gly306Asp 9.08E-05 0.01 tolerated Benign 0 1 0 0 0 0 0 0 0 0 0 0  
c.950G>A missense p.Arg317Gln 4.95E-05 3.61 tolerated Benign 0 0 1 0 2 0 0 0 0 0 0 0  
c.961G>A missense p.Ala321Thr 9.08E-05 0.02 tolerated Benign 0 0 2 0 2 1 0 0 0 0 0 0  
c.1084T>C missense p.Phe362Leu 8.25E-06 22.7 deleterious Damaging 0 0 0 0 1 0 0 0 0 0 0 0  
c.1139T>C missense p.Val380Ala 1.49E-04 20.1 tolerated Benign 0 2 0 0 0 0 0 0 0 0 0 0  
 
.. Secretion defects of disease associated BMP variants 
Firstly, I measured the concentration of secreted BMP in conditioned media with an anti-
growth factor domain sandwich ELISA. e amount of secreted growth factor domain from 
putatively pathogenic variants was significantly lower than from putatively benign variants 
(figure ). A reduction of ELISA immunoreactivity could result from reduced expression, 
secretion, stability or detection efficiency of BMP-variants compared to BMP-WT. To 
address the latter, I measured different dilutions of conditioned media, and plotted the 
absorbance of these against their imputed concentrations to generate detection efficiency 






















































































































Figure 8. ELISA measurement of secreted BMP9 growth-factor domain in conditioned media. 
HEK-EBNA cells were transfected with expression vectors for PreProBMP9-WT or variants, 
and placed in serum-free, chemically defined media. Six days post transfection, conditioned 
media was collected. This was serially diluted in PBS and BMP9 concentration in dilutions was 
measured by ELISA. Dilutions which gave absorbances in the linear part of the standard curve 
were used to calculate BMP9 concentration in the media. Three independent batches of HEK-
EBNA cell media were assayed independently. Mean ± SEM, n = 3, one-way matched 




































Figure 9a. Efficiency curves for ELISA measurements of BMP9-vairants. After the 
concentration of BMP9 in conditioned media was calculated using dilutions in the linear part 
of the standard curve, concentration of BMP9 in all other dilutions was imputed from this and 
plotted against absorbance, compared to a recombinant BMP9 standard. This showed BMP9 
was equally efficiently recovered from all dilutions of media for all variants. n = number of 
points for variant before absorbance became too low to quantify. 
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Secreted BMP could not be detected by the ELISA in conditioned media from HEK-
EBNA cells transfected with PreProBMP-RW, EK, YH and TN. I transfected 
expression vectors for these variants and a wildtype control into fresh cells, and analysed 
lysates by western blotting. Within cells transfected with wildtype vector, there were 
appreciable quantities of unprocessed ProBMP (figure b). ere was also some processed 
BMP dimer within cells, which could indicate intracellular cleavage or retention of cleaved 
BMP at the cell surface. However, the same anti-BMP used in the ELISA could not detect 
the variant proteins. is could either be because they were misfolded or poorly expressed.  
 
Figure 9b. Western blotting of cell lysates for BMP9 growth-factor domain (non-reducing) of 
transfected cells. Three independent batches were assayed. One representative blot shown. 
№ = molecular weight (kDa), (№) = species identification from figure 7. 
 
 
Figure 10. Western blotting of cell lysates for BMP9 prodomain (top) and growth-factor 
domain (bottom, reducing) of transfected cells. Three independent batches were assayed. 




An alternative anti-BMP growth-factor domain antibody, which only works in 
reducing conditions, revealed equal expression of unprocessed ProBMP-WT and ProBMP-
RW, EK, YH and TN within cells (figure  bottom). However, there was 
evidence these variants were otherwise defective, since there was no detectable processed 
BMP in cell lysates. Results obtained with an anti-BMP prodomain antibody reinforced 
these findings: there were high levels of unprocessed ProBMP in lysates but, the levels of 
processed prodomain were reduced in cells transfected with PreProBMP-RW, EK, 
YH and TN compared to PreProBMP-WT (figure  top). 
 
Figure 11. Western blotting of conditioned media for BMP9 prodomain (top, non-reducing) 
and growth-factor domain (bottom, reducing) from transfected cells. Three independent 
batches were assayed. One representative blot shown. № = molecular weight (kDa), (№) = 




Figure 12 (overleaf). Western blotting of conditioned media for BMP9 prodomain, variants 
titrated against wildtype. Indicated amounts of BMP9-WT were loaded, calculated based on 
ELISA quantification of BMP9-WT concentration. Indicated volumes of conditioned media 
were loaded for BMP9 variants. Additionally, this process was repeated with an antibody 
against the growth-factor domain for BMP9-M89V. Three independent batches were assayed. 


















































Figure 13. Relative amount of BMP9 prodomain in conditioned media. The relative signal 
intensity of variant prodomain compared to WT prodomain in Western blots from figure 12. 
This can be used to calculate the concentration of BMP9 in these samples based on ELISA 
quantification of the BMP9-WT samples. Three independent batches were assayed. Mean ± 
SEM. 
 
Figure 14. Western blotting of conditioned media for BMP9 prodomain (non-reducing) from 
transfected cells. Indicated amounts of BMP9 growth-factor domain equivalent were loaded 
based on quantifications from figure 8. Three independent batches were assayed. One 




Figure 15. Western blotting of conditioned media for BMP9 growth-factor domain (non-
reducing) from transfected cells. Indicated amounts of BMP9 growth-factor domain were 
loaded based on quantifications from figure 8. Three independent batches were assayed. One 




I used these antibodies to probe western blots of conditioned media. (figure ). e 
large majority of secreted BMP-WT was in its processed, active form. In media, there were 
vastly reduced amounts of detectable BMP-RW, EK, YH and TN, compared to 
BMP-WT. Interestingly, the anti-BMP prodomain antibody revealed substantial amounts of 
free prodomain in conditioned media from cells transfected with these variants, despite the 
absence of growth-factor domain. I titrated variants with very impaired growth-factor 
secretion to calculate the concentration of secreted prodomain (figure ; ).  
I undertook similar western blots of conditioned media for all other ProBMP variants 
(figure ). Reassuringly, when loading volume was calculated from the ELISA results, the 
intensity of bands corresponding to the processed growth factor domain dimer was equal 
across all samples (figure ). e relative intensity of growth factor domain bands compared 
to prodomain bands was reduced in media containing putatively pathogenic variants (figure 
). is suggests the Pro:BMP complex was destabilised and the growth factor domain was 
lost. Structural analysis by Dr. Wei Li revealed many of the PAH-associated changes 
substitute amino-acids at the interface of the growth factor domain and prodomain which 
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Figure 16. Molar ratios of BMP9 growth factor domain : prodomain in conditioned media 
calculated by western blotting densitometry. The relative signal intensity of variant growth 
factor domain compared to wildtype growth factor domain was measured on Western blots. 
This was repeated for prodomain (example in figure 13). I assumed that there is a 1:1 ratio of 
growth-factor domain : prodomain in Pro:BMP9-WT, so the relative intensity of the growth-
factor domain divided by the relative intensity of the prodomain equals molar ratio. Three 
independent batches were assayed independently. † indicates that the relative intensity of 
growth-factor domain was too low to quantify accurately. Mean ± SEM, n = 3, one-way 
matched ANOVA/Dunnett’s testing of variants compared to WT, * p<0.05, ** p<0.01, *** 
p<0.001. 
 
e growth-factor domains from pathogenic variants could have been degraded 
within cells or have been secreted then degraded in the media. I undertook a time course of 
BMP-MV signalling on endothelial cells compared to BMP-WT to assess growth factor 
domain stability. Importantly, I collected, aliquoted and stored conditioned media at - oC 
66 
 
within an hour, minimising prior degradation. ere was no significant difference in the 

























































Figure 17. Timecourse of signalling by Pro:BMP9-WT and -M89V. Quiescent human aortic 
endothelial cells were treated with 50 pg/ml of Pro:BMP9-WT or -M89V for the indicated time. 
Expression of ID2 mRNA was measured by qPCR, normalised to the housekeeping gene B2M. 
Mean ± SEM, n = 4. 
 
Western blots showed prodomain-DN was bigger than prodomain-WT. is 
missense variant is not associated with PAH, and is fairly common—allele frequency in 
gnomAD browser = . (Karczewski et al. ). e new asparagine residue could be a 
substrate for N-linked glycosylation. I treated conditioned media containing Pro:BMP-WT 
and Pro:BMP-DN with PNGase-F, which cleaves the bond between Asparagine and almost 
all oligosaccharides, and analysed the products by Western blotting. Deglycosylation restored 
size-parity between prodomain-WT and -DN, confirming the difference was due to 
glycosylation (figure ). Deglycosylated wildtype prodomains are smaller than native 
wildtype prodomains since there are two other glycosylation sites. As expected, there was no 
evidence the growth-factor domain was glycosylated. Notably, Susan-Resiga et al. () 
show a very similar pattern for wildtype Pro:BMP. 
 
Figure 18. Deglycosylation of conditioned media containing Pro:BMP9-WT and Pro:BMP9-
D218N using PNGaseF. One set of samples were denatured and reduced prior to treatment as 
this improves deglycosylation efficiency for some substrates. Left: Western blot probing for 
prodomain. Right: Western blot probing for growth-factor domain. Note that the anti-growth-
factor domain antibody used here cannot detect reduced BMP9 and it cross-reacts with a 
component of the deglycosylation treatment mix, giving a ~30 kDa non-specific band. № = 




Some PAH associated ProBMP variants exhibited a processing defect. Most strikingly, 
there was a huge excess of uncleaved dimers, uncleaved monomers, and partially cleaved 
dimers in conditioned media containing ProBMP-SC compared to ProBMP-WT (figure 
; ). Within cell lysates, there was a similar distribution of WT and SC species, 
indicating a processing defect concurrent with secretion. Cleavage usually occurs between 
amino-acids / but furin-like proteases are reported to be intolerant of cysteine in this 
position (Tian )(see .). e novel cysteine may also form inappropriate disulphide 
bridges. ese factors could prevent the engagement of processing enzymes. In the aligned 
amino acid sequences of BMP in every model organism, this residue is a serine (figure ). 
 
Figure 19. Western blotting for BMP9-WT and BMP9-S320C prodomain. On the left-hand 
blots 30 µg of total protein, or 1 ng of growth-factor domain equivalent calculated by ELISA 
quantification of each sample, was loaded per well. On the right-hand blot, different volumes 
of conditioned media were loaded per well to give a similar band intensity for BMP9-WT and -
S320C. Three independent batches were assayed. One representative blot shown. № = 
molecular weight (kDa), (№) = species identification from figure 7. 
 
 
Figure 20. Western blotting for BMP9-WT and BMP9-S320C growth-factor domain. Three 
independent batches were assayed. One representative blot shown. № = molecular weight 







Figure 21 (overleaf). Amino-acid sequence alignments of BMP9 across vertebrates. I used 
NCBI’s protein basic local alignment sequence tool to search for similar amino acid 
sequences to human PreProBMP9 across all life. I selected sequences from common model 
organisms and used NCBI’s constraint based multiple alignment tool to produce the figure. 
Shading = column quality score (how well the properties of an amino acid agree with the other 
amino acids of the column). The top row shows variants found in the PAH cohort (table 5) 
superimposed on the reference sequence of human BMP9. Purple arrows = putatively 
pathogenic substitutions; grey arrows = putatively benign substitutions. Letters = standard 
amino acid abbreviation; Circle = amino acid is the same as the top row. Bar = positions not 
found in the sequence of that species. Box = Furin recognition sequence by furin cleavage 
site. Numbers = sequence position for that species at which alignment starts and ends. 
 
.. Activity defects of disease associated BMP variants 
A luciferase-based cell signalling assay has been developed to assess the ability of BMP to 
bind and activate ALK receptor complexes (figure )(Wei et al. ; Wooderchak-
Donahue et al. ). Mouse myoblast CC cells do not ordinarily expresses high-affinity 
receptors for BMP. However, I transfected them with vectors containing genes for hALK 
and BMP signalling dependent firefly luciferase. Activity can be normalised to account for 
transfection efficiency and cell number. I trialled normalisation plasmids encoding sea-pansy 
(Renilla) luciferase driven by the promoter of the housekeeping gene thymidine kinase (TK) or 
cytomegalovirus (CMV). e best sensitivity and least variability was obtained when cells were 
transfected with  ng of hALK-plasmid and the luminescence produced by firefly 
luciferase was normalised to the luminescence produced by TK:Renilla luciferase (figure ). 
Nonetheless, there was some variability between experiments, so I linearly transformed data 
such that transfected myoblasts in serum free media without BMP had a relative luciferase 
activity of , and cells exposed to  pg/ml of Pro:BMP-WT had a relative luciferase 
activity of . Transfected cells had a high-affinity BMP response that was strictly 
dependent on ALK signalling in the physiological range of - pg/ml (figure ). 
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Figure 23. Optimisation of the Dual-Glo ALK1 signalling assay. C2C12 mouse myoblast cells 
were transfected with BRE:luciferase(firefly). Simultaneously, cells were transfected with 100-
400 ng/well of plasmid expressing human-ALK1, or 100-400 ng/well of empty expression 
plasmid. Additionally, cells were transfected with plasmids expressing Renilla luciferase under 
the constitutively active promoters for Thymidine kinase (TK) or cytomegalovirus (CMV). 
Transfected cells were treated with 10-100 pg/ml of BMP9 and firefly and Renilla luciferase 
activity were measured. Mean ± SEM, n = 3. Data show that neither CMV nor TK promoter 
activity was specifically enhanced in the presence of ALK1 and BMP9. The best sensitivity to 
10 pg/ml of BMP9 was obtained by measuring the firefly luciferase activity of cells transfected 
with 400 ng/well of hALK1, normalised with TK:Renilla(luciferase).  
 































Figure 24. Dose response of the Dual-Glo ALK1 signalling assay. Quiescent transfected cells 
were treated with 10-100 pg/ml of BMP9 and normalised luciferase activity was measured. 
Mean ± SEM, n = 6. Data show that these cells have no high-affinity response to BMP9 in the 
absence of exogenous hALK1.  
 
I assessed the BMP activity of conditioned media from HEK-EBNA cells transfected 
with variant PreProBMP vectors. I treated cells with equal concentrations of processed 
growth factor domain to compare ligand activity independently of secretion or processing 
defects. is was based on ELISA quantifications of the amount of growth-factor domain in 
each sample. For variants which did not produce detectable amounts of processed growth-
factor domain, I based dilutions on the concentration of prodomain (figure ). I ruled out 
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non-specific activity by treating some cells with large volumes of conditioned media from 
HEK-EBNA cells transfected with empty vectors. 
Interestingly, all variants detectable by ELISA had ALK signalling potency equivalent 
BMP-WT (figure  top). I quantified the concentration of Pro:BMP-WT and -MV by 
either ELISA for the growth factor domain or western blotting for the prodomain. is 
showed Pro:BMP-MV growth-factor domain is fully active but is present at a lower level 
than the prodomain quantification would suggest. Similarly, there was almost no activity of 
BMP-RW, EK, YH and TN in conditioned media, confirming an absence of 
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** ** ** **
 
Figure 25. ALK1 signalling of BMP9 variants. Quiescent transfected cells were treated with 
conditioned media containing 10-100 pg/ml of BMP9-WT or variants. The relative activity of 
100 pg/ml of BMP9-WT was set at 100%, and serum-free media at 0%. Top: BMP9 dose was 
calculated based on the amount of growth-factor domain (GFD) measured by ELISA. Bottom: 
BMP9 dose was calculated by Western blotting densitometry of prodomains. Mean ± IQR, n = 
3, van Elteren test, ** p < 0.01, *p < 0.05. A two-way ANOVA/Bonferroni testing of variants 
compared to WT showed the same groups had significantly lower activity at p < 0.001. For 
pathogenic variants with no activity, EC50 could not be determined, whilst for all other variants, 




I assessed whether BMP variants were able to promote pulmonary artery endothelial 
cell (PAEC) survival as this is a crucial protective effect of BMP (Teichert-Kuliszewska et al. 
; Long et al. ). erefore, I established a protocol for measuring the anti-apoptotic 
effect of BMP on serum starved PAECs using Caspase-GLO reagent. Overnight incubation in 
basal media with . FBS significantly increased apoptosis, whilst - pg/ml of BMP 
































Figure 26. Dose response of BMP9 anti-apoptotic activity. Pulmonary arterial endothelial cells 
incubated in full media or starved in serum-free basal media supplemented with 0-5 ng/ml of 
BMP9 overnight. Caspase activity was measured in cell lysates with a luminescent substrate. 
Mean ± SEM, n = 2. 
 
Mock conditioned media from HEK-EBNA cells could exacerbate PAEC apoptosis 
when present at > v/v, overwhelming the protection offered by of BMP (figure ). 
erefore, I prepared subsequent experiments using mixes of conditioned media from HEK-
EBNA cells transfected with variant BMP expression vectors and empty vectors: all PAECs 
were exposed to  pg/ml of BMP in a total of  v/v conditioned media, or  pg/ml of 

















































Figure 27. Dose response of BMP9 anti-apoptotic activity on cells supplemented with HEK-
EBNA cell conditioned media. Cell free: media+Caspase-Glo reagent in a well without cells. 
Full media: pulmonary arterial endothelial cells left in full growth media. 0.1% FBS: apoptosis 
induced by overnight incubation in basal media supplemented with 0.1% (v/v) FBS. Empty 
vector: apoptosis induced by overnight incubation in basal media supplemented with 0.1% 
(v/v) FBS and 1-10% (v/v) conditioned media from HEK-EBNA cells transfected with an empty 
vector. BMP9: apoptosis could be rescued by adding 0.5-5 ng/ml of Pro:BMP9. Empty vector 
+ BMP9: apoptosis could no longer be rescued when conditioned media from HEK-EBNA cells 
transfected with the empty expression vector was added to a final concentration of 10% (v/v). 
Mean ± SEM, n = 3. 
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e anti-apoptotic activity of variant BMP proteins on PAECs closely mirrored 
signalling activity through ALK. Variants which were detectable by ELISA were able to 
inhibit apoptosis robustly, whereas variants which destabilised the growth factor domain had 
little anti-apoptotic activity (figure ). Again, Pro:BMP-MV was quantified by either its 
growth factor domain or prodomain. Assaying potency relative to each confirmed a loss of 




























































































































































































































Figure 28. Anti-apoptotic activity of BMP9 variants. Apoptosis was induced in human 
pulmonary arterial endothelial cells by overnight incubation in basal media supplemented with 
0.1% (v/v) FBS and conditioned media from HEK-EBNA cells containing Pro:BMP9-WT or 
variants. The treatments were also supplemented with conditioned media from HEK-EBNA 
cells transfected with an empty expression vector such that wells contained 1% (v/v) 
conditioned media + 0.5 ng/ml of BMP9, or 2% (v/v) conditioned media + 1 ng/ml of BMP9. 
Top: BMP9 dose was calculated based on the amount of growth-factor domain (GFD) 
measured by ELISA. Bottom: BMP9 dose was calculated by Western blotting densitometry. 
Mean ± IQR, n = 3, van Elteren test, ***p < 0.001, **p < 0.01, * p < 0.05. A two-way 
ANOVA/Bonferroni testing of variants compared to WT showed the same groups had 
significantly lower activity at p < 0.001. 
 
To validate the Caspase-Glo assays, I used flow cytometry. Phosphatidylserine is 
presented on the outer leaflet of plasma membranes to opsonise cells during the early stages 
of apoptosis (Verhoven, Schlegel, and Williamson ). is can be visualised by staining 
with FITC-conjugated annexin-V. Annexin-V could stain phosphatidylserine on the inner 
leaflet if membrane integrity is lost due to damage, necrosis or later in apoptosis. erefore, 
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propidium iodide was used as counterstain since it is membrane impermeant. e Morrell 
group has previously shown BMP is able to supress basal apoptosis in quiesced endothelial 
cells, but the signal is stronger when TNFα is used to induce higher rates of apoptosis via the 
JNK/SPAK pathway (Long et al. ). TNFα can also stimulate a pro-survival transcriptional 
response, therefore the translation inhibitor cycloheximide is also added to cells 
(Dhanasekaran and Reddy ; Franzoso, Zazzeroni, and Papa ). Flowcytometry 
requires large numbers of cells and PAECs are expensive and cannot be expanded hugely. 
erefore, I used blood outgrowth endothelial cells, which have very similar BMP responses 
to PAECs, as a surrogate cell (Ormiston, Toshner, et al. ).  
 
Figure 29. Gating strategy for flow cytometry measurement of blood outgrowth endothelial 
cell apoptosis. X-axis = Annexin V staining compensated for interference from other signals. 
Y-axis = propidium iodide staining compensated for interference from other signals. Top left: 
unstained cells. Top right: quiescent cells. Bottom left: quiescent cells induced with 
cycloheximide and TNFα. Bottom right: quiesced cells treated with 5 ng/ml of BMP9 overnight 
prior to induction with cycloheximide and TNFα. Cells in the bottom left quadrant are viable, 
cells in the bottom right quadrant are undergoing early-apoptosis, and cells in the top right 
quadrant are undergoing late-apoptosis or necrosis.   
 
I quiesced BOECs overnight in basal media supplemented with  (v/v) FBS and HEK-
EBNA supernatants. e following morning, I spiked in TNFα and cycloheximide. e rate of 
apoptosis induction seemed dependent on cell passage and confluence, among other things. 
erefore, when cell morphology began changing, about . hours after induction, I 
trypsinised cells and placed them in ice-cold PBS to prevent further apoptosis whilst they were 
stained and analysed. Conditioned media from HEK-EBNA cells transfected with empty 
expression vectors increased the proportion of necrotic or late apoptotic cells, but did not alter 
the proportion of healthy cells (Annexin-V and propidium iodide negative)(figure ). 


































Figure 30. Dose response of BMP9 anti-apoptotic activity. Blood outgrowth endothelial cells 
were quiesced in 0-3 ng/ml of BMP9 overnight, prior to induction of apoptosis with 
cycloheximide and TNFα. Apoptosis was measured flow cytometry. PI-/AV- cells are viable, PI-
/AV+ cells are undergoing early apoptosis, and PI+/AV+ cells are undergoing late apoptosis or 
necrosis.    

























Figure 31. Effect of HEK-EBNA cell conditioned media on apoptosis assessment. Blood 
outgrowth endothelial cells quiesced in basal media supplemented with 2% (v/v) FBS. 10% 
(v/v) conditioned media from HEK-EBNA cells transfected with empty vector was also added 
where indicated. Apoptosis was induced with cycloheximide and TNFα and apoptosis was 
measured by flow cytommetry. PI-/AV- cells are viable, PI-/AV+ cells are undergoing early 
apoptosis, and PI+/AV+ cells are undergoing late apoptosis or necrosis. Mean ± SEM, n = 4, 
paired two-tailed Student’s t-test between cells with and without conditioned media, * p < 0.05, 





































































Figure 32. Anti-apoptotic activity of BMP9 variants. Blood outgrowth endothelial cells were 
quiesced in 3 ng/ml of BMP9 overnight as calculated by western blotting of the prodomain, 
prior to induction of apoptosis with cycloheximide and TNFα. Apoptosis was measured flow 
cytometry. PI-/AV- cells are viable, PI-/AV+ cells are undergoing early apoptosis, and PI+/AV+ 
cells are undergoing late apoptosis or necrosis. PI-/AV- cells are viable, PI-/AV+ cells are 
undergoing early apoptosis, and PI+/AV+ cells are undergoing late apoptosis or necrosis. Mean 
± SEM, n = 3, one-way matched ANOVA/Dunnett’s test of variants compared to WT using 
proportion of PI-/AV- cells, * p < 0.05, ** p < 0.01, *** p < 0.001. A non-parametric Friedmann 
test gave similar results.    
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I chose to measure PAH-associated Pro:BMP-MV, -RW, and -YH as they 
demonstrated instability due to mutations in either the prodomain or growth factor domain. 
Additionally, ProBMP-SC possessed a processing defect, whilst Pro:BMP-DN was not 
expected to be pathogenic but did exhibit a glycosylation defect. e mutation BMP-KR 
is common and not associated with PAH, so I included this variant as a control. Supernatants 
from HEK-EBNA cells transfected with an empty vector were used to rule out responses due to 
non-specific factors. Treatment with Pro:BMP-WT, DN and RK significantly increased 
the number of healthy cells (figure ). As expected, Pro:BMP-MV, RW and YH 
were significantly less functional than Pro:BMP-WT. Interestingly, Pro:BMP-SC also had 































































































































































































Figure 33. Transcriptional response of endothelial cells to BMP9. Quiescent blood outgrowth 
endothelial cells were treated with the indicated dose of recombinant BMP9 (pg/ml). mRNA 
from the indicated genes was measured by qPCR relative to the housekeeping gene B2M. 
SMAD9 produces two splice variants, a and b; SMAD9 relative expression includes both, whilst 






















































































































































































































































Figure 34 (overleaf). Transcriptional response of endothelial cells to BMP9 variants. 
Quiescent blood outgrowth endothelial cells were treated with 0.3-3 ng/ml of BMP9 as 
measured by Western blotting densitometry of the prodomain. mRNA from the indicated 
genes was measured by qPCR relative to the housekeeping gene B2M. SMAD9 produces two 
splice variants, a and b; SMAD9 relative expression includes both, whilst SMAD9va is specific 
for variant a. Mean ± SEM, n = 3, Two-way ANOVA/Bonferroni comparison of variants vs WT, * 
p < 0.05, ** p < 0.01, *** p < 0.001. A stratified van Elteren test showed the same groups had 
significantly lower activity at p < 0.05. 
Finally, I assessed transcriptional responses of quiescent BOECs to BMP variants. 
PAECs were able to discriminate between doses of BMP ranging from - pg/ml, with 
 pg/ml at the limit of sensitivity depending on the gene (figure ). Hence, I measured 
the transcriptional responses of BOECs to ,  and  pg/ml of BMP variants in 
conditioned media (figure ). As expected, Pro:BMP-DN, sc and -KR had normal 
stimulatory effects on BOECs. At doses calculated by Western blotting densitometry of the 
prodomain, Pro:BMP-MV, -RW and YH had reduced stimulatory effect on BOECs. 
is confirms loss of active growth-factor domain in these variants.  
 
.. BMP & pBMP levels & activity in GDF mutation carriers 
e PAH patients carrying pathogenic GDF mutations were heterozygotes. It is possible that 
dimerisation causes these mutations to act as dominant negatives, or wildtype alleles could 
compensate the mutated alleles. Many patients enrolled into the NIHR-BRIDGE study were 
also enrolled into the National Cohort of Idiopathic and Heritable PAH, which collected 
samples from patients. erefore, we sought plasma samples from PAH patients carrying 
pathogenic and benign mutations in GDF to validate my in vitro results. I measured 
circulating levels of BMP with an ELISA protocol validated by Dr. Paul Upton (see ..).  
We had samples from eleven PAH patients carrying putatively benign GDF missense 
variants, although I had not assessed all of these in vitro. A previous publication confirmed 
that BMP-RW is benign and it has a gnomAD frequency of . (Wooderchak-
Donahue et al. ; Karczewski et al. ). We had samples from four patients carrying 
putatively pathogenic missense variants. Additionally, two samples were from GDF deletion 
carriers with a deletion encompassing many flanking genes. ese patients had no evidence of 
comorbidities, and the flanking genes are only associated with recessive conditions. One 
sample was from a patient carrying a splice acceptor region mutation expected to cause a 
truncation. All the patient samples came from GDF heterozygous (or hemizygous) females, 
so we included samples from eight age-matched healthy females as controls.  
PAH patients carrying putatively pathogenic GDF missense variants had levels of 
plasma BMP significantly reduced to ~ of healthy controls or benign variant carrying 
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patients (figure ). Reduction in plasma BMP was due to the presence of pathogenic alleles, 
rather than as a consequence of PAH. e GDF deletion/truncation carriers had plasma BMP 
levels comparable to deleterious missense carriers. is could indicate missense variant 




















































































































































Figure 35. Plasma levels of BMP9 in PAH patients harbouring GDF2 mutations. ELISA against 
the BMP9 growth-factor domain. Plasma from female, age-matched, healthy controls, and 
female PAH patients harbouring heterozygous mutations in GDF2. Left: samples were 
assayed in duplicate, and the mean is shown. Right: data grouped according the classification 
of the GDF2 mutation. Mean ± SEM, one-way ANOVA with Bonferroni post hoc testing, * 
p<0.05, ** p<0.01. 
 
To validate the ELISA results, I undertook to measure plasma activity on quiescent 
aortic endothelial cells. e peptide GPRP can bind fibrin and prevent clotting so I trialled 
using this with high plasma concentrations to boost signal. However, GPRP inhibited the 
transcriptional response to BMP (not shown). erefore, I diluted plasma to  (v/v) in 
media to prevent clotting. I assessed induction of ID, and HEY since these were the 
strongest responders to recombinant BMP. However, there were no significant differences in 









































































































































































































Figure 36. Plasma activity of PAH patients harbouring GDF2 mutations. Quiescent human 
aortic endothelial cells treated with 1% (v/v) plasma. ID1, ID2 and HEY1 mRNA was measured 
by qPCR relative to the housekeeper B2M. Plasma from female, age-matched, healthy 
controls, and female PAH patients harbouring heterozygous mutations in GDF2 was assayed. 
Samples were assayed in singlet. 
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ere was a promising trend in these data, so I treated cells with  plasma, which 
led to some clotting, but boosted the transcriptional response (figure ). Plasma from PAH 
patients carrying pathogenic GDF alleles had reduced activity, which almost reached 
significance. is difference in activity was likely due to a reduction in BMP levels, since 




























































































































































































































































































































Figure 37. Plasma activity of PAH patients harbouring GDF2 mutations. Quiescent human 
aortic endothelial cells treated with with 3% (v/v) plasma. ID1, ID2 and HEY1 mRNA was 
measured by qPCR relative to the housekeeper B2M. Plasma from female, age-matched, 
healthy controls, and female PAH patients harbouring heterozygous mutations in GDF2 was 
assayed. Samples were assayed in singlet. Bottom: data grouped according the classification 
of the GDF2 mutation. Mean ± SEM, unpaired, one-tailed Student’s t-test of controls compared 
to pathogenic missense carriers. Control plasma from four healthy controls underwent a 
mock immunoprecipitation with non-specific IgG or anti-BMP9, before activity was assessed. 
A positive control consisting of 5 pg/ml of recombinant BMP9 is shown.  
 
Dr. Paul Upton generated a stable endothelial reporter cell line by transducing human 
microvascular endothelial cells with a BMP signalling driven luciferase gene (Korchynskyi and 
ten Dijke ; Ades et al. ). I confirmed these BRE-HMECs had a high affinity response 
to BMP and responded to plasma (figure ). Supplementation with GPRP and EDTA to 
inhibit clotting supressed the BMP response (not shown). Supplementing plasma with CaCl, 
to stimulate clotting to generate serum prior to treatment, did not work. I treated BRE-
HMECs with ,  or  (v/v) patient plasma, all of which gave a similar pattern. At  
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(v/v) plasma, some clotting occurred, but I added lysis reagent directly to the media so there 
was no risk of aspirating cells with the clot, and clotting did not reduce the BMP response. 
e activity of plasma mirrored the levels of BMP detectable by ELISA, with patients carrying 
pathogenic GDF variants having ~ the circulating activity of controls (figure ). 
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Figure 38. BRE-HMECs have a high affinity response to BMP9. Left: cells were treated with 
the indicated dose of recombinant BMP9. Right: cells were treated with 5% (v/v) plasma from 
four healthy volunteers. Plasma either underwent a mock immunoprecipitation, or 





















































































































Figure 39. Plasma activity of PAH patients harbouring GDF2 mutations. BRE-HMECs were 
supplemented with left 2% (v/v) or right 5% (v/v) of plasma. Plasma from female, age-
matched, healthy controls, and female PAH patients harbouring heterozygous mutations in 
GDF2 was assayed. Samples were assayed in triplet with mean plotted. Healthy control 
plasma underwent immunoprecipitation with non-specific IgG (mock) or anti-BMP9. Mean ± 
SEM, unpaired, one-tailed Student’s t-test of controls compared to pathogenic missense 
carriers, **p<0.01. 
 
It is possible BMP deficiency is compensated for by increased BMP expression. is 
did not appear to be the case in activity measurements of plasma from GDF deficient 
patients. Nevertheless, I assessed pBMP levels in these plasmas using an ELISA developed by 
Dr. Paul Upton (see ..). Surprisingly, patients carrying pathogenic GDF variants had 
greatly reduced levels of circulating pBMP (figure ). There was a striking correlation 
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between circulating BMP and pBMP levels, suggesting both a lack of compensation and a 
degree of co-regulation (figure ). Since the genetic mutation of GDF preceded a reduction 



























































































































































Figure 40. Plasma levels of pBMP10 in PAH patients harbouring GDF2 mutations. An ELISA 
using a capture antibody against the BMP10 growth-factor domain and a detection antibody 
against the BMP10 prodomain. Plasma from female, age-matched, healthy controls, and 
female PAH patients harbouring heterozygous mutations in GDF2 was measured. Left: 
samples were assayed in duplicate, and the mean is shown. Right: data grouped according 
the classification of the GDF2 mutation. Mean ± SEM, one-way ANOVA with Bonferroni post 
hoc testing, * p<0.05, ** p<0.01.  
 


























Figure 41. Plasma levels of BMP9 and pBMP10 is correlated in PAH patients harbouring 
GDF2 mutations and in healthy controls. Data from figures 35 and 40 were compared. 
 
 
.. BMP levels & activity in patients not carrying GDF mutations 
Dr. Paul Upton measured plasma BMP and pBMP levels in  PAH patients and  
age/sex-matched healthy controls (Hodgson et al. ). ese data confirmed that in 
general PAH is not associated with reduced BMP levels. Again, levels of BMP and pBMP 
were very tightly correlated in controls and patients. However, there was an over-
representation of patients which had very low or undetectable BMP levels, in addition to 
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those that carried GDF mutations. I re-measured samples from these patients with ELISA 
and activity assays. Both assays confirmed a loss of circulating ligands in a subset of PAH 



























































































Figure 42. Plasma levels of BMP9 and plasma activity was re-measured in a subset of PAH 
patients which had low levels of BMP9. Left: plasma BMP9 levels were measured in duplicate 
by ELISA. Right: activity was measured by treating quiesced aortic endothelial cells with 3% 
(v/v) plasma. ID1 & ID2 mRNA levels were measured by qPCR, relative to the housekeeping 
gene B2M. Age and sex matched healthy control plasmas were included as a control. n = 26 
patients, 24 controls, Mean ± IQR, unpaired, one-tailed Student’s t-test of controls compared to 
low BMP9 patients, * p < 0.05, ** p < 0.01, ***p < 0.001.  
 
.. Homozygous truncating mutations in paediatric HHT & PAH 
Wang et al. () reported a -yearold with PAH carrying a homozygous nonsense mutation, 
BMP -QX. Collaborators in Utah and Spain, to whom this patient was referred aged , 
hypothesised this mutation could be rescued by initiation of translation from Met, resulting 
in a short N-terminal truncation of the prodomain. ey provided me with expression vectors 
for PreProBMP-WT, QX and a version with the first  amino acids deleted (ORF). I 
validated that the expression vector sequences introduced the correct mutations. I transfected 
HEK-T cells with the wildtype vector and optimised transfection conditions and 
timepoints (not shown). e BMP from this vector had identical activity to recombinant 



















Figure 43. ELISA measurement of secreted BMP9 growth-factor domain in conditioned 
media. HEK-293T cells were transfected with expression vectors for myc/His tagged 
PreProBMP9-WT or variants, and placed in serum-free, chemically defined media. Three days 
post transfection, conditioned media was collected. This was serially diluted and BMP9 
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concentration in dilutions was measured by ELISA. Dilutions which gave absorbances in the 
linear part of the standard curve were used to calculate BMP9 concentration in the media. 
Three independent batches of HEK-293T cells were transfected and assayed independently. 
Mean ± SEM, n = 3, ND = not detectable. 
 
ere was no detectable secretion of Pro:BMP-QX or ORF into conditioned 
media as measured by ELISA (figure ) or Western blotting (figure ). Within cell lysates, 
there was good expression of unprocessed, but truncated, ProBMP (figure ). Despite this, 
there was no evidence of processed free prodomain or growth factor domain from the variant 
proteins. is contrasts wildtype BMP, which exhibited bands corresponding to the 
unprocessed and mature forms as expected. ese data suggest ribosomes can spontaneously 
initiate translation at Met. is produces ProBMP without a secretion signal peptide, so it 
may not enter the secretory and processing pathway. Alternatively, truncating the prodomain 
could simply disrupt folding which is essential to proper processing and secretion. 
 
Figure 44. Western blotting for BMP9 in conditioned media (reducing). 10 µl of WT 
conditioned media, or 50 µl of variants, were loaded per lane. Three independent batches were 
assayed. One representative blot shown. № = molecular weight (kDa), (№) = species 
identification from figure 7. 
 
Figure 45. Western blotting for BMP9 in cell lysates (reducing). Three independent batches 
were assayed. One representative blot shown. № = molecular weight (kDa), (№) = species 
identification from figure 7. 
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 A child with HHT, but no evidence of PAH, has been found with a second 
homozygous truncating variant BMP-EX. Samples from this child’s mother and father 
were available. erefore, I measured plasma BMP levels in the children, parents and control 
samples. As expected, plasma from the homozygous truncation carriers contained no 
detectable BMP (figure ). To try and confirm this, I used  µl of plasma and an alternative 
buffer in the ELISA to maximise sensitivity to low levels of BMP (figure )(see .). Notably, 
plasma levels of BMP in the heterozygous parents were reduced compared to controls, 









































































Figure 46. Plasma levels of BMP9 in paediatric PAH & HHT patients harbouring GDF2 
mutations. Plasma from four healthy adult males, three healthy adult females, a healthy 
female child, a female child with PAH harbouring a homozygous nonsense mutation BMP9-
Q26X, a female child with HHT harbouring a homozygous nonsense mutation BMP9-E179X, 
and the healthy parents each carrying BMP9-E179X heterozygously, were measured in 
















































































































Figure 47. Plasma levels of BMP9 in a PAH patient harbouring GDF2 mutations. Plasma from 
four healthy adult males, a healthy male child, a healthy female child and a female child with 
PAH harbouring a homozygous nonsense mutation were measured. The usual ELISA 
conditions were used (25% (v/v) plasma, 1% (w/v) BSA, 0.5% (v/v) triton-x100, 0.2% (v/v) goat 
serum in PBS) but 50% (v/v) plasma, and replacing PBS with BioRad plasma ELISA buffer was 
also tested. Samples were measured in duplicate and the mean is shown. 
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Secondly, I measured plasma levels of pBMP in these samples (figure ). ey 
demonstrated the same pattern seen in the previous data-sets, with GDF deficiency leading 
to reduced circulating pBMP. Similarly, I measured the activity of  (v/v) serum from 
these people on BRE-HMECs (figure ). ese data show truncating variants in GDF lead to 
a reduction in circulating BMP activity 










































































Figure 48. Plasma levels of pBMP10 in paediatric PAH & HHT patients harbouring GDF2 
mutations. Plasma from four healthy adult males, three healthy adult females, a healthy 
female child, a female child with PAH harbouring a homozygous nonsense mutation BMP9-
Q26X, a female child with HHT harbouring a homozygous nonsense mutation BMP9-E179X 
and the healthy parents carrying heterozygous BMP9-E179X mutations were measured in 
















































































Figure 49. Serum activity of paediatric PAH & HHT patients harbouring GDF2 mutations.  
Quiescent BRE-HMECs were supplemented with 10% (v/v) of serum from four healthy adult 
males, three healthy adult females, a healthy female child, a female child with PAH harbouring 
a homozygous nonsense mutation BMP9-Q26X, a female child with HHT harbouring a 
homozygous nonsense mutation BMP9-E179X, and the healthy parents each carrying 
heterozygous BMP9-E179X mutations. Samples were measured in triplicate and the mean is 




Robustly demonstrating BMP or BMP deficiency causes human disease increases 
confidence in potential therapies based on them. Additionally, most PAH cases are currently 
unexplained so it may aid clinicians and patients if some of their disease can be linked to 
BMP or BMP. Dr. Paul Upton undertook to measure plasma levels of BMP and BMP in 
a large cohort of PAH patients and healthy controls to see if levels are repressed in PAH. 
Another approach is to link mutations in GDF or BMP to disease. 
Gräf et al. () carried out a rare variant analysis with conservative parameters: only 
very rare variants which were predicted to be highly damaging and associated with PAH were 
classified as pathogenic. Missense mutations in GDF were significantly associated with PAH 
on a genome wide basis. We wanted to explore the mechanism by which these missense 
mutations lead to disease. Additionally, in silico predictions of deleteriousness are based on 
empirical analysis of many proteins, so it was important to validate the pathogenicity of the 
PAH associated variants. erefore, we selected a range of variants for analysis, including both 
those predicted to be pathogenic and benign. 
An overexpression system was used to generate missense variants. is system 
revealed that the preeminent defect of putatively pathogenic pBMP variants was improper 
processing and secretion of the mature growth-factor domain. Variant pro-proteins were 
expressed at similar levels within cell lysates, but active growth-factor domain dimers were 
found at heavily reduced concentrations in the conditioned media. Structural analysis revealed 
that many of the putatively pathogenic mutations altered residues at the prodomain / growth-
factor domain interface. ese two observations led us to hypothesise the active Pro:BMP 
complex of pathogenic variants is unstable, which leads to the loss of the growth-factor.  
Over-expression systems can introduce artefacts, since they saturate the cellular 
translation, folding and secretion machinery (Jones et al. ; Israel et al. ). For 
example, pule-chase experiments involving cells transfected with BMP reveal the majority of 
protein is degraded before secretion (Israel et al. ). Nevertheless, there were highly 
reproducible results across three transfections. Moreover, in silico predictions of 
deleteriousness were consistent with the in vitro results. 
e only exception is that BMP-PL was inefficiently secreted despite being 
assigned as benign. Unlike pathogenic variants, BMP-PL exhibited normal molar ratios of 
growth-factor domain to prodomain, and the patient plasma sample contained high levels of 
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BMP and activity. Structural analysis by Wei Li indicated that residue  is located on a 
loop domain of the prodomain which does not contact other parts of BMP. 
PAH patients harbouring pathogenic GDF mutations had reduced plasma BMP levels 
and activity on endothelial cells. A previous report shows transfecting cells with a mix of 
variant and wildtype BMP to causes dominant-negative deficiency via dimerisation (Daher et 
al. ). However, this does not necessarily reflect how cells express endogenous BMP from 
different alleles (Elowitz et al. ). Our patients carrying pathogenic missense variants were 
heterozygous, and their circulating BMP levels were about  lower than controls, 
supporting in vitro evidence of a stability defect and a haploinsufficiency model. Based on 
these results, figure  shows how either deficiency in receptor levels or ligand levels can 
contribute to PAH, and how this may be rectified with exogenous BMP. It is not known if 
BMP levels in plasma are a good predictor of BMP activity on the pulmonary vasculature, 
since there could be local sources or buffers. Similarly, the prodomains could stabilise and 
target the growth-factor domain in vivo, so patients carrying missense variants might have 
dysfunctional signalling beyond reduced circulating levels.  
 
 
Figure 50. In healthy people, BMP9 circulates at active levels, and contributes to endothelial 
cell quiescence. Insufficient BMPR2 signalling, including BMPR2 mutations, is a well-
established contributor to PAH. The Morrell group has shown that administering exogenous 
BMP9 is able to reverse disease in animal models with defective BMPR2 signalling. Here, I 
present evidence showing a subset of patients carry deleterious BMP9 variants or have 
insufficient circulating levels of BMP9. These patients may also be amenable to treatment 
with exogenous BMP9. 
 
Pathogenic mutations in GDF led to a striking reduction in plasma pBMP levels. 
BMP expression could be induced by BMP, or plasma BMP could be sequestered to 
vacant BMP binding sites. Alternatively, Tillet et al. () suggest BMP and BMP are 
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heterodimeric. GDF mutations actually led to a greater loss of pBMP than BMP; further 
evidence that any physical association between them is not :. It is possible that GDF 
mutations contribute to PAH via their effect on BMP, or this could be an unrelated effect.  
During the course of this project, another group carried out a similar analyses of 
pathogenic BMP proteins discovered in a Chinese PAH cohort (Wang et al. ). ey 
reproduced several findings, including reduced secretion but normal ALK signalling of 
variant BMP proteins in vitro and a processing defect of ProBMP-SC. However, in their 
hands, pathogenic BMP variants exhibited no anti-apoptotic activity on PAECs in a caspase-
GLO assay. is could be because they did not treat cells with normalised amounts of 
conditioned media—I showed conditioned media itself stimulates apoptosis. Although Wang 
et al. report reduced plasma BMP levels in PAH patients carrying pathogenic GDF variants, 
they also observe a general reduction in PAH patients, and report mean healthy plasma BMP 
levels of just ~ pg/ml. is is likely because they are not using an ELISA protocol suitable 
for measuring BMP levels in plasma (see ..).  
A European group used a targeted gene panel to find two truncating mutations in 
GDF and rediscovered Pro:BMP-EK (Eyries et al. ). Similarly, Pro:BMP-RW and 
RW missense mutations were re-discovered in an American cohort (Zhu et al. ). 
Neither group carried out in vitro analyses. A previous group reported a mutation, BMP-
RQ, in the furin recognition sequence associated with HHT (Hernandez et al. ). 
However, Tillet et al. () expressed this variant in vitro and observed no processing defect. 
Notably, residue  is unspecified in canonical furin recognition sequences, whereas furin is 
intolerant of cysteines in the motif region (Tian ). is highlights the importance of in 
vitro analysis to uncover structural defects. Nonetheless, although Pro:BMP-DN is 
aberrantly glycosylated, it is fully functional, showing the importance of in silico analysis. 
Missense variants predicted to benign in silico did not show significantly reduced 
levels or activity in vitro or in vivo. However, there was a tendency for them to be secreted 
less efficiently than Pro:BMP-WT in vitro, mirrored by a tendency for carriers to have slightly 
reduced circulating levels and activity of BMP and BMP. GDF is exceptionally well 
conserved across species, which indicates powerful purifying selection, so it is likely that all 
these rare/very-rare variants are deleterious to an extent. 
HHT and PAH are known to have overlapping genetics. Interestingly, I analysed two 
children with severe manifestations of each disease. Both children were homozygous carriers 
of completely non-functional alleles. e heterozygous parents were haploinsufficient but 
showed no disease. is hints that complete GDF deficiency may be more severe than 
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haploinsufficiency or acquired loss of circulating BMP. It is unclear what triggers some 
patients develop HHT without PAH or vice versa. It seems likely that mutations in HHT are 
more penetrant, although symptoms might not manifest until old-age, after some patients 
have died from PAH (Girerd et al. ). Therefore, these children and their haploinsufficient 
parents should be monitored overtime to assess whether they begin to manifest HHT or PAH. 
 
 
4. Characterising circulating BMP & BMP  
4.1. Introduction 
Scientific consensus suggests BMP is produced and cleaved within the liver, then circulates in 
complex with its prodomains until it binds a target receptor (Bidart et al. ). Some reports 
find active Pro:BMP in the blood, which is thought to be secreted from the right atrium 
(Jiang et al. ). Plasma and serum have complex compositions and plasma requires agents 
to prevent clotting. is interferes with many antibodies, enzymes and cell-based assays. 
BMP and BMP have similar properties so it can be difficult to know which is being 
assessed in activity assays. Few ELISA protocols for measuring BMP and BMP in plasma or 
serum have been validated, so we do not know their recovery efficiency or what species of 
BMP and BMP they detect. e following properties of circulating BMP and BMP are 
ambiguous in the current literature: whether the liver and the right atria are the only source of 
circulating BMP and BMP respectively; the proportion of circulating pBMP and pBMP 
which is processed and active versus unprocessed; the concentration of BMP and BMP in 
plasma and serum; and whether BMP and BMP bind to carrier proteins in blood (see .). 
 
 
Figure 51. Schematic of species detected by different ELISAs. The pBMP10 ELISA is able to 
detected both processed and unprocessed BMP10, whilst the BMP9 and BMP10 growth 
factor domain ELISAs are only able to detect processed species. The ProBMP9 detects an 
unprocessed form of ProBMP9 of uncertain identity. See following sections for how this was 
determined. See figure 7 for a schematic of how BMP9 and BMP10 are processed. 
 
Several sandwich ELISAs are available for measuring human BMP and BMP (figure 
). Different capture and detection antibodies are targeted against their prodomains or 
growth-factor domains, so could be used in combination to detect processed and/or 
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unprocessed species. Activity neutralisation and immunoprecipitation protocols have also 
been published. erefore, I used these to assay circulating BMP and BMP. Secondly, I 
investigated the potential existence of circulating BMP and BMP binding proteins.  
 
.. Minimal circulating processed Pro:BMP is detectable by ELISA 
e pBMP ELISA we use comprises capture antibody specific for the growth-factor domain 
and detection antibody specific for the pro-domain. A second ELISA using both capture and 
detection antibodies against the BMP growth-factor domain is commercially available. It 
was unclear whether each ELISA measures both processed and unprocessed forms of pBMP. 
erefore, I tested both the pBMP and BMP growth-factor domain ELISAs with standards 
of either processed Pro:BMP or unprocessed ProBMP. The latter was generated by Jingxu 
Guo by introducing a BMP-RA mutation in the furin recognition sequence (see figure 
)(Susan-Resiga et al. ). e BMP growth-factor domain ELISA was able to detect 
processed Pro:BMP and recombinant BMP growth-factor equally efficiently, but not 
unprocessed ProBMP-RA—log(EC) = . ± ., . ± . and ~ respectively 
(figure ). e pBMP ELISA was equally efficient at detecting Pro:BMP and ProBMP-
RA—log(EC) = . ± . and . ± . respectively . In combination, these ELISAs 
could be used to distinguish processed and unprocessed BMP.  
































































Figure 52. The pBMP10 ELISA detects dimeric Pro:BMP10 or ProBMP10, whilst the BMP10 
growth-factor domain ELISA detects Pro:BMP10. Purified Pro:BMP10 was produced by He 
Jiang, whilst unprocessed ProBMP10-R313A was purified by Jingxu Guo. Immunoreactivity in 
the pBMP10 (left) and BMP10-growth factor domain (right) ELISAs was measured. Mean ± 
SEM of duplicates, curves = four parameter logistic regression, n = 3 with one representative 
experiment shown. 
 
Dr. Paul Upton optimised the pBMP ELISA. I optimised the BMP growth-factor 
domain ELISA for use with plasma based on the same additives and dilutions. e BMP 
growth-factor domain ELISA was not very efficient at recovering exogenous BMP spiked 
into plasma (figure ). Unspiked plasmas gave readings below the blanks, indicating plasma 
introduced non-specific inhibition, perhaps due to the high protein concentration of plasma. 
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I replaced  (w/v) BSA in PBS as the diluent base with BioRad ELISA diluent which contains 
high levels of goat serum proteins. is resulted in efficient recovery of Pro:BMP (figure ). 






















Figure 53. Recovery efficiency of the BMP10 growth factor domain ELISA from plasma. 
Recombinant BMP10 was serially diluted in plasma or 1% (w/v) BSA in PBS. Thirty µl samples 
were diluted with 70 µl 1% (w/v) BSA in PBS supplemented with 0.5% (v/v) Triton-X100, 0.2% 
(v/v) goat serum and 5 mM EDTA. Immunoreactivity was measured in the BMP10 growth-
factor domain ELISA by colourimetry. Mean ± SEM of duplicates, n = 1. Dashed line = 


































Figure 54. BioRad diluent results in high recovery efficiency from plasma in the BMP10 
growth-factor domain ELISA. Pro:BMP10 was serially diluted in plasma or BioRad ELISA 
buffer (standard). Thirty µl samples were diluted with 70 µl of BioRad ELISA buffer 
supplemented with 0.5% (v/v) Triton-X100, 0.2% (v/v) goat serum and 5 mM EDTA. 
Immunoreactivity was measured in the BMP10 growth-factor domain ELISA by colourimetry. 
Curves = four parameter logistic regression, dashed line = absorbance of blank. Mean ± SEM 
of duplicates, n = 3, one representative experiment shown. 
 
Surprisingly, the growth-factor domain ELISA only detected - pg/ml of 
endogenous Pro:BMP in plasma. ese values are below the reliable quantification limit of 
this ELISA—replicates fell anywhere in this range (not shown). Similar data were generated 
by Dr. Paul Yu’s group using the same ELISA (personal communication). The pBMP ELISA 
detected ~ ng/ml of endogenous pBMP. The discrepancy between ELISAs was either 
because endogenous BMP primarily consists of unprocessed ProBMP, or endogenous 
Pro:BMP is somehow masked from the growth-factor domain ELISA.   
As expected, immunoprecipitation of plasma with hALK-Fc cleared all endogenous 
BMP. I tried numerous conditions to immunoprecipitate purified Pro:BMP from PBS or 
plasma using several anti-BMP antibodies. Unfortunately, they could not clear BMP (not 
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shown). is is consistent with findings that anti-BMP antibodies also fail to neutralise any 
plasma activity (Jiang et al. ). e anti-BMP antibody mAb worked in ELISAs, so 
can bind natively folded BMP within plasma. To trouble-shoot the immunoprecipitation, I 
confirmed antibody was binding to the protein G beads by eluting them followed by SDS-
PAGE and Coomassie staining (figure ). Next, I supplemented samples with EDTA and 
detergents to mimic the ELISA conditions. Unfortunately, EDTA had no beneficial effect, 
whilst detergents were incompatible with cell-based assays (not shown). Finally, I extended 
the incubation time of sample with antibody-beads from  minutes to over-night at room 
temperature. is facilitated successful clearance of Pro:BMP from the samples.  
 
Figure 55. Reducing SDS polyacrylamide gel electrophoresis & Coomassie staining of 
immunoprecipitations. Top: Eluates Bottom: Analytes. 1 = protein G conjugated metal beads 
with Pro:BMP10 alone, 2 = beads with ALK1-Fc and Pro:BMP10, 3 = beads covalently linked to 
ALK1-Fc with 5 mM BS3 with Pro:BMP10, 4 = beads covalently linked to ALK1-Fc with 1 mM 
BS3 in PBS with Pro:BMP10, 5 = beads and anti-BMP10 (mAb2926) with Pro:BMP10, 6 = ALK1-































































































































































































Figure 56. Endogenous BMP10 behaves like ProBMP10 or Pro:BMP10 in 
immunoprecipitations and the pBMP10 ELISA. Left: EDTA-plasma from four healthy males. 
Plasmas were spiked with 2.5 ng/ml of Pro:BMP10 or 5 ng/ml of ProBMP10-R313A where 
indicated. Samples were immunoprecipitated with non-specific IgG (mock), hALK1-Fc, or anti-
BMP10. Immunoreactivity was measured in the pBMP10 ELISA. Right: The raw absorbance of 






































































































































































































Figure 57. Endogenous BMP10 does not cross-react to any great extent in the BMP10 
growth-factor domain ELISA. Left: EDTA-plasma from four healthy males. Plasmas were 
spiked with 2.5 ng/ml of Pro:BMP10 or 5 ng/ml of ProBMP10-R313A where indicated. 
Samples were immunoprecipitated with non-specific IgG (mock), hALK1-Fc, or anti-BMP10. 
Immunoreactivity was measured in the BMP10 growth-factor domain. Right: The raw 
absorbance of the same ELISA. Mean of duplicates plotted. Mean ± SEM, n = 4. Dashed line = 
absorbance of blank. 
 
I was then able to show endogenous pBMP, and both exogenous ProBMP and 
Pro:BMP, could be immunoprecipitated from plasma using ALK-Fc and anti-BMP (figure 
; ). Immunoprecipitation led to a large decrease in endogenous immunoreactivity in the 
pBMP ELISA. Immunoprecipitation caused very little change in endogenous 
immunoreactivity in the growth-factor domain ELISA. This further showed endogenous 
pBMP has almost no immunoreactivity in the growth-factor domain ELISA (otherwise 
absorbance would decline below the blank samples after immunoprecipitation). erefore, we 
conclude unprocessed ProBMP is the major circulating species.  
 
4.3. Active levels of circulating Pro:BMP are detectable by ELISA 
We refined a commercially available ELISA for measuring BMP growth-factor domain to 
maximise accuracy of plasma measurements. Most of the optimisation was undertaken by 
Drs. Paul Upton, Paul Yu, and Ivana Nikolic who established dilution factors and additives 
(see ..). I validated that diluting  ul of plasma from four healthy males in  ul of buffer 
containing . (v/v) goat serum and . (v/v) triton x- gave the most reproducible 
results and most efficient recovery of endogenous BMP (figure ).  
BMP was undetectable in serum using this ELISA. Additionally, Drs. Paul Upton and 
Claudia Mitrofan found BMP was measurable in sodium-citrate plasma, but not heparinised 
plasma. e most obvious technical difference between measurable and unmeasurable 
substrates is the presence of chelating agent. Accordingly, I showed equally efficient recovery 
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of BMP from EDTA-plasma and serum supplemented with  mM EDTA (figure ). Dr. Paul 
Upton then showed BMP was recoverable in heparinised plasma supplemented with EDTA. 
Hence, chelating agent should be present in all samples used in this ELISA. 
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Figure 58. Validation of BMP9 growth factor domain ELISA. EDTA-plasma and serum were 
prepared from the same 4 healthy male volunteers. The indicated volumes of sample were 
diluted with 1% (v/v) BSA in PBS to give a total volume of 100 ul. Final concentrations of 0.2% 
(v/v) goat serum (GS), 0.5% (v/v) triton x-100 and 5 mM EDTA were added to diluted samples 
where indicated. For the 100 ul sample volumes, the additives were added directly to neat 
plasma or serum, to give a final volume of 105 ul. Endogenous BMP9 was precleared from the 
serum IP and plasma IP samples. Immunoreactivity was measured in the BMP9 growth-factor 
domain ELISA. Mean of duplicates plotted. Comparison between individual conditions = 
paired, two-tailed Student’s t-tests. Comparison of the effect of additives on plasma = 
matched two-way ANOVA. Mean ± SEM, n = 4, * p<0.05, ** p<0.01, *** p<0.001, NS = not 
significant. 
 
e BMP growth-factor domain ELISA could plausibly cross-react with unprocessed 
ProBMP and processed Pro:BMP. Nikolic et al. () immunoprecipitated endogenous 
BMP from human serum using the capture antibody and analysed it by Western blotting 
using the detection antibody as a probe. ey only found cross-reactivity with a ~ kDa 
band, so concluded the ELISA only detects processed growth-factor domain. However, the 
antibodies may have different sensitivity to processed and unprocessed species in an ELISA 
format or healthy serum may only contain processed BMP. 
I confirmed this ELISA only detected processed BMP in chapter .. Densitometry of 
Western blots suggested there was a ~ fold excess of unprocessed monomeric and dimeric 
ProBMP-SC in conditioned media compared to processed growth-factor domain (figure 
; ). Unprocessed species did not interfere with the ELISA—doses of BMP-SC and 
BMP-WT calculated from ELISA results had equal activity on cells and equal intensity of 
processed growth-factor domain on Western blots (figure ; ).  
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As expected, immunoprecipitation using either anti-BMP or hALK-Fc completely 
cleared plasma of detectable endogenous BMP (figure ). Samples immunoprecipitated with 
hALK-Fc had slightly lower absorbances than samples immunoprecipitated with anti-BMP, 
which could indicate hALK-Fc is more efficient at clearing BMP. 
 
 
























Figure 59. The BMP9 ELISA only detected processed dimers. Immunoreactivity of 
recombinant BMP9 (standard, seven dilutions) and processed or unprocessed PreProBMP9-
S320C (as determined by western blotting, figure 19) in the BMP9 growth-factor domain 































































































Figure 60. Plasma and serum immunoreactivity in the BMP9 ELISA could be cleared by 
immunoprecipitation with anti-BMP9 or ALK1-Fc. Plasma and serum were collected from 
four healthy males. Samples were immunoprecipitated with non-specific IgG (mock), anti-
BMP9 or hALK1-Fc. Immunoreactivity was assessed in the BMP9 ELISA. Right: raw-
absorbance data. Mean of duplicates plotted. Mean ± SEM, n = 4, matched two-tailed 
Student’s t-testing, * p<0.05, ** p<0.01. Dashed line = absorbance of blank (diluent alone). 
 
 
e immunoreactivity of plasma and serum cleared of BMP was below that of blanks, 
indicating plasma and serum introduced non-specific inhibition. Again, BioRad ELISA diluent 
reduced the immunoreactivity of the standard curve so cleared samples gave similar 
absorbances to blanks (figure ). Hence, BioRad ELISA diluent could be used in place of  



































































Figure 61. BioRad buffer mimicked the non-specific inhibition of immunoreactivity of plasma 
& serum, improving BMP9 ELISA sensitivity. Left: standard curves were prepared by serially 
diluting recombinant BMP9 in 1% (w/v) BSA in PBS, or BioRad ELISA buffer and 
immunoreactivity was measured in the BMP9 ELISA. The upper dashed line is the blank in 1% 
(w/v) BSA, whilst the lower dashed line is the blank immunoreactivity of BioRad ELISA buffer. 
Mean ± SEM of duplicates, n = 1. Right: Plasma and serum from four healthy males were 
cleared of BMP9 by immunoprecipitation using anti-BMP9. Mean ± SEM, n = 4. 
 
4.4. No circulating unprocessed ProBMP is detectable 
Based on the results of the BMP ELISAs, we trialled a pBMP ELISA which uses a capture 
antibody against the growth-factor domain and a detection antibody against the prodomain. 
e pBMP ELISA did not react potently with purified cleaved Pro:BMP, but was sensitive to 
conditioned media containing ProBMP-SC. is suggested the pBMP ELISA primarily 
detects unprocessed ProBMP, and I will refer to it as the ProBMP ELISA. The ProBMP-
SC media appeared to contain a mix of unprocessed and semi-processed covalent and non-
covalent dimers on immunoblots, so it is unclear which the ProBMP ELISA detects (figure 
). Additionally, the extra cysteine may cause misfolding of this protein which could 
influence its immunoreactivity.  
I validated the ProBMP ELISA for measuring unprocessed ProBMP in plasma and 
serum. e recovery efficiency of ProBMP-SC from plasma was ~ (figure ). Low 
recovery could have been due to non-specific interference—absorbances from unspiked 
plasmas were below the blanks. erefore, I tested the BioRad buffer, and this improved the 
sensitivity of the ProBMP ELISA. Immunoreactivities were still below the blanks suggesting 
this ELISA protocol is not well suited to plasma (figure ). Since the concentration of 
endogenous unprocessed ProBMP could not be precisely quantified due to non-specific 
inhibition, I measured the relative absorbance of samples after immunoprecipitation to 
establish whether any unprocessed ProBMP was present. Immunoprecipitation with anti-
BMP did not change the endogenous immunoreactivity of plasma in the ProBMP ELISA. 
This suggested there is no circulating unprocessed ProBMP (figure ).  
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Figure 62. Recovery efficiency of the ProBMP9 ELISA was low in plasma. ProBMP9-S320C 
was serially diluted in plasma or 1% (w/v) BSA in PBS. Immunoreactivity was measured in the 
ProBMP9 ELISA. Mean of duplicates plotted. Dashed line = absorbance of blank. n = 1. 
 







































































Figure 63. BioRad ELISA buffer improved the sensitivity of the ProBMP9 ELISA. Left: 
ProBMP9-S320C was serially diluted in plasma or BioRad diluent. Immunoreactivity was 
measured in the ProBMP9 ELISA. Mean ± SEM of duplicates n = 1. Right: Plasma and serum 
from four healthy males was measured in the ProBMP9 ELISA by colourimetry. Mean of 
















































































Figure 64. Plasma and serum immunoreactivity in the ProBMP9 ELISA were unchanged by 
immunoprecipitation with anti-BMP9 or ALK1-Fc. Plasma and serum from four healthy males 
were spiked with ProBMP9-S320C where indicated, then immunoprecipitated with IgG (mock), 
anti-BMP9 or hALK1-Fc. Immunoreactivity was assessed in the ProBMP9 ELISA. Mean of 
duplicates plotted. Mean ± SEM, n = 4, matched two-tailed Student’s t-testing, ns = not 
significant. Dashed line = absorbance of blank. 
 
As controls, I spiked samples with ~ pg/ml of ProBMP-SC before 
immunoprecipitation which confirmed anti-BMP successfully cleared unprocessed ProBMP. 
In contrast, ALK-Fc was incapable of clearing any immunoreactivity from samples spiked 
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with ProBMP-SC (figure ). ALK-Fc was able to immunoprecipitate ProBMP-RA, 
which suggests either ProBMP behaves differently, or the ProBMP ELISA detects monomeric 
or misfolded ProBMP-SC. Hence, I can conclude the BMP growth-factor domain ELISA 
used in many reports only detects active BMP, but not whether unprocessed BMP circulates.  
 
.. Western blotting circulating BMP & BMP 
A complementary approach to investigate whether circulating BMP is processed is by Western 
blotting. Plasma and serum cannot be denatured without clotting, so I attempted to 
immunoprecipitate BMP and BMP. Nikolic et al. () used immunoprecipitation 
followed by Western blotting with two anti-BMP growth-factor domain antibodies to show 
only processed BMP was present in pooled serum. However, they did not demonstrate both 
antibodies are able to bind epitopes of unprocessed BMP. In contrast, I have selected 
antibodies that are able to detect both processed and unprocessed BMP on Western blots. 
I tested the capacity of anti-prodomain, anti-growth-factor domain and ALK-Fc to 
immunoprecipitate Pro:BMP from conditioned media. I probed blots with anti-prodomain, 
since this antibody had highest sensitivity. Only anti-prodomain could immunoprecipitate 
Prodomain (figure ). e recovery efficiency of this protocol was good at physiological 
concentrations of Pro:BMP (figure ). I included controls spiked with Pro:BMP-DN 
because this should give a shifted band and we were curious if this variant is hyper-
glycosylated in human carriers. Unfortunately, when using plasma, the lanes were smeared 
due to carry-over of non-specific proteins (figure ). In future, I could use metal, rather than 
sepharose, protein-G beads and include a larger amount of detergent in wash steps. 
For blotting endogenous BMP, I found ALK-Fc was more efficient at 
immunoprecipitating BMP from plasma than anti-BMP antibodies (see .). ALK-Fc 
dimers are a similar weight to ProBMP dimers and ALK-Fc cross reacted with anti-goat 
and anti-mouse detection antibodies to a small extent, despite having a human Fc domain 
(not shown). CleanBlot (ermo ) is a reagent designed not to cross-react with 
denatured Fc domains, but in my hands, it resulted in poor specific signal and high non-
specific signal (not shown). erefore, I covalently linked ALK-Fc to protein G beads using 
BS reagent. Coomassie staining showed BS prevented elution of ALK-Fc when used at both 
 mM and  mM (figure ). However, BS reagent also inhibited immunoprecipitation.  
I carried out Western blots of non-BS ALK-Fc immunoprecipitates using Pro:BMP 
spiked plasma as a positive control and ALK-Fc alone as a negative control. Although the 
controls worked, the pattern of bands potentially representing endogenous pBMP was 
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variable between blots (not shown). In future, I could spike samples with physiological 




Figure 65. Western blotting of Pro:BMP9 immunoprecipitated from 1% BSA in PBS. 
PreProBMP9 was diluted in 1% (w/v) BSA in PBS to a final volume of 2 ml at the indicated final 
concentrations and immunoprecipitated with anti-prodomain, anti-growth-factor domain or 
ALK1-Fc. Precipitate was analysed by Western blotting. Probe = anti-BMP9 prodomain. N = 3, 





Figure 66. Western blotting of Pro:BMP9 immunoprecipitated from 1% BSA in PBS. 
PreProBMP9-WT and D218N was diluted in 1% (w/v) BSA in PBS to a final volume of 1.5 ml at 
the indicated final concentrations. These samples were immunoprecipitated with anti-
prodomain and precipitates were analysed by Western blotting. Probe = anti-BMP9 




Figure 67. Western blotting of Pro:BMP9 immunoprecipitated from Plasma. Pro:BMP9 was 
spiked into plasma where indicated and immunoprecipitated with non-specific IgG (mock) or 
anti-prodomain. Additionally, a sample of plasma immunoprecipitated with anti-prodomain 
was put back through the protocol with anti-prodomain as a negative control (pre-cleared). 
Precipitate was analysed by Western blotting. Probe = anti-BMP9 prodomain. n =3, one 




.. BMP constitutes a minor proportion of circulating activity 
Dr. Claudia Mitrofan generated data showing serum, EDTA-, citrate- and heparin-plasma 
possess BMP or BMP activity. Similarly to BMP, I was able to show pBMP was 
detectable in serum by ELISA if EDTA is added (figure )(see .). Recovery of pBMP from 
serum+EDTA was ~ lower than for EDTA-plasma. I undertook to analyse plasma and 
serum BMP and BMP activity on endothelial cells. I reproduced published results showing 
a large majority of plasma BMP activity can be neutralised by anti-BMP (figure ; ). ese 
data were produced by treating quiescent human aortic endothelial cells with  (v/v) of 
plasma, plasma which had been immunoprecipitated with anti-BMP, or recombinant BMP, 
for  hour followed by measurement of transcriptional responses. I generated similar results 
treating four pulmonary artery endothelial cell lines (not shown). Similarly, Gdf knockout 
mice had no circulating BMP activity (figure ). e reduction in activity caused by anti-
BMP immunoprecipitation compared to the activity of recombinant BMP suggested plasma 



























Figure 68. The pBMP10 ELISA recovers pBMP10 from plasma or serum supplemented with 
EDTA. EDTA-plasma, serum and serum spiked with EDTA from four healthy males was 
measured in the pBMP10 ELISA. Mean of duplicates plotted. Mean ± SEM, n = 4, matched 
two-tailed Student’s t-test, *p < 0.05. 
 
Serum and EDTA-plasma possessed equal BMP activity on HMEC cells when ID 
and ID induction was measured after one hour (figure ). Serum perhaps had slightly 
higher activity than plasma when luciferase induction in BRE-HMECs treated for six hours was 
measured (figure ). It is not clear why the transduced cells respond differently to serum and 
plasma. It could reflect the longer time they have to respond to serum factors in a -hour 
luciferase protocol versus -hour qPCR protocol.  
In further contrast to qPCR activity measurements, luciferase induction was only 
reduced by ~ after sera and plasmas were cleared of BMP by immunoprecipitation (figure 
; ). erefore, I cleared samples of BMP using anti-BMP antibodies. Serum gave 
more robust and reliable results than plasma because cells could be treated with higher 
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concentrations of serum without clotting. I found ~ of circulating BMP activity was 
neutralised by anti-BMP treatment. ALK-Fc or a combination of both anti-BMP and anti-

























































Figure 69. BMP9 activity of plasma and serum measured by qPCR. Quiescent HMEC1 cells 
were treated with the indicated amounts of plasma or serum from four healthy individuals. 
Levels of ID1 mRNA were assessed by qPCR relative to the housekeeping gene B2M. 
Plasmas/sera were immunoprecipitated with anti-BMP9 or ALK1-Fc where indicated. Mean ± 
SEM, n = 4, matched two-tailed Student’s t-testing, *p < 0.05, NS = not significant. Dashed line 
















































Figure 70. BMP9 activity of plasma and serum. Quiescent BRE-HMEC1 cells were treated with 
the indicated amounts of plasma or serum from two individuals. Plasmas/sera were 
immunoprecipitated with ALK1-Fc where indicated. FBS = foetal bovine serum. Mean ± SEM, n 































































































































Figure 71. Circulating BMP9 and BMP10 activity measured by luciferase induction. Plasma 
and serum from four healthy males were immunoprecipitated with non-specific IgG (mock), 
anti-BMP9, anti-BMP10, anti-BMP10 prodomain (Pro), or ALK1-Fc, and/or 5 ng/ml of 
Pro:BMP10 where indicated. Quiescent BRE-HMEC1 cells were treated with 10% (v/v) of 
serum (left) or 3% (v/v) or plasma (right). One-way matched ANOVA/Dunnett’s test of 
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immunoprecipitated samples compared to mock treatment, mean ± SEM, n = 4, mean of 
triplicates plotted. For plasma, extra samples prepared from the same individuals were 
available. Dashed line = luciferase activity of untreated quiescent cells. 
 
ese luciferase induction data are still consistent with most endogenous BMP being 
active, and most endogenous BMP being inactive, since there is vastly more circulating 
pBMP than BMP. As expected, Pro:BMP induced a strong response in BRE-HMECs, 
whilst ProBMP-RA did not possess high-affinity activity (figure ). is could indicate 
most circulating BMP is unprocessed. 
To quantify the amount of circulating BMP activity, I spiked Pro:BMP back into 
serum which had been cleared with ALK-Fc. Surprisingly, ~ ng/ml of Pro:BMP was 
needed to reconstitute the activity of cleared serum (figure ). is is much greater than the 
combined circulating amount of BMP and pBMP measured by ELISA. Serum spiked with 
Pro:BMP had depressed activity compared to serum-free media spiked with Pro:BMP, 
which suggested serum contains factors which inhibit BMP signalling. ese results could be 
explained if ALK-Fc cleared serum of circulating BMPs, other than BMP and BMP, which 
usually add to their effects, or if some ALK-Fc remained within serum after beads were 
removed, neutralising exogenous Pro:BMP. Samples could be incubated with excess protein 
G beads to remove unconjugated ALK-Fc. 



















Figure 72. Activity of Pro:BMP10 and ProBMP10. BRE-HMECs treated with ProBMP10-R313A 
or Pro:BMP10. Mean ± SEM, mean of duplicates plotted. n = 3 with one representative 




















Figure 73. Reconstituting signalling activity of serum cleared with ALK1-Fc. Serial dilutions of 
Pro:BMP10 were prepared in serum-free media or serum precleared with ALK1-Fc. 10% (v/v) 
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of these samples, or uncleared serum (endogenous) were incubated with BRE-HMECs. Curves 




.. Furin treatment of serum  
I found endogenous BMP may be predominantly unprocessed. ProBMP contains a furin 
recognition sequence and serum contains adequate free calcium to activate furin. Hence, I 
treated neat serum with furin and quenched the reaction with  mM EDTA. Furin treatment 
did not increase immunoreactivity of serum in the BMP growth-factor domain ELISA, 
which suggests furin did not cleave endogenous ProBMP (figure ). Furin treatment did 
not increase the activity of serum on cells, reinforcing this result (figure ). Furin treatment 
did not lead to an increase in processed Pro:BMP as measured by the BMP growth-factor 
domain ELISA (figure ). Instead, there was a modest reduction in BMP levels, possibly 













































Figure 74. Serum Pro:BMP10 levels are not increased by furin treatment. Serum from four 
healthy males was incubated with furin or EDTA, then the reaction was quenched with EDTA. 
Immunoreactivity was measured in the BMP10 growth-factor domain ELISA. Mean of 































Figure 75. Serum activity is not increased by Furin treatment. Cells were incubated with 5% 
(v/v) of serum and the level of ID1mRNA was measured by qPCR relative to the housekeeper 


































Figure 76. Serum Pro:BMP9 levels are not increased by serum treatment. BMP9 levels were 
measured in the growth-factor domain ELISA. Mean of duplicates plotted. Mean ± SEM, n = 4, 
matched two-tailed Student’s t-test, **p < 0.01, NS = not significant. 
 
I needed a positive control to demonstrate furin was active under these conditions. 
Fluorometric readouts of furin activity comprise the furin recognition peptide quenching the 
fluorophore AMC (Pyr-Arg-Thr-Lys-Arg-AMC). I added it to serum in identical conditions to 
those used above. Furin treatment significantly enhanced fluorescence, showing furin was 
active (figure ). However, there was significant cleavage in serum without furin or with 
EDTA. is indicated serum contains calcium-independent proteases which were able to 
cleave this peptide, despite the protective pyroglutamyl residue on this molecule.  
 









































Figure 77. Furin is active in serum. Serum was incubated with furin, EDTA and/or fluorometric 
furin substrate. At the times indicated, fluorescence was measured. Mean ± SEM of 
duplicates. The experiment was performed on three separate occasions and one 
representative is shown. Dashed line = non-specific fluorescence of serum. 
 
To investigate whether serum ProBMP is likely to be a furin substrate, I analysed the 
twenty amino-acid furin binding region of ProBMP and ProBMP using the structural and 
empirical analysis of Tian (). As expected, both proteins show characteristics of good 
furin substrates: ProBMP has an RIRR316↓ motif aligned with RRKR↓ in ProBMP, both of 
which correspond to furin’s most favoured recognition sequence, RX[K/R]R↓. However, the 
furin binding region of ProBMP contains several large, inflexible residues in positions where 
small residues are expected to aid furin binding (figure ). is could predict that furin 




Figure 78. Furin recognition sequences of ProBMP9 & ProBMP10. BMP9: The amino acid 
sequence of ProBMP9 from residue 308-325 annotated according to the properties of those 
amino acids. BMP10: The amino acid sequence of ProBMP10 from residue 305-322 annotated 
according to the properties of those amino acids. Favoured: The characteristics of the most 
efficiently cleaved Furin substrates according to Tian (2009). Cleavage occurs between 
residue 1 and 1’. The box is the most important furin recognition sequence, whilst the 
surrounding twenty amino-acid region tends to have particular motifs. 
 
To assess whether ProBMP is processed during secretion ex vivo, I took mouse 
right-atria, left-atria, livers and lungs, and cultured them in serum-free media alone, or media 
supplemented with foetal bovine serum, BMP, or lipopolysaccharide. I was able to recover 
low levels of secreted processed BMP in conditioned media from right-atria, but not other 
organs, using the BMP growth-factor domain ELISA (figure ). Similarly, conditioned 
media from right-atria, but not other organs, had activity on cells (figure ). Unfortunately, 
the pBMP ELISA did not cross-react with mouse samples (not shown), and western blots of 
the atrial conditioned media contained several non-specific bands (not shown). erefore, I 
was unable to show what proportion of secreted BMP is processed versus unprocessed. 
ese results suggest the correlation in plasma BMP and pBMP levels is not via BMP 
stimulating atrial BMP secretion. 



























Figure 79 (overleaf). Processed BMP10 is secreted from mouse right atria ex vivo. Mouse 
organs were transferred into DMEM media supplemented with 5 ng/ml BMP9, 1 µg/ml LPS or 
10% FBS where indicated. Levels of BMP10 in conditioned media were measured in the 
BMP10 growth-factor domain ELISA. No BMP10 was detectable in conditioned media from 











































































Figure 80. Processed BMP10 is secreted from mouse right atria ex vivo. Quiescent HMECs 
were incubated with 10% (v/v) conditioned media and the level of ID1& ID2 mRNA was 
measured by qPCR relative to the housekeeper B2M. Mean ± SEM, n = 3, dashed line = 
expression in untreated quiescent cells (SFM). 
 
.. Circulating BMP & BMP may be in complex 
We found circulating levels of BMP and ProBMP are tightly correlated (figure ), and 
Tillet et al. () report cross-immunoreactivity of endogenous, but not pure, BMP and 
BMP in ELISAs and affinity columns. is suggests these ligands may be in complex, 
perhaps with other proteins.  
Immunoprecipitation with anti-BMP antibodies cleared about one-third of the 
ProBMP from plasma as measured by ELISA (figure ). Conversely, immunoprecipitation 
with anti-BMP antibodies cleared about one-quarter of the Pro:BMP from plasma. is 
suggested a proportion of the two ligands are physically coupled in plasma. Any physical 
association between BMP and BMP appears not to be : based on the very different 
circulating concentrations of BMP and BMP, and the fact vastly more BMP is cleared by 

































































Figure 81. Immunoprecipitating BMP9 from plasma pulls-down some pBMP10 and vice 
versa. I immunoprecipitated plasma from four healthy males with anti-BMP9, anti-BMP10 or 
non-specific IgG (mock). Immunoreactivity was measured in the pBMP10 (left) and BMP9 
GFD (right) ELISAs. Mean of duplicates plotted. Mean ± SEM, n = 4, matched two-tailed 




Neither BMP nor BMP could be detected by ELISA in serum without the presence 
of the calcium chelator EDTA. is could be because chelation reduces non-specific 
inhibition, or there may be a factor that binds and masks BMP and BMP in a divalent 
cation dependent way. To investigate the effect, I spiked Pro:BMP into human serum with 
and without  mM EDTA and measured its immunoreactivity by ELISA (figure ). At high 
concentrations of exogenous BMP, recovery efficiency was similar with and without EDTA—
-. With EDTA, recovery efficiency increased above  at low concentrations of 
exogenous BMP, as expected when endogenous BMP is also being recovered. When the 
concentration of endogenous BMP was subtracted from the concentration of recovered 
BMP, recovery of exogenous BMP was - efficient to a limit of ~ pg/ml. Without 
EDTA, recovery abruptly dropped to  at ~ pg/ml of exogenous BMP. Since detection of 
both endogenous and exogenous BMP is inhibited without EDTA, either there is a non-
specific cause, or a binding protein is present in excess.  
 
 




































Figure 82. EDTA is needed for the detection of endogenous and exogenous BMP9 in serum. I 
prepared serial dilutions of Pro:BMP9 in serum, serum supplemented with EDTA, and PBS. 
Immunoreactivity was measured in the BMP9 growth-factor domain ELISA. BMP9 
concentration in each sample was calculated based on a curve fitted with four parameter 
logistic regression to the PBS samples. I subtracted the concentration of endogenous BMP9 
from the total BMP9 concentration recovered from spiked serum to leave the amount of 
exogenous BMP9 recovered. I then normalised the BMP9 concentration recovered from 
serum by the BMP9 concentration recovered from PBS to calculate the proportion of 
exogenous BMP9 recovered. In the presence of EDTA, 20-40 pg/ml of exogenous BMP9 was 
the minimum amount required for efficient recovery. In the absence of EDTA, 200 pg/ml of 
exogenous BMP9 was the minimum amount required for efficient recovery. Mean ± SEM of 














































Figure 83. EDTA relieves specific inhibition of BMP9 immunoreactivity in serum. Serum from 
four healthy males was cleared with anti-BMP9 where indicated. EDTA was added where 
indicated. Immunoreactivity was measured in the BMP9 GFD ELISA. Mean of duplicates 
plotted. Mean ± SEM, n = 4, matched two-tailed Student’s t-testing, * p < 0.05. Blank = diluent 
alone without serum. 
 
EDTA had no effect on immunoreactivity in blank wells of the ELISA, so EDTA does 
not have a serum-independent effect (figure ). Presence versus absence of EDTA barely 
altered the immunoreactivity of serum cleared of BMP by immunoprecipitation—EDTA did 
not relieve much non-specific inhibition of immunoreactivity. In the absence of EDTA, BMP-
immunoprecipitation barely altered the immunoreactivity of serum—BMP had minimal 
immunoreactivity without EDTA. In the presence of EDTA, BMP immunoprecipitation 
resulted in a profound reduction in immunoreactivity—BMP had high immunoreactivity 
with EDTA. ese data indicate the biggest effect of EDTA was to relieve specific inhibition, 
perhaps a binding protein. 
To test whether BMP and BMP are bound to macromolecules within serum, I 
undertook column-based size-exclusion chromatography. Firstly, I assessed columns of 
different lengths, different fraction collection volumes, and different matrices with samples 
comprising molecular weight markers, Pro:BMP and recombinant BMP. It was particularly 
important that there were several fractions separating blue-dextran, a marker of void volume 
(~ MDa), and Pro:BMP, since any Pro:BMP complexes would resolve here. Sephacryl S- 
in a  cm column gave sufficient resolution.  
Firstly, I assayed a ladder comprising coloured size markers, recombinant BMP 
growth-factor domain and Pro:BMP. Next, I assayed EDTA-plasma supplemented with the 
same size-markers, but without exogenous BMP or Pro:BMP (figure ). For both, the 
eluent was PBS supplemented with EDTA to prevent plasma clotting. I measured the 
immunoreactivity of samples in the BMP and pBMP ELISAs. Most plasma BMP and 
BMP eluted in the same volume as Pro:BMP, although there was some immunoreactivity 
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in later fractions, perhaps representing BMP and BMP which bound the matrix or non-
specific immunoreactivity. Secondly, there was a peak of immunoreactivity in early fractions, 
which could have been complexes, aggregates, BMP bound to blue-dextran, or non-specific 
immunoreactivity.  
Next, I assayed serum using PBS containing calcium and magnesium as the eluent, to 
stabilise any EDTA-sensitive complexes. To measure immunoreactivity in the ELISAs, I 
supplemented EDTA back into fractions so eluted BMP and pBMP could be measured. 
Serum immunoreactivity was confined to fractions eluting with blue-dextran, or late 
fractions, with no peak eluting in the same volume as Pro:BMP. Since there was some 
immunoreactivity in the ladder in early fractions, I re-ran the ladder and serum excluding 
blue-dextran as a marker. is prevented the elution of exogenous BMP or Pro:BMP in 
early fractions of the ladder, showing this was an artefact of BMP binding to blue-dextran. 
is did not reduce the elution of endogenous immunoreactivity in early fractions of serum, 
showing this is due to complexes, aggregates or non-specific immunoreactivity (figure ). I 
also eluted serum supplemented with EDTA in PBS supplemented with EDTA. is 
recapitulated the pattern seen with EDTA-plasma, confirming the hypothesis that BMP 




































































Figure 84. Size exclusion chromatography of BMP9, Pro:BMP10, plasma & serum. Ladder 
comprised BMP9 GFD and Pro:BMP10.  Plasma & ladder were eluted in PBS supplemented 
with EDTA. Serum was eluted in PBS with calcium & magnesium. The centre of the elution 
peak for dextran blue and equine myoglobin is indicated. Immunoreactivity was measured in 
the BMP9 ELISA (top) and pBMP10 ELISA (bottom). Technical duplicates, mean ± SEM, n = 1. 
Curves have been shifted by up to 1 position to align the ladder between samples. Absorbance 
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Figure 85. Size exclusion chromatography of BMP9, Pro:BMP10 & serum. Ladder comprised 
BMP9 GFD and Pro:BMP10.  Serum + EDTA was eluted in PBS supplemented with EDTA. 
Serum and ladder were eluted in PBS with calcium & magnesium. Immunoreactivity was 
measured in the BMP9 ELISA (top) and pBMP10 ELISA (bottom). Technical duplicates, mean 
± SEM, n = 1. Curves have been shifted by up to 1 position to align the ladder between 
samples. Absorbance is normalised for each sample so the highest absorbance = 1, and 
lowest = 0. 
 
To show these peaks are due to specific immunoreactivity, I measured the activity of 
different fractions on BRE-HMECs. Unfortunately, there was insufficient Pro:BMP activity in 
the ladder to stimulate HMECs, and serum contained potentially non-specific activity in a 
large number of fractions (figure ). ese experiments will be repeated with serum from 
three individuals to confirm these findings. 
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Figure 86. Size exclusion chromatography of BMP9, Pro:BMP10 & serum. Fractions from 
figure 85. 10% (v/v) of ladder fractions or 25% (v/v) serum fractions were added to quiescent 
BRE-HMECs. Mean of duplicates plotted ± SEM, n = 1. Curves have been shifted by up to 1 
position to align the ladder between samples. 
 
.. Discussion 
I demonstrated the BMP growth-factor domain ELISA only detected processed BMP, 
supporting the assumption of Nikolic et al. (). is contrasts Bidart et al. () who 
speculated this antibody pair detects both processed and unprocessed BMP. Therefore, we 
conclude Pro:BMP circulates at active concentrations in healthy adults, and GDF mutation 
carriers have reduced circulating levels of active BMP. Conversely, an ELISA which only 
detects ProBMP-SC did not detect any endogenous circulating ProBMP. e ProBMP 
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ELISA was inefficient in plasma but depleting endogenous BMP lead to very little change in 
immunoreactivity. erefore, I hypothesised there is very little circulating ProBMP. To test 
this, recovery efficiency from plasma of a non-processable but otherwise properly folded and 
secreted variant of ProBMP could be tested.    
 I demonstrated the BMP growth-factor domain ELISA only detects processed 
BMP. This ELISA detected low levels of endogenous immunoreactivity, despite high 
recovery efficiency of exogenous Pro:BMP from plasma. Depleting endogenous BMP leads 
to little change in immunoreactivity. erefore, I hypothesised only low levels of Pro:BMP 
circulate in healthy people. Conversely, the pBMP ELISA detected both Pro:BMP and 
ProBMP, and recovered high levels of endogenous immunoreactivity. erefore, I 
hypothesised ProBMP is the predominant circulating species. 
Unfortunately, I have not been able to Western blot endogenous BMP and BMP to 
visualise the circulating species of each. Similarly, I was unable to cleave endogenous 
ProBMP by furin treating serum. Positive controls comprised of wildtype ProBMP and 
ProBMP, perhaps produced by overexpression in HEK-EBNA cells treated with prohormone 
convertase inhibitors, would be ideal. Additionally, plasma/serum size fractions may be more 
amenable to analysis since they are likely to contain less non-specific immunoreactivity. 
I found anti-BMP could clear - of the activity of a -hour treatment of  
serum or  plasma on microvascular, aortic and pulmonary artery endothelial cells as 
measured by ID gene expression. But I found anti-BMP could only clear ~ of the activity 
of a -hour treatment of  serum or  plasma on BRE-HMECs. e receptors expressed 
by HMEC and pulmonary artery endothelial cell lines were characterised in Upton et al. 
(). ey express ALK,,, BMPR, and , enabling them to respond to BMP,,, and 
. Nonetheless, in developing the BRE-HMEC line, Dr. Benjamin Dunmore tested their 
responses and found minimal responses to  ng/ml of BMP and , a small response to  
ng/ml of BMP, but a maximal response to BMP at just . ng/ml. Hence, these cells are 
unlikely to be responding to other BMPs in plasma or serum. Confirming this, 
immunoprecipitation with anti-BMP and anti-BMP together cleared almost all activity.  
Complicating assessment of the relative contribution of BMP and BMP to serum 
activity, some BMP is removed by immunoprecipitating BMP and vice versa. Unlike 
immunoprecipitations, BMP neutralisations should only alter BMP activity. Herrerra and 
Inman () found anti-BMP can neutralise ~ of the activity of a -hour treatment of 
 serum on CC cells transfected with BRE:LUCIFERASE. Similarly, Chen et al. () 
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find anti-BMP neutralises ~ of the activity of serum on human umbilical cord endothelial 
cells as measured by SMAD expression (details not explained).  
In contrast, Jiang et al. () report anti-BMP can clear  of the activity of a -
hour treatment of  plasma on pulmonary artery endothelial cells as measured by ID gene 
expression. David et al. () and Bidart et al. () report anti-BMP can neutralise 
~ of the activity of a -hour treatment of  plasma and serum on NIH-T cells 
transfected with ALK and BRE:LUCIFERASE. Nikolic et al. () find anti-BMP neutralises 
- of the activity of a -minute treatment of  serum on pulmonary microvascular 
endothelial cells as measured by nuclear phospho-SMAD staining. Similarly, David et al. 
() report anti-BMP can neutralise ~ of the activity of a -hour treatment of  
serum on microvascular endothelial cells as measured by phospho-SMAD blotting. 
ere are no obvious patterns in cell-type, treatment length, assay readout or substrate 
concentration to explain the different degree of residual activity after BMP neutralisation. 
is has implications for whether circulating BMP is active—Chen et al. claim BMP 
accounts for ~ of activity and Jiang et al. , whilst others conclude all activity is 
accounted for by BMP. My data suggests BMP accounts for ~ of circulating activity as 
measured by BRE-luciferase experiments, but < as measured by ID  transcription. I showed 
Gdf knockout mice and homozygous nonsense children have little-to-no residual circulating 
BMP/ activity, although the latter also have low circulating pBMP levels. Ricard et al. 
report Gdf knockout mice have normal BMP levels, but no plasma activity on NIH-T 
cells transfected with ALK and BRE:LUCIFERASE. Whatever the nuance, all reports agree 
circulating BMP has more activity than circulating BMP, suggesting the latter is 
predominately unprocessed. My ELISA data supports this interpretation.  
HEK-EBNA cells overexpressing ProBMP readily process it with endogenous 
proteases. However, HEK-EBNA cells overexpressing ProBMP must be transfected with 
additional furin, and processing remains less efficient than for ProBMP (Jiang et al. ). 
Less efficient processing of ProBMP compared to ProBMP was also reported by David et al. 
(). ese observations lend weight to the idea that circulating ProBMP is unprocessed 
and resistant to furin cleavage despite the fact that ProBMP can be processed by furin and 
other prohormone convertases in vitro (Susan-Resiga et al. ). 
Active BMP was secreted from mouse right-atria, validating Jiang et al. (), 
although it is not clear if any secreted BMP is unprocessed. In future, I could develop tissue 
extract ELISAs and Western blots to look at frozen human atria, which are more tractable 
with the antibodies we have. Circulating ProBMP may be processed in specific tissues, 
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whilst circulating Pro:BMP is already fully active. is could partly explain the different 
disease associations, activities, and knockout animal phenotypes of GDF and BMP.  
Immunoprecipitations reveal that a minority of plasma BMP and BMP are in 
complex with one another. is would seem unlikely to be an artefact of cross-reactivity since 
similar amounts of antibody were used in ELISAs and Dr. Paul Upton demonstrated 
Pro:BMP and Pro:BMP do not cross-react in ELISAs. Nonetheless, samples of Pro:BMP or 
Pro:BMP in PBS could be assayed through the same immunoprecipitation protocol to check 
for non-specific effects. Some of the complexes may represent a heterodimer, as proposed by 
Tillet et al. (). However, we have shown the majority of each are not in a dimeric 
complex. Moreover, EDTA can relieve something which masks the immunoreactivity of 
endogenous and exogenous BMP in serum. Size exclusion chromatography suggests this is 
likely to be a large macromolecule, since serum BMP and BMP eluted in the void volume, 
and the matrix has an upper resolution limit of ~. million Daltons. is changes the 
interpretation of Tillet et al.’s results. e potential existence of BMP and BMP binding 
proteins is important because they could alter their stability, activity and bioavailability. 
 
5. Pharmacokinetics of BMP 
5.1. Introduction 
The Morrell group is interested in using BMP therapeutically and in animal models, so 
understanding its stability and utilisation in the circulatory system is important. BMP is 
secreted from the liver, and perhaps the lung, and mediates endothelial SMAD signalling 
(David et al. ; Bidart et al. ). BMP is secreted from the right-atrium, and perhaps 
the liver, and mediates SMAD signalling proximal to the heart (Tillet et al. ; Laux et al. 
). Endogenous BMP and BMP need only travel a short distance before reaching the 
pulmonary vasculature (figure ). Pulmonary artery endothelial cells highly express high-
affinity BMP and BMP receptors. erefore, it has been hypothesised there is gradient of 
BMP and BMP activity, with the pulmonary vasculature stimulated by the greatest levels 
(Li et al. ). is could partly explain why the pulmonary vasculature is particularly 
sensitive to loss of BMP in PAH. 
No one knows whether BMP and BMP distribute across compartments or are confined to 
the blood. eir prodomains may mediate binding to extracellular molecules, and they may be 
sequestered to specific vascular beds. If circulating BMP is predominately unprocessed (see 
.), then specific tissues may process ProBMP. There may be local sources of each ligand, 
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especially in the lung, which expresses GDF and to a lesser extent, BMP. Circulating 
binding proteins, suggested to exist in ., may stabilise or modulate the availability of BMP 
and BMP. In humans, neither the pharmacokinetics of BMP nor BMP has been explored.  
 
 
Figure 7. The pulmonary vasculature is the first organ bed endogenous BMP9 and BMP10 
travel through. Endogenous BMP9 is primarily expressed in the liver. Hepatic capillary beds 
drain into the hepatic veins which join the inferior vena cava close to where it empties into the 
right atrium. BMP10 is primarily expressed in the right atrium and vessels here drain into the 
right-atrial lumen. From the right atria, blood flows into the right ventricle, and is expelled into 
the pulmonary arteries. 
 
We wanted to investigate the half-life of circulating BMP and where it binds. 
erefore, Dr. Paul Upton, Stephen Moore, Dr. Alexi Crosby and I gave wildtype and Gdf 
knockout mice purified human Pro:BMP intravenously and I measured BMP levels in 
different compartments over time. To explore the distribution of endogenous BMP in 
humans, Drs. Emilia Swietlik and Kasia Zalewska collected blood from different blood 
vessels of the same patients and I measured BMP levels in the plasma. 
 
. Administration of Pro:BMP toGdf knockout mice 
First, we administered exogenous Pro:BMP into Gdf knockout mice by intravenous injection 
(figure ). is ensures that a known amount of BMP entered the circulation at a known 
time and that all detectable protein and activity is due to the exogenous dose. We used 
purified human Pro:BMP since the Morrell group routinely produces this and it has almost 
identical signalling activity and immunoreactivity to mouse BMP.  
We diluted the Pro:BMP in PBS supplemented with mouse-serum albumin. is 
vehicle minimises osmotic shock and reduces adsorption of Pro:BMP to syringes etc. 
Concentrated aliquots were stored at - oC in siliconized tubes. To reduce variability, we 
normalised the injection volume by body weight of each mouse. To increase sensitivity, we 
used a supraphysiological dose of . µg of Pro:BMP per kg of bodyweight, which is 




Figure 88. Experimental plan of Pro:BMP9 administration to Gdf2 knockout mice. Purified 
human Pro:BMP9 was diluted to 0.5 ng/µl in 1% (w/v) mouse serum albumin in PBS. Five µl/g 
(~10% blood volume, 2.5 µg/kg) of Pro:BMP9 solution or vehicle was administered by tail vein 
injection to three mice each. After 5 minutes, blood was withdrawn from the saphenous vein, 
and after 20 minutes, a lethal dose of pentobarbitone was administered. Mice were 
exsanguinated by cardiac puncture. Blood was collected into EDTA tubes, and plasma 
collected by centrifugation. The circulatory system was flushed with heparinised saline and 
liver and lung were snap frozen. One lung was inflated and fixed with formalin. 
 
I measured plasma levels of BMP in blood taken  minutes and  minutes after 
injection of Pro:BMP or vehicle. Surprisingly, I was unable to detect any BMP in any of these 
plasmas by ELISA (figure ). Similarly, I was unable to detect any plasma BMP activity on 
endothelial cells (figure ). Importantly, BMP recovery efficiency from the residual fluid in 






































Figure 89. Intravenously administered Pro:BMP9 is undetectable in plasma by ELISA. Gdf2 
knockout mice were given Pro:BMP9. After 5 & 20 minutes, plasma was collected. BMP9 
levels were measured in an aliquot of Pro:BMP9 which was passed through a syringe to 
simulate injection and diluted to bring it into range of the ELISA, and plasmas. Samples were 

































































































Figure 90 (overleaf). Gdf2 knockout mice have no plasma BMP9 activity on endothelial cells 
even after intravenously administering Pro:BMP9. Mice were given Pro:BMP9 or vehicle. After 
5 & 20 minutes, plasma was collected. Quiescent aortic endothelial cells were incubated with 
1% (v/v) plasma, or diluted Pro:BMP9 solution from the syringe, or with 15 ng/ml of 
recombinant BMP9. The latter serves as a positive control for the expected plasma activity of 
mice given Pro:BMP9. mRNA levels of ID1 and ID2 were measured by qPCR relative to the 
housekeeping gene B2M. Mean ± SEM, n = 3, dashed line = expression in untreated quiescent 
cells (0.1%). 
Pro:BMP spiked into human plasma can be recovered with ~ efficiency (Hodgson 
et al. ). I spiked Pro:BMP into whole human blood in EDTA-tubes, incubated it for  
hour at  oC, centrifuged it, and measured recovery from the plasma fraction (figure ). 
Simultaneously, I spiked Pro:BMP into pre-prepared EDTA-plasma. Recovery from spiked 
whole blood-plasma was more efficient than for spiked plasma. is could be explained by 
Pro:BMP being excluded from cells and so concentrated in the smaller plasma compartment: 
plasma and blood spike-recovery curves overlay if haematocrit is assumed to be ~. 
Recovery from spiked PBS was least efficient, perhaps because of adsorption to pipettes and 
tubes. ese data confirmed that exogenous Pro:BMP would be detectable from blood. 

























Figure 91. Pro:BMP9 is efficiently recovered from blood. I serially diluted human Pro:BMP9 in 
whole human blood treated with EDTA to prevent clotting, EDTA-plasma prepared from the 
same blood and PBS. I incubated samples for 1 hour at 37 oC then centrifuged to collect 
plasma from the EDTA-blood. I measured BMP9 levels in samples by ELISA using 
recombinant BMP9 in 1% (w/v) BSA in PBS as the standard. Mean ± SEM of technical 
duplicates, n = 3 with one representative experiment shown. 
 
Since exogenous BMP was not present in the blood of injected mice, I investigated 
whether it was sequestered into the liver or lungs—two organs which are known to express 
BMP receptors highly. I developed an ELISA protocol to quantify BMP levels in frozen tissue 
extracts. First, I checked whether RIPA tissue lysis buffer was compatible with the ELISA we 
use for plasma (figure ). RIPA buffer had no effect on the immunoreactivity of BMP 
standards when ≤  µl was present per  µl well. I tested the immunoreactivity of BMP 
standards made up in tissue extracts from Gdf knockout mice versus plain RIPA buffer (figure 
). is showed liver extract inhibited BMP detection, but diluting extract to ≤  (v/v) 
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enabled efficient recovery. In lung extracts, recovery efficiency decreased with increasing 
BMP concentrations, but quantification was more accurate below ~ pg/ml (figure ).   























Figure 92. RIPA tissue lysis buffer is compatible with the BMP9 growth-factor domain ELISA. 
I serially diluted recombinant BMP9 in 0-25% (v/v) RIPA buffer. I measured the 
immunoreactivity of these samples by ELISA. Mean ± SEM of technical duplicates. 
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Figure 93. Liver extract may repress BMP9 detection by ELISA unless diluted. I serially diluted 
recombinant BMP9 in either empty RIPA buffer or liver extract from a Gdf2 knockout (KO) 
mouse. I measured the immunoreactivity of these samples by ELISA. Mean ± SEM of 
technical duplicates. 
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Figure 94. Lung extract may repress detection of high concentrations of BMP9 by ELISA. I 
serially diluted recombinant BMP9 in either empty RIPA buffer or lung extract from a Gdf2 
knockout (KO) mouse. I measured the immunoreactivity of these samples by ELISA. Mean ± 
SEM of technical duplicates. 
 
Next, I compared BMP levels in livers from wildtype versus Gdf knockout mice, 
since the former is very likely to contain BMP, whilst the latter should not. As expected, 
diluting extracts  in  lead to highest recovery of BMP from wildtype livers (figure ). 
Importantly, there was some non-specific signal in Gdf knockout mice which gave an 
absorbance equivalent to ~ pg/mg of tissue in liver extracts and ~ pg/mg in lung extracts.  
 EDTA was necessary to recover BMP from serum. To see if it was necessary for tissue 
extracts, I measured immunoreactivity of liver samples from wildtype mice with and without 
118 
 
EDTA (figure ). I also assessed lung extracts of wildtype mice injected with Pro:BMP, since 
there was little BMP in wildtype lungs at baseline (see .). EDTA did not alter recovery, but 
I elected to continue including EDTA. Since the ELISA measurements were affected by the 
concentration of tissue extract, I decided to add exactly  ml of RIPA buffer per  mg of 
tissue before homogenising experimental samples. erefore, although absolute 
quantifications likely have some small error, the relative absorbances and concentrations of 
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Figure 95. The ELISA can discriminate effectively between positive and negative control 
tissue. I prepared liver lysates from wildtype (WT) and Gdf2 knockout (KO) mice. Total protein 
concentration of lysates was measured by Lowry assay. I diluted 5–25 ul of lysate and 
measured ELISA immunoreactivity. Left: Raw absorbances of samples. Right: Concentration 
of BMP9 in samples. Technical duplicates with mean plotted, n = 2, line = grand mean. 






















Figure 96. EDTA hardly affects BMP9 measurement in tissue extracts. Liver lysates from 
wildtype mice, and lung lysates from wildtype mice injected with Pro:BMP9, were prepared ± 5 
mM EDTA. I measured immunoreactivity of the samples in the BMP9 ELISA. Technical 
duplicates with mean plotted, n = 2, line = grand mean.  
 
Having optimised a tissue ELISA protocol, I compared BMP levels in the flushed 
livers of Gdf knockout mice injected with Pro:BMP or vehicle (figure ). ere was no 
significant difference between groups. is could indicate BMP is not taken up by the liver to 
a great extent, in fitting with the idea BMP is primarily an autocrine/paracrine in the liver. I 
confirmed this by looking at Id mRNA levels, since these are expressed by hepatic cells in 
response to BMP signalling (see ..). ere was no difference in levels between mice given 
Pro:BMP or vehicle (figure ).  
I also assessed whether exogenously administered Pro:BMP was sequestered to the 
lung. ELISA revealed lung lysates from mice injected with Pro:BMP had significantly higher 
immunoreactivity than lung lysates from mice given vehicle (figure ). As mentioned, there 
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was consistently ~ pg/ml of non-specific immunoreactivity in lungs of Gdf knockout mice 






































Figure 97. Intravenously administered BMP9 does not accumulate in the liver. Gdf2 knockout 
mice were given Pro:BMP9 or vehicle by tail vein injection. After 20 minutes, mice were killed. I 
measured liver extracts in the BMP9 ELISA. Samples were measured in duplicate and the 
mean is plotted. Left: BMP9 concentration plotted as normalised concentration per mg of 
tissue. Mean ± SEM, n = 3. All values are within the range of non-specific background for this 
assay (0-20 pg/mg). Right: Immunoreactivity of 5 µl and 25 ul lysates shown to demonstrate 

























Figure 98. Intravenous administration of BMP9 does not increase in BMP9 signalling in the 
liver. Gdf2 knockout mice were given Pro:BMP9 or vehicle. After 20 minutes, mice were killed. 
Liver RNA was extracted and levels of Id1 mRNA was measured compared to three house-




































Figure 99. Intravenous administration of BMP9 leads to an increase in BMP9 levels in 
flushed lungs. Gdf2 knockout mice were given Pro:BMP9 or vehicle. After 20 minutes, mice 
were killed. I measured lung extracts in the BMP9 ELISA. Samples were measured in duplicate 
and the mean is plotted. Left: normalised concentration per mg of tissue. Mean ± SEM, n = 3, 
unmatched two-tailed Student’s t-test. **p<0.01. Note ~15 pg/mg non-specific signal. Right: 
Immunoreactivity of 5 µl and 25 ul lysates shown to demonstrate the pattern is not an artefact 
of sample volume. 
 
To assess whether BMP was signalling in the lungs, I measured transcriptional 
induction of Id. Transcription was trending upwards in the lungs of mice injected with 
Pro:BMP compared to controls (figure ). is was not significant, but the duration of 
treatment was brief ( minutes) and there were only  mice in each group. Id expression in 
the lung was no higher in wildtype mice than Gdf knockout mice, so did not represent a 


























Figure 100. Intravenous administration of BMP9 may lead to a small increase in BMP9 
signalling in the lungs. Gdf2 knockout mice were given Pro:BMP9 or vehicle. After 20 minutes, 
mice were killed. Lung levels of Id1 mRNA was measured compared to three house-keeping 
genes (B2M, Hprt, bAct) by qPCR. Mean ± SEM, n = 3, unmatched two-tailed Student’s t-test.  
 
5.3 Administration of Pro:BMP to wildtype mice 
We hypothesised rapid clearance of exogenous Pro:BMP from Gdf knockout mice was a 
consequence of sequestration to a potential abundance of unoccupied receptors. Wildtype 
mice may have differing levels of BMP binding proteins and receptors, depending on 
feedback mechanisms, and will have endogenous BMP occupying some of these sites. We 
gave wildtype mice a higher dose of Pro:BMP, equivalent to ~ ng of recombinant BMP per 
ml of blood, to make it easier to detect and see whether we could saturate animals’ buffering 
capacity. We introduced a second group of mice that were followed for longer and included 
four mice per group to improve statistical power (figure ). 
 
Figure 101. Experimental plan of Pro:BMP9 administration to wildtype mice. Purified human 
Pro:BMP9 was diluted to 2.5 ng/µl in 1% (w/v) mouse serum albumin in PBS. Five µl/g (~10% 
blood volume, 12.5 µg/kg) of Pro:BMP9 solution or vehicle was administered by tail vein 
injection to eight mice respectively. Four vehicle and Pro:BMP9 injected mice had blood taken 
from the saphenous vein after 5 minutes and a lethal dose of pentobarbitone was 
administered after 30 minutes. The remaining mice had blood taken from the saphenous vein 
after 15 minutes and a lethal dose of pentobarbitone was administered after 60 minutes. Mice 
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were exsanguinated by cardiac puncture. Blood was collected into EDTA tubes, and plasma 
collected by centrifugation. The circulatory system was flushed with heparinised saline and 
tissues were collected and snap frozen. 
 
Again, I measured circulating levels of Pro:BMP by ELISA (figure ). There was a 
small, significant increase in plasma BMP levels in mice given exogenous Pro:BMP compared 
to vehicle (two-way unmatched ANOVA, p = .). is increase did not account for the vast 
majority of exogenous Pro:BMP we administered. It was hard to see if the magnitude of this 
increase was stable across the time-course: there was no significant interaction between 
treatment and time for mice in the - minute arm (p = .), but there was a significant 
interaction in the - minute arm (p = .). erefore, I could not calculate the half-
life of exogenous Pro:BMP. ere was a significant decrease in plasma BMP levels in mice 
over time (p < .). is could be due to factors such as increased circulatory volume 
(injection volume ~ blood volume), stress or heat exposure (used to enable intravenous 
injections).  
















Figure 102. Intravenously administering Pro:BMP9 increases plasma levels. Mice were given 
Pro:BMP9 or vehicle by tail vein injection. After 5, 15, 30 & 60 minutes, plasma was collected. 
BMP9 levels were measured plasmas by ELISA. Technical duplicates with mean plotted. Mean 





































Figure 103. Plasma activity of mice after intravenous administration of Pro:BMP9. Mice were 
given Pro:BMP9 or vehicle by tail vein injection. After 5, 15, 30 & 60 minutes, plasma was 
collected. Quiescent aortic endothelial cells were incubated with 1% (v/v) plasma and mRNA 
levels of ID1 and ID2 were measured by qPCR compared to the housekeeping gene B2M. 
Mean ± SEM, n = 4 (except for 60 min samples). 
 
Plasma activity did not show a robust pattern (figure ). As expected, ID 
expression in endothelial cells was upregulated after exposure to plasma from mice treated 
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with Pro:BMP compared to vehicle (p = .), but ID expression was not (p = .). 
Plasma activity increased significantly with time (p = . and . for ID and ID 
respectively). Discordance between plasma BMP levels and activity could be explained 
because: BMP levels only changed subtly; activity assays were relatively noisy; activity assays 
had lower sample sizes because sufficient plasma was not available from all mice; the activity 
of circulating BMP could be modulated independently of levels; or other factors, such as 
BMP, may also respond to Pro:BMP treatment. ese experiments were undertaken before 
BRE-HMEC cells, which offer a better signal-to-noise ratio, were developed. 
In the liver, BMP levels measured by ELISA tended to be lower in mice killed  
minutes after injection versus  minutes (p = .), but levels were not different between 
mice given Pro:BMP or vehicle (figure ). is again suggests circulating BMP is not 
sequestered into the liver. Instead, the liver may have either secreted more endogenous BMP, 
or reduced Gdf expression, over time. Id mRNA levels were similar in the livers of all groups 
(figure ). I am unsure if Id transcription was a good marker of hepatic BMP signalling, 
since levels were not different between Gdf knockout and wildtype mice. Addante et al. 
() also reported this, but believed it was due to accommodation in chronically BMP 
deficient animals, whereas acute ALK-Fc administration was able to reduce Id transcription.  
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Figure 104. Intravenously administered BMP9 does not accumulate in the liver. Mice were 
given Pro:BMP9 or vehicle. After 30 or 60 minutes, mice were killed, and I measured 
immunoreactivity of liver extracts in the BMP9 ELISA. Samples were measured in duplicate 
and the mean is plotted. Left: normalised concentration per mg of tissue. Mean ± SEM, n = 4. 
Dashed line = non-specific background of this assay. Right: Immunoreactivity of 5 µl and 25 ul 
lysates shown to demonstrate the pattern is not an artefact of sample volume. 

























Figure 105. Intravenous administration of BMP9 does not increase BMP9 signalling in the 
liver. Mice were given Pro:BMP9 by tail vein injection. After 30 or 60 minutes, mice were killed. 
Liver RNA was extracted and levels of Id1 mRNA were measured compared to three house-





In the lung, BMP levels were higher in mice given Pro:BMP compared to vehicle 
(figure ). is increase was greater in those mice killed at  minutes than  minutes, 
which suggested exogenous BMP was cleared from lungs over this time. ese data were 
mirrored by BMP signalling in the lung as measured by Id transcription (figure ). 
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Figure 106. Intravenously administered BMP9 accumulates in flushed lungs. Mice were given 
Pro:BMP9 or vehicle. After 30 or 60 minutes, mice were killed, and liver extracts were 
measured in the BMP9 ELISA. Samples were measured in duplicate and the mean is plotted. 
Left: normalised concentration per mg of tissue. Mean ± SEM, unpaired two-tailed Student’s t-
test, * p<0.05, ** p<0.01, n = 4. Dashed line = non-specific background of this assay. Right: 
Immunoreactivity of 5 µl and 25 ul lysates shown to demonstrate the pattern is not an artefact 
of sample volume. 
 
 





0.4 ** p = 0.07



















Figure 107. Intravenous administration of BMP9 leads to an increase in BMP9 signalling in 
the lungs. Mice were given Pro:BMP9 or vehicle. After 30 or 60 minutes, mice were killed, and 
lung levels of Id1 mRNA were measured compared to three house-keeping genes (B2M, Hprt, 
bAct) by qPCR. Mean ± SEM, n = 4, unpaired two-tailed Student’s t-test ** p<0.01. KO = sample 
from Gdf2 knockout mouse. 
 
5.4. Endogenous BMP in pharmacokinetic mice 
I assessed the expression of endogenous Gdf by qPCR in the livers and lungs of mice given 
exogenous Pro:BMP to explore whether compensation occurs (figure ). In the liver, Gdf 
transcripts were more abundant at  minutes than  minutes post injection (p = .), 
and slightly higher in animals given Pro:BMP compared to vehicle (p = .). ELISA and 
qPCR data are consistent with blood volume increasing after injection, followed by secretion 
of BMP protein from the liver, compensated by increased Gdf transcription.  
124 
 
As expected, Gdf expression was much lower in lungs compared to liver. 
Nonetheless, some BMP may be produced endogenously within lungs, since Gdf mRNA was 
more abundant in lungs from wildtype mice than Gdf knockouts. is confirms previous 
reports (Bidart et al. ; Hao Chen et al. ). Importantly, lung Gdf mRNA levels did 
not change in response to administration of exogenous Pro:BMP, indicating the increased 
ELISA immunoreactivity of these lungs was due to them sequestering exogenous Pro:BMP.  




























Figure 108. Gdf2 is expressed in the liver and lungs. Liver expression increased over the 
time-course of the experiment whereas lung expression was stable. Mice were given 
Pro:BMP9 or vehicle. After 30 or 60 minutes, mice were killed, and levels of Gdf2 mRNA were 
measured compared to three house-keeping genes (B2M, Gapdh, bAct) by qPCR. Mean ± SEM, 
n = 4, KO = sample from Gdf2 knockout mouse. 
 
I analysed tissue lysates from all the pharmacokinetic mice simultaneously. erefore, 
I could compare BMP levels in the lungs of wildtype and Gdf knockout mice given vehicle. 
Interestingly, wildtype lungs did not contain significantly more BMP than Gdf knockout 
lungs (figure ), despite experiencing more signalling (figure ). ere was a slight 
tendency for wildtype lungs to have higher immunoreactivity, and there were only three 
knockout lungs for comparison. Nevertheless, these data suggest endogenous BMP protein 
exists in an equilibrium where it does not accumulate greatly in the lungs. is is consistent 





































Figure 109. Endogenous BMP9 does not accumulate within the lungs. Samples from mice 
given vehicle were measured in duplicate in the BMP9 ELISA and the mean is plotted. Left: 
normalised concentration per mg of tissue. Mean ± SEM. Non-specific background of this 
assay ~ 15 pg/ml. Right: Immunoreactivity of 5 µl and 25 ul lysates shown to demonstrate the 




5.5. Binding of BMP to endothelial cells in vitro 
Some factors bind matrix secreted by their target cells and local pools stimulate prolonged 
signalling. It is unknown how long BMP remains active once bound to its receptors, or if 
endothelial cells maintain a reservoir of active BMP after exposure. I studied the signalling 
kinetics of endothelial cells in vitro to assess whether exogenous BMP, which is rapidly 
cleared from plasma, could be sequestered by endothelial cells and if it could have a 
prolonged stimulatory effect.  
Firstly, I exposed human aortic endothelial cells to physiological doses of BMP. After 
 minutes, I washed them with fresh media which either also contained BMP or did not 
(figure ). Cells incubated for  hour after a pulse of BMP exposure had the same 
transcriptional response as continuously exposed cells. However, the efficacy of the pulse 
rapidly tailed off between  and  hours, indicating cells did not sequester a pool of BMP able 
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Figure 110. Brief exposure to BMP9 elicits a brief transcriptional response. Human 
aortic endothelial cells grown to confluence in 6-well plates were quiesced overnight and then 
media was replaced with fresh 0.1% (v/v) FBS in EBM2 that was supplemented with 0, 30 or 
300 pg/ml BMP9. After 5 minutes, this was replaced with fresh 0.1% FBS (v/v) in EBM2 
supplemented with 0 (spike), or 30 and 300 (constant) pg/ml BMP9. Cells were incubated for 
1, 4 or 8 hours. Levels of ID1 and ID2 mRNA were measured by qPCR compared to the 
housekeeping gene B2M. Technical triplicates, mean plotted, n = 1. 
 
Secondly, I treated endothelial cells with physiological concentrations of BMP for  
minutes or  hours. I then transferred this media onto fresh cells to measure residual activity 
(figure ). is experiment indicated endothelial cells needed longer than  minutes to 
appreciably clear BMP activity, but could consume all available BMP within  hours. I 
performed a similar experiment and used an ELISA to show that a confluent monolayer of ~ 
million endothelial cells could almost completely clear  ng of BMP within  hours (figure 
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). Taken together, these data are consistent with endothelial cells consuming BMP 











































































































Figure 111. Endothelial cells clear media of BMP9 activity over the course of hours Human 
aortic endothelial cells grown to confluence in 6-well plates were quiesced overnight in 0.1% 
(v/v) FBS in EBM2. Cells, or empty wells (cell-free) were then incubated with 0.1% (v/v) FBS in 
EBM2 containing 0, 30 or 300 pg/ml of BMP9. After 30 minutes, or 30 hours, this media was 
collected and frozen and cells were lysed. The conditioned media or cell-free control media 
were then thawed and incubated with fresh quiesced cells for 1 hour before lysis. Levels of ID1 
and ID2 mRNA were measured by qPCR compared to the housekeeping gene B2M. Technical 
triplicates with mean plotted, n = 1. Conditioned media exposed to cells for 30 minutes 
remained fully active, whilst conditioned media exposed to cells for 30 hours had no activity. 










































































































Figure 112. Endothelial cells clear media of BMP9 activity over the course of hours by 
removing BMP9 protein from the media. Human aortic endothelial cells were grown to 
confluence in 6-well plates and quiesced overnight. Cells, or empty wells (cell-free) were then 
incubated with 0.1% FBS (v/v) in EBM2 containing 0 or 3000 pg/ml BMP9 for 24 hours. I 
collected conditioned media and lysed these cells. I aliquoted conditioned media for 
measurement in the BMP9 ELISA and incubated the rest with fresh quiescent cells. I lysed the 
fresh cells after 1 hour. Left, middle: levels of ID1 and ID2 mRNA were measured by qPCR 
compared to the housekeeping gene B2M. Right: BMP9 levels in conditioned media as 




5.6. Transvascular gradients of BMP & pBMP in humans  
Intravenously administered exogenous Pro:BMP appeared to primarily accumulate in mouse 
lungs, but not peripheral venous plasma or liver. is led us to hypothesise that in 
unmanipulated animals and humans, pulmonary arterial blood contains high levels of 
endogenous BMP, which is quickly bound by the endothelium of the lung vasculature, so 
systemic blood has relatively reduced levels of BMP. Although we suspect circulating BMP 
is mostly unprocessed, we hypothesised the pulmonary vasculature binds and activates it. 
To assess these hypotheses, I obtained plasma samples collected from different human 
vascular beds by clinical researchers at Royal Papworth Hospital. Samples from  female and 
 male IPAH patients, aged -, were available. As a comparison group, I selected  females 
and  males with a patent foramen ovale (PFO), both to confirm IPAH samples did not have 
an unusual pattern, and because cardiac defects may be associated with BMP deficiency.  
Plasmas were from the superior vena cava (SVC), pulmonary artery (PA) and brachial 
artery (Art). I measured these in the BMP (figure ) and pBMP (figure ) ELISAs. For 
each individual, the transpulmonary gradient is PA-Art, whilst the gradient across systemic 
organs is Art-SVC. e data may not be normally distributed (D'Agostino-Pearson p < . 
sexes grouped; too few to assess when split) so I analysed data with Friedman tests. ere was 
no significant difference between IPAH and PFO groups. Males had reduced levels of both 
BMP and pBMP, as expected, although this did not reach significance. Unexpectedly, BMP 
levels were very slightly lower in pulmonary arteries ( ±  pg/ml) and brachial arteries 

























































Figure 113. BMP9 growth-factor domain levels measured in plasma from different vessels 
by ELISA. Plasma from 15 female & 3 male PAH patients, 8 female & 7 male PFO patients, 
collected from the superior vena cava (SVC), brachial artery (Art) and pulmonary artery (PA). 
Left:  data grouped according to disease classification and sampling location. Lines connect 
samples from the same individual. Right: data grouped according to sex and sampling 
location. Controls = four samples taken from the cephalic vein of healthy adults. Samples 
were assayed in duplicate with the mean plotted. Bar = grand mean.  
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Surprisingly, pBMP levels followed a different pattern, with levels higher in the 
pulmonary arteries ( ±  pg/ml) than brachial arteries ( ±  pg/ml) than 
superior vena cava ( ±  pg/ml), as expected (p = .). I also measured samples from 
the cephalic vein of four healthy males and females, since this is the location sampled in other 
cohorts. Levels of BMP and pBMP in cephalic vein samples showed pronounced sex 
differences as expected. Unexpectedly, levels were higher in these controls than the great 


























































Figure 114. pBMP10 levels measured in plasma from different vessels by ELISA. Plasma 
from 15 female & 3 male PAH patients, 8 female & 7 male PFO patients, collected from the 
superior vena cava (SVC), brachial artery (Art) and pulmonary artery (PA). Left:  data grouped 
according to disease classification and sampling location. Lines connect samples from the 
same individual. Right: data grouped according to sex and sampling location. Controls = four 
samples taken from the cephalic vein of healthy adults. Samples were assayed in duplicate 
with the mean plotted. Bar = grand mean.  
 
I hypothesised the slight fall in total pBMP levels across the pulmonary vasculature 
could represent utilisation of processed Pro:BMP. erefore, I measured plasma activity of 
these samples on BRE-HMECs (figure ). is showed no significant difference between 
plasmas from different vessels. Notably, PAH patients tended to have lower plasma activity 
than PFO patients (p = .) driven by plasma from the superior vena cava. BRE-HMECs 
possibly process endogenous ProBMP and serum is a preferable substrate to plasma. (see 
.). Hence, I directly measured levels of processed BMP in these samples by ELISA (figure 
). There was no evidence of a transpulmonary gradient in Pro:BMP levels. 
As expected from ., most samples contained no detectable processed Pro:BMP as 
measured by the BMP growth-factor domain ELISA. However, plasmas from all three 
vessels within / patients contained - pg/ml of Pro:BMP, suggesting some people 
have meaningful circulating Pro:BMP levels. I investigated correlations between Pro:BMP, 
Pro:BMP and total pBMP levels (figure ). As expected, there was a tight correlation 
between BMP and pBMP levels in all samples. Surprisingly, Pro:BMP and pBMP levels 
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were not as robustly correlated. In contrast, processed BMP was only detectable in plasma 
samples with > pg/ml of BMP, and levels were well correlated with BMP. This could 
suggest some co-regulation between the amount of circulating BMP and processed BMP. 
Notably, one male with a patent foramen ovale had very high levels of both Pro:BMP 
(~ pg/ml) and Pro:BMP ( pg/ml), with levels of BMP higher than measured by the 
Morrell group before (maximum in controls ~ pg/ml). e plasma activity of this patient 
was relatively high, although these results may still be due to non-specific immunoreactivity. 
e levels of pBMP in these samples were not notable. Exclusion of this patient does not 

























































Figure 115. Activity of plasma from different vessels. Quiescent BRE-HMECs treated with 
1.5% (v/v) plasma from 15 female & 3 male PAH patients, 8 female & 7 male PFO patients, 
collected from the superior vena cava (SVC), brachial artery (Art) and pulmonary artery (PA). 
Left:  data grouped according to disease classification and sampling location. Lines connect 
samples from the same individual. Right: data grouped according to sex and sampling 
location. Samples were assayed in duplicate with the mean plotted. Bar = grand mean. 
































































Figure 116. Pro:BMP10 levels measured in plasma from different vessels by BMP10-GFD 
ELISA. Plasma from 15 female & 3 male PAH patients, 8 female & 7 male PFO patients, 
collected from the superior vena cava (SVC), brachial artery (Art) and pulmonary artery (PA). 
Left:  data grouped according to disease classification and sampling location. Lines connect 









































































































































































Figure 117. Correlations between data from figures 113-116. Dashed lines = axis breaks. 
Linear regressions excluding the three outlying samples. 
 
 
5.7. Discussion  
It is important to know if BMP and BMP are classic endocrines, secreted from the liver and 
right atrium respectively, binding cells according the expression level of ALK/endoglin. Or 
they may also be paracrines/autocrines produced locally, require local processing or have 
modulating binding partners. is could impact the design of BMP-based drugs, whether 
activity on a given vascular bed correlates with plasma levels, and influence which tissues are 
most vulnerable to GDF deficiency. 
We expected circulating BMP to have long half-life because it is able to exert 
protective effects in animals when administered once daily (Long et al. ). However, most 
animal experiments use intraperitoneal injections, so rate of uptake into the circulation is 
unclear. Previously, Dr. Claudia Mitrofan was unable to recover recombinant BMP 
administered intravenously or intraperitoneally by ELISA but did detect some increased 
plasma activity after  hour and not longer time-points (unpublished). erefore, we 
administered high doses of Pro:BMP to both wildtype and Gdf knockout mice and took 
samples  minutes to  hour after administration. I similarly found plasma levels of BMP 
changed very little after intravenous administration of exogenous Pro:BMP. 
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 To identify where exogenous BMP was being sequestered, I validated a protocol for 
measuring BMP levels in tissue extracts by ELISA. These ELISAs recovered BMP efficiently, 
but they gave some non-specific signal in the absence of BMP. Despite this, the 
quantifiability, specificity, sensitivity and dynamic range of the ELISA is greater than 
alternative techniques. Moreover, the ELISA gave good discrimination between the livers of 
wildtype and Gdf knockout mice.  
Using the ELISA, I found exogenous BMP was bound by the lungs. ere is a risk this 
result is due to incomplete flushing of the pulmonary vasculature. However, there was no 
detectable BMP in the blood of Gdf knockout animals and Id transcription was also 
activated in lungs. I did not find evidence exogenous BMP accumulated in the liver by ELISA. 
I could use some of the BMP responsive targets identified in ., or phospho-SMAD stains to 
confirm a lack of activity in the liver. Labelled-BMP could be given to animals to allow rapid 
assessment of levels in all organs. e technique used should be compatible with whole-body 
analysis. One possibility could be to use I-labelled BMP, with mice killed, frozen, sectioned 
and exposed to autoradiograph film immediately after injection (Maguire, Kuc, and 
Davenport ). Labelling might disrupt the physiology of BMP so the tissue ELISAs could 
be used to validate findings with unlabelled Pro:BMP. 
We found BMP was completely cleared from the circulation of Gdf knockout mice 
within  minutes of administration. ere was only a subtle increase in circulating BMP in 
wildtype mice given Pro:BMP apparent between  minutes and  hour after administration. 
Blood completes ~three circuits around the vasculature every minute, so these data could be 
explained by exogenous BMP binding vacant sites within its first few circuits. e wildtype 
mice were given a higher dose of BMP, and have some endogenous BMP and BMP, which 
may explain why excess remained in their circulation. Mice could be given escalating doses of 
Pro:BMP to measure when binding capacity is saturated and plasma retention occurs. 
 Nonetheless, this model does not explain why endogenous BMP is constitutively 
present in plasma when exogenous BMP was rapidly cleared from it. Perhaps binding 
partners of endogenous BMP stabilise it in the circulation. Alternatively, endogenous BMP 
may be continuously secreted, so some is always present in the plasma prior to being cleared. 
Similarly, BMP did not accumulate in the lungs of wildtype animals compared to Gdf 
knockouts, so endogenous BMP may normally be degraded or released from the lungs as 
rapidly as it binds. 
 I found Gdf mRNA and BMP protein was most highly expressed in the liver, 
although there is transcript in the lungs. erefore, we hypothesised BMP protein is 
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constitutively secreted from the liver, travels through the right-heart, then binds and activates 
signalling in the lungs, with residual BMP travelling to the systemic circulation. However, 
there was no evidence of a transpulmonary gradient of BMP levels in humans. is suggests 
either: lung binding sites are relatively saturated; lung binding is relatively slow; plasma BMP 
is masked from lung binding sites, perhaps by circulating binding partners; or lungs secrete as 
much BMP as they bind. e first explanation is inconsistent with the mouse 
pharmacokinetic data, but the latter are plausible. 
 In contrast to BMP, we hypothesised circulating BMP is predominately unprocessed 
(see .). erefore, it may display different kinetics, only being taken up by those cells able 
to process it. However, ProBMP was able to bind ALK, so it may be adsorbed onto 
endothelial cells similarly to Pro:BMP. Additionally, circulating Pro:BMP and ProBMP 
appeared to be at least partially in complex (see .), so they may be released into blood and 
taken up from it simultaneously, or exist in independent equilibriums. Since there are such 
high levels of circulating BMP, whether it competes for the same binding sites may strongly 
impact the pharmacokinetics of BMP. 
 Surprisingly, there was a slight drop in pBMP levels as plasma traversed the lungs. 
is could be because the lungs express GDF robustly, but much less BMP, so any BMP 
which binds is not replaced. Alternatively, lungs may preferentially bind BMP over BMP, 
or it may simply be easier to detect a very small change in pBMP levels because they are 
much higher. Results from the BMP growth-factor domain ELISA and activity assay suggest 
lungs are unlikely to be preferentially binding Pro:BMP over ProBMP, but did reveal some 
people have active levels of circulating Pro:BMP which may be co-regulated with Pro:BMP.  
 
 
. Phenotyping of Gdf knockout mice 
.. Introduction 
In mouse lungs, BMP promotes endothelial barrier function, and exogenous BMP can 
reverse histological and haemodynamic signs of PAH (Long et al. ). In humans, 
hypomorphic GDF mutations cause PAH and HHT (Gräf et al. ; Wooderchak-Donahue 
et al. ). GDF mutations have not been associated with other pathologies and there are 
not obvious differences between PAH patients carrying them and idiopathic patients. Two 
patients with early-onset PAH and HHT were found to carry homozygous GDF loss-of-




In PAH patients, low plasma BMP levels were associated with elevated circulating 
levels of bilirubin. Low plasma pBMP levels were associated with significantly reduced 
circulating levels of albumin and significantly increased levels of alkaline phosphatase (ALP) 
(Hodgson et al. ; Nikolic et al. ). These are signs of liver dysfunction, but on 
average levels were not outside the healthy range, and levels of alanine aminotransferase 
(ALT) and aspartate aminotransferase (AST), which are enzymes released into the blood after 
liver damage, were not correlated with BMP levels. A recent report measured serum levels of 
ALT and lactate dehydrogenase in Gdf knockout mice, and found that both were slightly 
elevated, indicating liver dysfunction (Desroches‐Castan et al. ). Importantly, this was 
reported in /Ola mice which spontaneously develop severe liver fibrosis, whereas C/BL 
mice do not. 
BMP is reported to be insulin sensitising and stabilises expression of metabolic 
enzymes in the liver (Chen et al. ; Breitkopf-Heinlein et al. ). In human PAH 
patients, BMP and pBMP levels correlated with body mass index and type-II diabetes 
(Hodgson et al. ). is hints BMP deficiency may disrupt metabolism. Additionally, 
BMP deficiency may be inflammatory and weakly pro-fibrotic at baseline (Desroches‐Castan 
et al. ; Desroches-Castan et al.  b; Addante et al. ). Similarly, levels of C-
reactive protein were significantly elevated, and above the normal range, in PAH patients with 
low circulating BMP or pBMP levels (Hodgson et al. ). Finally, in mouse livers, BMP 
prevents proper healing and promotes fibrosis following induced injury, so BMP deficiency 
promotes regeneration. 
 We have a colony of Gdf knockout mice on a CBL/J background, although recent 
genotyping suggests the presence of some CBL/N haplotypes. We undertook to assess 
whether these mice have exacerbated PAH-like symptoms, metabolic dysfunction, or 
endothelial dysfunction. erefore, we exposed Gdf knockout and wildtype mice to sugen-
hypoxia to induce PAH and analysed haemodynamic and histological differences. We are 
prospectively collecting tissues and blood from Gdf heterozygous, knockout and wildtype 
mice to assess BMP levels, liver and lung transcriptomics and histology. Finally, we 
developed a protocol to assess pulmonary endothelial permeability using Evans blue dye. 
ese data could suggest co-morbidities to assess in patients with BMP deficiency and 




.. Gdf deficiency did not exacerbate sugen-hypoxia induced PAH 
Dr. Alexi Crosby and Stephen Moore measured haemodynamic parameters in Gdf knockout 
and wildtype mice given sugen- then placed in hypoxia for  weeks. Genotype did not 
have any significant impact on the development of pulmonary hypertension. Mice were also 
assessed at baseline (table ). I measured Fulton index (right ventricular weight normalised 
by left ventricular and septum combined weight) and this was significantly decreased in Gdf 
deficient mice (figure ). Mark Southwood performed a histological analysis of lung 
samples I prepared and found a tendency for Gdf knockout mice to have less muscularised 
vessels, consistent with Tu et al. () and the Fulton index. is reflects the role of BMP 









Pulmonary acceleration time (ms) 2 .7 ± 2 23.  ± 1 2 .  ± 0.9 
Pulmonary ejection time (ms) 72.7 ± 4.2 .9 ± 2.4 75 ± 1.4 
Stroke volume (µl) 52.1 ± 4.2 4 .4 ± 3.1 51.  ± 3 
Ejection fraction (%) 5 .4 ± 2.4 5 .9 ± 2.9 0 ± 2.7 
Cardiac output (ml/min) 20 ± 1.9 19.  ± 1.4 20.  ± 1 
Fulton index 0.29 ± 0.02 0.24 ± 0.01 0.22 ± 0.01 
Right ventricular systolic pressure (mmHg) 23.4 ± 0.7 24.1 ± 0.9 22.4 ± 0.  
Table 11. Assessment of right-heart function in Gdf2 knockout mice. Five wildtype, 10 Gdf2 
heterozygous & 13 knockout mice assed by echocardiography and right-heart catheterisation 






















Figure 11 . Assessment of Fulton index in Gdf2 knockout mice. Right-ventricular wall was 
cut away from the left-ventricle and septum. The two pieces were weighed, and right-ventricle 
weight was normalised by the rest of the heart. One-way unmatched ANOVA/Bonferroni test, 
Mean ± SEM.   
  
.. Levels of serum factors in Gdf knockout mice 
Markers of metabolic and organ health in serum from Gdf knockout and wildtype mice were 
measured by the Addenbrooke’s Core Biochemical Assay Laboratory. Only sera from male 
mice were included to remove confounding due inter-sex differences. I performed statistical 
comparisons by t-testing, but after correcting for the number of markers measured, no 
differences would be significant. I also assessed the correlation of plasma BMP levels with 
serum markers in wildtype mice. No significant correlations were observed (not shown).  
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Cholesterol and triglycerides are components of cell-membranes and precursors for 
biosynthetic and metabolic pathways. ey are transported in blood as low-density 
lipoproteins (LDL) and high-density lipoproteins (HDL). Non-esterified fatty-acids (NEFA) 
are a product of the hydrolysis of triglycerides, and are transported bound to proteins such as 
albumin. ere was no obvious dysfunction in lipid handling in Gdf knockout mice (figure 
). e ratio cholesterol : HDL, which is a risk factor for heart disease in humans, was not 
different between genotypes (not shown). Gdf knockout mice had lower serum glucose 
levels than wildtype littermates (figure ). is was surprising because BMP is reported to 
be an anti-glycaemic and insulin-sensitising factor. e diets of these mice were not 
restricted, and they were not fasted prior to sample collection, which could contribute to the 
unexpected result. e ratio glucose : insulin, which is an indicator of dysfunctional blood-










































































Figure 119. Serum lipid levels in Gdf2 knockout and wildtype mice. Six wildtype and seven 
Gdf2 knockout male mice, aged 4-  months. Cholesterol, high-density lipoprotein (HDL), low-
density lipoprotein (LDL), triglyceride and non-esterified fatty acid (NEFA) levels were 










































Figure 120. Glucose handling in Gdf2 knockout and wildtype mice. Six wildtype and seven 
Gdf2 knockout male mice, aged 4-  months. Glucose and insulin levels were measured in 













































































Figure 121. Markers of organ function in Gdf2 knockout and wildtype mice. Six wildtype and 
seven Gdf2 knockout male mice, aged 4-  months. Alanine amino-transferase (ALT), alkaline 
phosphatase (ALP), albumin, lipase and calcium levels were measured in sera. Mean ± SEM, 
unpaired Student’s two-tailed t-test.    
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ALT and ALP are metabolic enzymes, predominantly of the liver, so levels can be 
elevated after feeding or liver damage. Albumin levels can be depressed after liver damage. 
Gdf knockout mice had reduced serum albumin levels, but hepatic enzymes were not 
elevated in serum (figure ). Lipase can be released into serum after damage to the 
pancreas and serum calcium levels depend on absorption/secretion from the intestines, bone 
and kidney. Levels of lipase and calcium were the same in Gdf knockout and wildtype mice. 
 
.. Liver transcriptome of Gdf knockout mice 
Serum markers provided inconclusive evidence that Gdf knockout mice had dysfunctional 
livers. erefore, I measured the level of mRNAs encoding metabolic enzymes in whole-liver 
extracts from Gdf knockout and wildtype mice by qPCR (figure ). ese genes were found 
to be regulated by BMP in vitro by Chen et al. (). Phosphenolpyruvate carbokykinase  
(Pck) catalyses the rate-limiting step of gluconeogenesis. As such, Pck is transcriptionally 
repressed by insulin, but should be upregulated when blood-glucose levels are low. Despite 
Gdf knockout mice having lower blood-glucose levels than wildtype littermates, Pck 
expression was not significantly different between genotypes.  
Fatty acid synthase (FASN) catalyses the biosynthesis of aliphatic molecules from 
acetyl-CoA, so is upregulated after feeding and when glucose levels are high, and ultimately 
leads to the liver secreting lipids. e expression of Fasn was not significantly different 
between genotypes. Sterol regulatory element binding protein  (SREBP) upregulates the 
expression of genes required lipogenesis, including Fasn. SREBP is primarily regulated by 
protein cleavage and translocation, but is also transcriptionally activated by insulin. e 
expression of Srebp was not significantly different between genotypes but the qPCR primers I 
used were specific to isoforms a and b. Isoform c should be checked since Yang et al. 
() report BMP overexpression can regulate it in vivo (they did not test a or b).  
NADP-dependent malic enzyme (ME) generates NADPH which is the reducing agent 
required for fatty acid biosynthesis. Me expression can be regulated by diet, thyroid 
hormones and other factors. Interestingly, Me expression was significantly reduced in Gdf 
knockout mice compared to wildtype littermates. Importantly, the difference remains 
significant even after correcting for testing multiple genes. ere was also a sex-based trend in 
Me expression, with female mice having lower levels than males, but this was not statistically 
significant. Since these metabolic enzymes are regulated by insulin, I tested correlations 
between their expression level and serum insulin and glucose levels. ere were no robust 


































































































WT KO  
Figure 122. Markers of liver metabolism function in Gdf2 knockout & wildtype mice. Six male 
& 4 female wildtype, and 7 male & 3 female Gdf2 knockout mice, aged 4-  months. Liver levels 
of Pck1, Fasn, Srebp1 & ME1 liver mRNA were measured compared to three house-keeping 
genes (B2M, Hprt, bAct) by qPCR. Mean ± SEM. Two-way unpaired ANOVA, ***p < 0.001. 
    
 
To get a comprehensive view of the liver phenotype, I sent whole liver RNA samples to 
Dr. Mattia Frontini for RNAseq analysis. He returned a list of genes up or downregulated in 
Gdf knockouts compared to wildtype littermates with a posterior probability of . ( 
genes) or . ( genes). I calculated the mean expression level of each gene in each 
genotype and the relative fold-change in expression between genotypes (figure ). 
Reassuringly, there was a high probability of Gdf expression being different between groups. 
Me expression was also different between groups, which I had already shown by qPCR. 
In order to predict the consequences of these transcriptome changes, I carried out 
pathway analysis. Firstly I analysed the list of genes differently expressed between wildtype 
and Gdf knockout mice with the Gene Ontology Consortium’s GO-term enrichment 
analysis tool (Ashburner et al. ; e Gene Ontology Consortium ). Genes involved 
in lipid metabolism were heavily overrepresented (padj < -) in this list. Fatty-acid 
metabolism was particularly dysregulated (padj < -), but so were various other lipid handling 
pathways. Consistent with the data for ME, most of these genes appeared to be 
downregulated in Gdf knockout mice, suggesting reduced lipid metabolism. Additionally, 
xenobiotic metabolism or oxidative catabolism pathways were downregulated in Gdf 
knockout mice (padj < -), including several cytochrome Ps, glutathione S-transferases 
and genes involved in the peroxisome. Strikingly, factors involved with circadian regulation of 
gene expression were disrupted (padj < -). Finally, responses to misfolded proteins, vesicle 
budding, and transport may have been impaired. 
 
 
Figure 123 (overleaf). Genes dysregulated in Gdf2 knockout mice. Five wildtype and Gdf2 
knockout male mice, aged 4-  months analysed by RNAseq. Top: genes with higher 
expression in wildtype livers. Bottom: genes with lower expression in wildtype livers. X-axis = 
mean relative fold change in expression between genotypes, y-axis = posterior probability, 






To confirm these results and identify additional pathways, I used network analysis of 
reported gene interactions using the STRING consortium tool (Szklarczyk et al. ). As 
expected, many genes differently expressed between Gdf knockout and wildtype mice were 
linked in a cluster responsible for fatty-acid and xenobiotic metabolism (figure ). e tool 
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imputed the involvement of genes that were not themselves dysregulated in Gdf knockout 
mice if they were linked with high confidence to those that were. is produced a cluster 
involved in circadian rhythms, including Cry, Per and Clock genes. Several genes involved in 
the endoplasmic reticulum, glycosylation, protein translation and transport etc. were also 
clustered. ese results validated the gene ontology analysis. Unexpectedly, many genes 
encoding components of the spliceosome were implicated by network analysis. Dr. Mattia 
Frontini is re-analysing the RNAseq data to search for mRNA splice-variants, rather than just 
transcript counts, to see what affects this might have. Similarly, several core cell-cycle 
regulators were linked to genes dysregulated in Gdf knockout mice. ese included genes 




Figure 124. Network analysis of genes dysregulated in Gdf2 knockout mice. Genes up/down 
regulated in Gdf2 knockout mice compared to wildtype littermates with posterior probability > 
0.5 were used as query genes (coloured nodes) in the Search Tool for Retrieval of Interacting 
Genes/Proteins. Other genes (white nodes) in the network were imputed by their relationship 
to query genes. Thickness of edges = strength of evidence linking nodes. Evidence includes 
experimentally determined interactions, predicted interactions, text-mining, co-expression and 
homology. Only genes linked in the network are shown. I manually identified clusters by eye, 
and by K means clustering with 5 clusters, and assigned processes by reviewing the function 
of each gene in each cluster.    
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BMP is reported to modulate hepatic inflammation and fibrosis. Inflammation 
associated genes were not significantly overrepresented among those dysregulated in Gdf 
knockout mice. However, GO-term enrichment and network analyses did not take many 
factors, including the direction, degree and confidence of expression change, the organ of 
interest, or the phenotypes of interest, into account. erefore, I identified all genes 
dysregulated in Gdf knockout livers with a posterior probability > . which were associated 
with terms related to inflammation and liver disease/regeneration (figure ).  







































Figure 125. Inflammation & damage associated gene expression in Gdf2 knockout livers. 
Genes associated with gene ontology terms related to inflammation and liver disease are 
shown. I have manually classified these as markers of fibrosis or inflammation. X-axis = mean 
relative fold change in expression between genotypes. 
 
Several genes upregulated in Gdf knockout mice with high confidence are markers of 
inflammation. ese include: Ccr, encoding a chemokine receptor; Ighg, encoding the 
constant region of immunoglobulin heavy chain γ; Elane, encoding neutrophil elastase;  
Orm, encoding an acute-phase protein which is reported to be secreted by stressed livers 
(Porez et al. ); Ptafr, encoding a platelet activating receptor; Appl, encoding a positive 
regulator of inflammation and proliferation associated with fatty-liver disease (Barbieri et al. 
); and Uncd, encoding a protein involved with release of cytolytic granules from 
immune cells. Similarly, Pparg which encodes a receptor involved with triglyceride 
metabolism, but is known to have anti-inflammatory effects, is downregulated in Gdf 
knockout livers (Martin ).  
ree genes downregulated in Gdf knockout livers are markers of fibrosis or 
cirrhosis. ese are: Rtn, which is upregulated in cirrhosis with Rtn knockout mice 
protected from fibrosis (Gao et al. ; D. Zhang et al. ); Sulf, which is upregulated in 
cirrhosis and injury induced regeneration (Singer et al. ; Graham, Murphy, and Dhoot 
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); and Vnn, which is upregulated after liver injury with Vnn knockout mice 
predisposed to liver injury (Chen et al. ; Ferreira et al. ). 
However, Icam was upregulated in Gdf knockout mice, and is a marker of fibrosis,  
with Icam knockout mice protected from liver disease (Kono et al. ; eruvath et al. 
). However, ICAM also facilitates regeneration and proliferation, so this might be 
expected (Selzner et al. ). Similarly, Ccl, which encodes an inflammatory chemotaxic 
chemokine, is downregulated in Gdf knockout mice. Notably, Cola, encoding type- 
collagen, which is a read-out in models of fibrosis, was not differently expressed between 









































Figure 12 . Marker of liver fibrosis in Gdf2 knockout and wildtype mice. Six male & 4 female 
wildtype, and 7 male & 3 female Gdf2 knockout mice, aged 4-  months. Levels of Col1a1 
mRNA were measured compared to three house-keeping genes (B2M, Gapdh, bAct) by qPCR. 
Mean ± SEM. 
 
 .. Gdf knockout mice have normal blood cell counts  
Some transcriptional markers of inflammation were increased in Gdf knockout mice. 
Additionally, the Morrell group has found Bmpr deficient mice have different numbers of 
circulating immune cells than wildtype mice (Crosby et al. ). e Morrell group and 
others found PAH patients have altered white blood cell profiles, and there is evidence that 
PAH is associated with immunological dysfunction (Ormiston et al. ; Holmes et al. 
). In humans with PAH, those with the lowest plasma BMP levels had significantly 
higher red-cell distribution widths (RDW) and significantly lower platelet counts than patients 
with normal plasma BMP levels (although the averages of both are within the healthy range) 
(Hodgson et al. ). Similarly, patients with the lowest plasma pBMP levels have 
significantly higher RDWs, and higher white blood cell counts (WBC) than patients with 
normal plasma pBMP levels. WBC also trends to be lower in patients with low plasma BMP 
levels (p = .)(Hodgson et al. ). erefore, I performed cell counts of EDTA-blood 
from Gdf knockout, heterozygous and wildtype mice (figure ). In mice, there were 
significant differences in blood counts between sexes, but no significant differences or 
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promising trends between genotypes. Nonetheless the effect sizes in humans for RDW, WBC 
and platelet count were small (-), which this mouse study was underpowered to detect. 










































































































































































Figure 127. Blood counts of Gdf2 knockout, heterozygous and wildtype mice. Blood cell 
properties were analysed by a Wooley ABC cell-counter. WBC = white blood cell count, RBC = 
red blood cell count, RDW = red blood cell distribution width (MCV deviation / MCV x 100), 
MCV = mean cell volume, HGB = haemoglobin concentration, HCT = haematocrit, MCH = 
mean amount of haemoglobin per red blood cell, PLT = platelet count, MPV = mean platelet 
volume, LYM = lymphocytes, MON = monocytes, GRA = granulocytes. Mean ± SEM 
 
 .. BMP & BMP levels in Gdf knockout mice 
Bmp is primarily expressed in the right atrium, but it may also be expressed in the liver. 
Gdf is primarily expressed in the liver, but also the lung. In humans we observed 
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heterozygous GDF mutation carriers had BMP levels reduced by about , very low levels 
of pBMP, and this predisposed them to disease (see .). We wanted to assess how Gdf 
mutations alter BMP and BMP expression and signalling in different tissues, to understand 
why the pulmonary vasculature is destabilised. I undertook to measure mRNA and protein 
levels of BMP and BMP in different organs by qPCR and ELISAs in Gdf knockout, 
heterozygous and wildtype mice.  
Since I already had the samples, I began by measuring mRNA levels in livers. Both 
Gdf and Bmp were more highly expressed in the livers of females than males (figure ). 
Consistent with transcriptomic databases, Bmp expression was much lower than Gdf 
expression in the liver. In accordance with Tillet et al. (), liver Bmp expression was not 
disrupted in Gdf knockout mice. In human plasma, BMP and pBMP levels are correlated. 
erefore, I assessed the correlation of their transcripts in mouse livers. ere was a striking 
correlation between Gdf and Bmp expression in wildtype mice (p = .). However, 
unlike the correlation in plasma levels, this was entirely explained by sex (figure ). 
e expression of Gdf and Bmp in the liver was well correlated due to sex, and 
both decline after insults such as LPS injection (figure ). erefore, both genes may be 
regulated by the same transcription factors. To investigate this, I interrogated both genes on 
Genevestigator which ranks the correlation in expression between genes 
(https://genevestigator.com/gv/). For both mouse and human datasets, of all genes, GDF 
expression was most correlated with BMP expression. However, I could not assess how 
comprehensive and reliable the underlying datasets are.  
   I used ChIP-Atlas to investigate which transcription factors may regulate both Gdf 
and Bmp (Oki et al. ). Both genes bound many factors, with binding sites clustered in 
certain regions as expected. Gdf appeared to have a fairly canonical architecture, with the 
greatest number of factors binding immediately upstream of the transcription start site. 
Bmp was more difficult to analyse since the most active regulatory region appeared to be 
within the intron, shortly downstream of the transcription start site. Several transcription 
factors bound to both Gdf and Bmp, including numerous binding sites for sex-hormones 
(oestrogens, progestrogen, glucocorticoids) which could explain the sex difference in 
expression. Nonetheless, ChIPseq data is notoriously noisy, and it is difficult to assign 
functional importance to these binding sites. Moreover, it is difficult to assess whether certain 
factors bind Gdf and Bmp more than expected compared to other genes, and whether they 






























































Figure 12 . Gdf2 & Bmp10 expression in Gdf2 knockout & wildtype mouse livers. Six male & 4 
female wildtype, and 7 male & 3 female Gdf2 knockout mice, aged 4-  months. Levels of Gdf2 
and Bmp10 mRNA were measured compared to three house-keeping genes (B2M, Gapdh, 
bAct) by qPCR. Two-way unmatched ANOVA/Bonferroni test, ***p < 0.001, ns = not significant, 















































Figure 129. Gdf2 & Bmp10 expression in Gdf2 knockout & wildtype mouse livers. Left: 
Correlation between data in figure 12 . Right: left, repeated with 15 males. 
 
.. Use of Evans blue to measure pulmonary vascular leak  
Evans blue is a dye which can be administered to live animals and binds albumin. e 
Morrell group reported that pulmonary vascular permeability to macromolecules, as measured 
by the accumulation of Evans blue in lungs, can be supressed by administering BMP to mice 
(Long et al. ). Conversely, anti-BMP enhanced pulmonary vascular leak (Li et al. ). 
In these studies, some mice were given LPS by intraperitoneal injection to stimulate vascular 
leak. Sixteen hours after LPS administration, a solution of Evans blue and bovine serum 
albumin was given by intraperitoneal injection. After a further hour, mice were killed, and 
lungs were flushed with heparinised saline to remove Evans blue remaining within blood 
vessels. e amount of residual Evans blue in lungs was measured. 
 We assessed the extravasation of Evans blue into lungs of Gdf knockout and 
heterozygous mice, and Bmpr-Cw and Bmpr-RX heterozygous mice. We gave Evans 
blue intravenously, rather than intraperitoneally, to control the concentration of circulating 
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dye. We did not have many littermates of each genotype, so this study was underpowered. 
ere was no trend for Gdf deficient mice to have increased extravasation of Evans blue into 
lungs (figure ). Unlike published results for Bmpr-RX heterozygous mice, CW and 
RX mice exhibited no evidence of reduced endothelial integrity (figure ).   





































Figure 130. Leak of Evans blue across the pulmonary vasculature of Gdf2 knockout, 
heterozygous and wildtype mice. 1 % (w/v) Evans blue dye was dissolved in PBS 
supplemented with 4% endotoxin free BSA. Mice were given 20 mg/kg of Evans blue 
intravenously. After 30 minutes, mice were killed and flushed. The amount of residual Evans 
blue extracted from lungs was measured by colourimetry. Left: Separated by sex Right: 






















Figure 131. Leak of Evans blue across the pulmonary vasculature of Bmpr2 heterozygous 
and wildtype mice. 1 % (w/v) Evans blue dye was dissolved in PBS. Mice were given 20 mg/kg 
of Evans blue intravenously. After 30 minutes, mice were killed and flushed. The amount of 
residual Evans blue extracted from lungs was measured by colourimetry. Mean ± SEM. 
 
We were not sure if our Evans blue protocol was working, and if so, we wanted to 
stress mice to reveal a phenotype. Firstly, we replicated existing results by showing 
intraperitoneal injections of LPS increased extravasation of intraperitoneally administered 
Evans blue into lungs by approximately the expected amount (figure ). However, the 
intestines of these mice appeared to accumulate Evans blue, and there were large amounts of 
unabsorbed Evans blue within the abdomen. is protocol used intraperitoneal injection of 
Evans blue and LPS, which potentially means altered uptake of Evans blue from the abdomen 
into blood, rather than altered pulmonary vascular leak, determines the absorbance of lung 
extracts. To investigate this, I measured the wet to dry weight ratio of lungs from the same 
mice, to assess whether oedema fluid was accumulating in the lungs of LPS treated mice 
(figure ). However, lungs must be flushed thoroughly prior to Evans blue extraction, and 
the high pressures used may also cause oedema. 
Intravenous administration of Evans blue is more likely to give an unconfounded 
measure of pulmonary vascular leak. Some protocols use higher concentrations of Evans blue, 
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or Evans blue that is not premixed with albumin (Akla et al. ; Wick et al. ). e 
optimal time for assessing leak is reported to be one-hour after injection of Evans blue 
(Moitra, Sammani, and Garcia ). e dose, route of administration and duration of LPS 





















Figure 132. Leak of Evans blue across the pulmonary vasculature of mice given LPS. Male 
mice were given 1 mg/kg LPS (B5 serotype) or PBS vehicle control intraperitoneally. 1 % (w/v) 
Evans blue dye was dissolved in PBS supplemented with 4% endotoxin free BSA. After 20 
hours, mice were given 40 mg/kg of Evans blue solution intraperitoneally. After 0 minutes, 
mice were killed and flushed. The amount of residual Evans blue extracted from lungs was 
measured by colourimetry. Unmatched one-tailed Student’s t-test, *p < 0.05, n = 5, mean ± 
SEM. 



























Figure 133. Leak of fluid across the pulmonary vasculature of mice given LPS. Male mice 
were given 1 mg/kg LPS (B5 serotype) or PBS vehicle control intraperitoneally. After 20 hours, 
mice were killed. Left: lungs were weighed before (wet) and after (dry) a 4 -hour incubation at 
0 oC in unsealed tubes. Right: the ratio of wet weight / dry weight was calculated for each 
lung. . Unmatched one-tailed Student’s t-test, n = 5, mean ± SEM. 
 
To optimise a protocol for studying pulmonary vascular leak, I used column filtration 
to show the majority of Evans blue in treatment solutions was not bound to albumin (figure 
). is is consistent with early reports of binding kinetics (Freedman and Johnson ). 
erefore, we used free Evans blue in subsequent protocols as a method to assess the leak of 
small molecules, rather than a composite of small molecules and macromolecular complexes. 
Firstly, we administered  mg/kg of LPS intraperitoneally. e next morning, we 
administered  mg/kg of free Evans blue intravenously one-hour before mice were killed. 
e mice became very sick after LPS injection and several had to be euthanised which 
precluded us from repeating this protocol. Moreover, there was no evidence of increased leak 
across the pulmonary vasculature of LPS treated mice compared to control mice (figure ). 
We tested several different isoforms of LPS, since there are reports they stimulate different 
responses. Isoform did not appear to make a difference. 
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Figure 134. Size exclusion chromatography of Evans blue. Evans blue (1% or 0.5% (w/v)) 
dissolved in PBS or PBS supplemented with 4 % mouse serum albumin was analysed by size 
exclusion chromatography. The amount of Evans blue in fractions was assessed by 
colourimetry. 




































Figure 135. Leak of Evans blue across the pulmonary vasculature of mice given LPS. Male 
mice were given 2 mg/kg LPS or PBS vehicle control intraperitoneally. 1 % (w/v) Evans blue 
dye was dissolved in PBS. After 20 hours, mice were given 20 mg/kg of Evans blue solution 
intravenously. After 0 minutes, mice were killed and flushed. The amount of residual Evans 
blue extracted from lungs was measured by colourimetry. Left: serotypes of LPS shown, right: 
composite of serotypes, unmatched one-tailed Student’s t-test, n = 5, mean ± SEM. 
 
Next, we referred to data showing transcriptional markers of inflammation in the liver 
and lungs respond to lower doses of intraperitoneal LPS if shorter time-points are assessed 
(Morrell unpublished). We designed a protocol where mice were given . mg/kg LPS for  
hours, which does not cause unacceptable sickness, prior to an intravenous injection of Evans 
blue. Power was calculated based on the variability and effect size reported in Long et al. 
(). Again, there was no evidence of increased pulmonary vascular leak caused by LPS 
(figure ; ). To confirm the LPS was active, I assessed the expression of Gdf, which is 


















Figure 13 . Leak of Evans blue across the pulmonary vasculature of mice given LPS. Male 
mice were given 0.1 mg/kg LPS (B5 serotype) or PBS vehicle control intraperitoneally. 1 % 
(w/v) Evans blue dye was dissolved in PBS. After 3 hours, mice were given 40 mg/kg of Evans 
blue solution intravenously. After 0 minutes, mice were killed and flushed. The amount of 
residual Evans blue extracted from lungs was measured by colourimetry. Unmatched one-
tailed Student’s t-test, n = 20, mean ± SEM. 
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Figure 137. Leak of fluid across the pulmonary vasculature of mice given LPS. Male mice 
were given 0.1 mg/kg LPS (B5 serotype) or PBS vehicle control intraperitoneally. After 4 hours, 
mice were killed. Left: lungs were weighed before (wet) and after (dry) a 4 -hour incubation at 
0 oC in unsealed tubes. Right: the ratio of wet weight / dry weight was calculated for each 
lung. Unmatched one-tailed Student’s t-test, n = 20, mean ± SEM. 


























Figure 13 . Transcriptional response to intraperitoneal LPS administration. Male mice were 
given 0.1 mg/kg LPS (B5 serotype) or PBS vehicle control intraperitoneally. After 4 hours, mice 
were killed. Liver levels of Gdf2 and Bmp10 mRNA were measured compared to two house-
keeping genes (B2M, Gapdh). Unmatched one-tailed Student’s t-test, n = 20, mean ± SEM. 
 
We then tried intranasal administration of LPS as this is used in models of acute 
respiratory distress syndrome. ree hours after LPS inhalation, mice were given Evans blue 
intravenously and killed after a further hour. I found no evidence of increased pulmonary 
vascular leak in these mice (figure ). I assessed whether there was an inflammatory 
response in the lungs to LPS by qPCR. ere was a slight reduction in lung Smad and Gdf 
relative expression, but LPS treatment increased the expression of housekeeping genes used for 
normalisation, likely because this model causes neutrophils to accumulate within the lungs 
(figure ). Nonetheless, IL expression was strongly upregulated, which would be even 
more pronounced if housekeepers were stable. erefore, intranasally administered LPS 




















Figure 139. Leak of fluid across the pulmonary vasculature of mice given LPS. Male mice 
were given 0.1 mg/kg LPS (B5 serotype) or PBS vehicle control intranasally. 1 % (w/v) Evans 
blue dye was dissolved in PBS. After 3 hours, mice were given 40 mg/kg of Evans blue 
solution intravenously. After 0 minutes, mice were killed and flushed. The amount of residual 
Evans blue extracted from lungs was measured by colourimetry. Unmatched one-tailed 
Student’s t-test, n = 5, mean ± SEM. 
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Figure 140. Lung inflammation in mice lungs given LPS. Male mice were given 0.1 mg/kg LPS 
(B5 serotype) or PBS vehicle control intranasally. 1 % (w/v) Evans blue dye was dissolved in 
PBS. After 4 hours, mice were killed. Lung expression of Smad9, Il , Gdf2, Bmp10 and the 
housekeepers bAct, Hprt and B2M was assessed by qPCR. n = 5, mean ± SEM. 
 
Protocols simulating acute respiratory distress syndrome often wait one to three days 
after LPS exposure before disease reaches its greatest severity (Moitra, Sammani, and Garcia 
; Schlosser et al. ; Honglei Chen et al. ; Birukova et al. ). erefore, we 
repeated the intranasal LPS protocol, but did not administer Evans blue until the following 
day. ese mice showed increased pulmonary vascular leak as measured by Evans blue 
extravasation, indicating targeted administration of LPS could disrupt the pulmonary 
endothelium after  hours (figure ).  
In summary, I was able to show intravenous injection of  mg/kg Evans blue  hour 
prior to sacking is an appropriate way to assess pulmonary vascular leak. As a positive control, 
or to exacerbate leak phenotypes, LPS could be administered intranasally  hours before 
assessing leak. To reduce batch effects, all mice should be put through the protocol together. 
Where this is impossible, lungs should be frozen until Evans blue can be extracted 
simultaneously and control mice should be present in each batch. Gdf deficient mice did not 
have pulmonary endothelial leak at baseline, when given  mg/kg of Evans blue  minutes 
prior to killing. is is in contrast to what Li et al. () found with acute BMP 
neutralisation, suggesting chronic loss may be partially accommodated. LPS could be given to 
reveal any cryptic pulmonary vascular leak phenotype of Gdf knockout mice.  























Figure 141. Leak of fluid across the pulmonary vasculature of mice given LPS. Male mice 
were given 0.1 mg/kg LPS (B5 serotype) or PBS vehicle control intranasally. 1 % (w/v) Evans 
blue dye was dissolved in PBS. After 15 hours, mice were given 40 mg/kg of Evans blue 
solution intravenously. After 0 minutes, mice were killed and flushed. The amount of residual 
Evans blue extracted from lungs was measured by colourimetry. Two batches of mice 
underwent the protocol on separate days, and results were analysed by unmatched two-way 





BMP administration or overexpression has been shown to alter glucose and lipid handing 
(Chen et al. ; Yang et al. ). However, this has never been assessed in the more 
physiological setting of Gdf deficiency. Serum markers provided no evidence of impaired 
lipid handling although there was a tendency for glucose levels to be altered in Gdf knockout 
mice. Expression of insulin sensitive enzymes was not changed in the livers of Gdf knockout 
mice, but more nuanced glucose tolerance tests and assessments of body fat, in mice given 
more inducive diets, may reveal a phenotype. For example, Yang et al. () found Fasn 
expression was only dysregulated in BMP over-expressing mice fed a high-fat diet. Besides, 
for the first time, we undertook an unbiased, comprehensive assessment of gene expression in 
Gdf knockout mice. Liver transcriptomics revealed they had disrupted fatty acid metabolism 
and oxidative catabolism. 
 In the liver, BMP signalling inhibits hepatocyte proliferation and predisposes to 
injury. I saw evidence of this in the liver transcriptome of Gdf knockout mice, with cell-cycle 
pathways dysregulated, some markers of inflammation upregulated, and some markers of 
injury downregulated. It would be sensible to measure circulating cytokines in Gdf knockout 
mice and people with mutations or low BMP levels, especially because an inflammatory 
milieu may predispose to PAH.  
 Nonetheless, the liver did not appear to be profoundly damaged in Gdf knockout 
mice, since serum markers such as ALP, ALT and albumin were normal, and liver collagen 
expression was not elevated. is is not consistent with data in Desroches‐Castan et al. , 
however they had ten mice in each group and relatively high variability. Moreover, they 
recently reported the hepatic inflammatory and fibrotic phenotype of Gdf knockout mice is 
only seen on the /Ola background, not C/BL or BALB/c mice (Desroches-Castan et al. 
 b). Similarly, BMP levels in wildtype mice did not correlate with markers of liver 
dysfunction and inflammation, although there were some subtle relationships in human 
serum (Hodgson et al. ). Mark Southwood is undertaking a histological analysis of livers 
I collected from Gdf knockout and wildtype littermates to look for gross abnormalities. 
Staining for inflammatory cells may be interesting since Desroches-Castan et al. report they 
accumulate within Gdf knockout livers. Overall, the unbiased whole-transcriptome data 
provides more robust evidence supporting the current literature suggesting Gdf deficiency 
causes relatively subtle liver dysfunction. 
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 Surprisingly, there was transcriptomic evidence that circadian rhythms, splicing and 
protein handling were disrupted in the livers of Gdf knockout mice. ese are novel 
findings, which need validating and could have broad implications. For example, we expected 
BMP deficiency to alter cell proliferation, and circadian cycles are often synchronised to cell 
cycles (Heltberg and Jensen ; Droin, Paquet, and Naef ). Many metabolic pathways 
are circadian controlled or regulated by alternative splicing (Reinke and Asher ). 
erefore, it is unclear exactly which pathways are direct targets of BMP.  
To reproduce these findings, I am collecting tissues from fresh Gdf knockout, 
heterozygous and wildtype mice. Additionally, I could look at these transcripts in mice given 
anti-BMP or BMP-AAV, which are models of short-term Gdf deficiency and short-term 
overexpression respectively, already being prepared. I am preparing lung samples from Gdf 
knockout mice for RNAseq, and it will be interesting to see if the same pathways are 
dysregulated here. BMP levels could be measured in plasmas collected at different times of 
day to see if levels oscillate.  
Plasma levels of BMP and BMP are tightly correlated in humans, and they are 
expressed in the same organs, albeit at different levels. Similarly, there is some evidence Gdf 
and BMP mRNA levels are correlated. We are collecting samples to assess levels of both 
factors in different organs (right-atria, liver, lung, kidney, spleen) in Gdf knockout, 
heterozygous and knockout mice. is may shed light on their co-regulation. Additionally, 
markers of BMP/ signalling will also be assessed in these organs to develop a 
comprehensive picture of how Gdf deficiency affects them. 
 
Discussion & future directions 
Mutations in BMPR cause the majority of heritable PAH, and deficiency of BMPR-II receptor 
complex signalling has been invoked to explain the majority of PAH. Nonetheless, Gräf et al. 
() were the first to systematically link mutations in the gene encoding the high-affinity 
ligand for this receptor, GDF, to PAH. More recently, Wang et al., Eyries et al., and Zhu et 
al. () also discovered rare, PAH-associated missense variants in GDF predicted to be 
deleterious in silico. We expressed GDF missense variants found in PAH in vitro and showed 
only those predicted to be pathogenic in silico have impaired secretion due to instability of 
the processed Pro:BMP complex. Previous reports showed a secretion defect in some 
missense variants predicted to be pathogenic, but did not compare them to those predicted to 
be benign, or attempt to explain the secretion defect (Wang et al. ; Wooderchak-
Donahue et al. ). Notably, no single predictor of deleteriousness was sufficient to define 
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whether missense variants were pathogenic or benign. For example, Pro:BMP-DN 
contained a novel glycosylation site, but had normal bioactivity. Pro:BMP-YH has 
severely impaired secretion and activity in vitro and in vivo, disrupting the core of BMP, but 
was not significantly over-represented in PAH in the British cohort. 
Surprisingly, measurement of patient samples revealed that GDF mutation carriers 
have heavily reduced plasma levels of both BMP and pBMP. erefore, both ligands could 
be necessary to protect the pulmonary vasculature from PAH. e Morrell group has an 
inducible Bmp knockout mouse, so the haemodynamics and histology of this animal could 
be measured in the sugen-hypoxia model of PAH. However, given this approach did not 
reveal a phenotype in Gdf knockout mice, a negative result should not rule out a role for 
BMP in protecting against PAH. Larger genetic analyses may definitively link loss-of-
function BMP mutations in humans to PAH, building on the cases reported by Eyries et al. 
and Gräf et al.   
 Levels of circulating total pBMP are ~ ng/ml in healthy people, but consensus in 
the literature suggests half to all circulating activity is due to BMP (Jiang et al. ; Chen et 
al. ; Bidart et al. ). erefore, I compared levels of unprocessed ProBMP and 
processed Pro:BMP by ELISAs, immunoprecipitations and activity assays. ese suggested 
plasma pBMP is predominately unprocessed in most people. To confirm this novel 
hypothesis, Western blots of endogenous pBMP could be refined, perhaps by 
immunoprecipitation of fractions separated by size exclusion chromatography, which may be 
cleaner than immunoprecipitation of neat plasma/serum. Similarly, furin treatment of these 
fractions could be attempted, which may work more efficiently than treatment of neat serum. 
Finally, tissue extracts of human right atria could be probed by ELISA to establish the 
proportion of processed versus unprocessed pBMP within them, and live biopsies could be 
incubated in media to demonstrate these species are also secreted.  
To investigate whether certain cells can process circulating ProBMP, wildtype BMP 
and BMP could expressed in the presence of protease inhibitors, as in Susan-Resiga et al. 
(). en, different endothelial cell lines could be incubated with ProBMP-WT 
compared to uncleavable ProBMP-RA to show whether cells can activate them. 
Similarly, cells could be stimulated with different factors, such as inflammatory cytokines, to 
see if this alters their ability to process ProBMP. If ProBMP predominates over Pro:BMP 
and Pro:BMP in blood, dynamic regulation of processing could be a major determinant of 
signalling. Demonstrating whether the pulmonary vasculature is stimulated by BMP would 
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help answer whether the loss of plasma pBMP in GDF mutation carriers and a subset of 
other PAH patients contributes to their disease. 
 A minority (~) of people (only PAH and PFO patients were tested) seemed to have 
plasma levels of processed Pro:BMP similar to levels of Pro:BMP. Royal Papworth Hospital 
may hold more information about the clinical phenotype of these patients, which might 
reveal why a subset have higher levels of detectable Pro:BMP. ese people had 
unremarkable levels of total pBMP, but perhaps higher than average levels of Pro:BMP. 
is suggests there may be co-regulation between BMP and BMP processing. Serum from 
such people would allow us to assess the impact of this on circulating activity. In addition, 
levels of Pro:BMP and total pBMP are tightly correlated, and Tillet et al. () suggested 
they may be heterodimers. Since levels of pBMP are much higher than BMP, we instead 
hypothesised they are in larger complexes. 
 I found in serum that BMP and pBMP appeared to circulate in large 
macromolecular complexes. In EDTA-plasma, the majority appeared to circulate as a simple 
Pro:BMP complex, and this form was also present in EDTA-serum. Similarly, BMP and 
BMP are masked from ELISAs except in the presence of chelating agent. Hence, we 
hypothesised the current consensus that BMP and BMP circulate as a simple Pro:BMP 
complex are a result of only assessing EDTA plasma, and purification steps prior to 
chromatography. It will be interesting to perform size exclusion chromatography of heparin-
plasma, to see whether solely calcium presence determines the size of the complex, or it has 
something to do with clotting.  
Unpublished data from the Morrell group suggests levels of BMP are correlated with 
levels of kallikrein and factor , and associated with genes encoding bradykinin and clotting 
pathways by quantitative trait loci studies. erefore, co-immunoprecipitations with these 
factors could be investigated, which may implicate BMP and BMP in regulating responses 
to vessel damage. Secondly, a minority of plasma BMP could be immunoprecipitated with 
BMP and vice versa. e results of such immunoprecipitations may be more striking in 
serum where a much greater proportion of BMP and BMP appears to be in large 
complexes. 
 We struggled to elucidate the pharmacokinetics of BMP because exogenous BMP is 
cleared rapidly from the circulation of mice, which appears to be at least partly due to binding 
and signalling in the lung, but there were no transpulmonary gradients of BMP or BMP 
levels in humans. Preliminary evidence also suggested endogenous BMP does not accumulate 
in the lungs of wildtype mice. If endogenous BMP and BMP do circulate in 
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macromolecular complexes, this may stabilise them in the blood by restricting their binding 
to the pulmonary endothelium. Lungs from mice given exogenous Pro:BMP were fixed and 
sent to Mark Southwood who will stain them to see if BMP binds the endothelium and 
activates signalling here. ese samples can be compared to untreated Gdf knockout and 
wildtype mice to confirm that lungs do not normally accumulate BMP.  
 PAH patients carried heterozygous GDF loss-of-function alleles, although two 
paediatric cases of PAH and HHT carried homozygous mutations. We are collecting samples 
from wildtype, Gdf knockout and heterozygous mice to assess BMP levels and signalling in 
different organs. It will be interesting to see whether pulmonary vascular signalling is more 
sensitive to loss of BMP than other tissues, and how low plasma levels are in heterozygotes 
compared to wildtype animals. For the first time, we generated data from humans suggesting 
neither the wildtype Gdf allele, nor BMP, is sufficient to maintain normal plasma activity.  
Some evidence hints long-term loss of BMP is partially accommodated, since 
Addante et al. () report hepatic Id expression is reduced by acute ALK-Fc 
administration, but not germline Gdf deletion (although BMP may be acting here). 
Similarly, Ricard et al. () found anti-BMP and ALK-Fc cause a similar retinal 
vascularisation defect in neonatal mice, but germline Gdf deletion does not result in any 
defect. I found Id genes were not differently expressed in the livers of wildtype and Gdf 
knockout mice. However, preliminary data suggested Gdf knockout mice have reduced 
signalling in the lungs, and we will assess this by qPCR and phospho-SMAD staining in a 
larger number of samples. Secondly, the Morrell group is undertaking acute and chronic 
neutralisation studies with anti-BMP, so the lung transcriptome of these mice could be 
compared with Gdf knockouts. 
 We expected the hepatic transcriptome to be dysfunctional in Gdf knockout mice. 
Reports suggest BMP deficiency is weakly inflammatory, not affecting hepatic inflammation 
in all mouse strains or people, and my data supported this since a few markers were 
upregulated in our Gdf knockout mice. ere is mixed evidence BMP deficiency contributes 
to hepatic fibrosis in healthy mice, since it depends on genetic background and the markers 
assessed. For example, Addante et al. () and Desroches-Castan et al. () report no 
increase in Cola expression or fibrotic area in the livers of Gdf knockout C/BL mice, 
but another group reports a small upregulation in Cola. Similarly, Breitkopf-Heinlein et al. 
() showed BMP reverses markers of inflammation and fibrosis of hepatocytes in vitro, 
but find no upregulation of Cola in Gdf knockout mice. ey did however find desmin 
and vimentin were upregulated. Finally, Desroches-Castan et al. show Gdf knockout mice 
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on an /OLA background spontaneously develop severe hepatic fibrosis and inflammation. 
Using an unbiased approach, I found limited evidence markers of fibrosis were depressed in 
Gdf knockout C/BL mice.  
ere is ample evidence BMP enhances injury in models of severe hepatic damage, 
but evidence in humans is mixed (Addante et al. ; Breitkopf-Heinlein et al. ; Li et 
al. ; Nikolic et al. ; John et al. ). erefore, it seems likely BMP has complex 
context dependent roles in liver regeneration. orough histological analysis to assess the cell-
types, tissue architecture and cell morphology of Gdf knockout livers could be insightful, 
since current reports only assess specific cell types or use models of severe liver damage. 
 BMP overexpression has been shown to inhibit glucogenesis and lipogenesis in mice 
(Yang et al. ). In contrast Chen et al. () found BMP upregulates lipogenic genes in 
vitro. Consistent with Chen et al., I found Gdf knockout livers downregulated lipogenic 
pathways, but I did not implicate the exact same genes. erefore, BMP’s role in metabolism 
may also be context, cell-type and concentration dependent. Mice could be placed on 
different controlled diets and assessed throughout their circadian cycles to investigate this. 
e transcriptome of Gdf knockout mice will be reanalysed to search for splice variants, 
since network analysis suggested the spliceosome signature was altered. is could reveal 
further roles for BMP in the liver. 
 Exogenous BMP did not appear to stimulate the livers of mice, which could be useful 
if supraphysiological doses are to be given to PAH patients without an adverse effect on 
metabolism. However, longer-term studies could be undertaken, perhaps using markers 
robustly downregulated in the Gdf knockout transcriptome, such as the cytochrome P 
(CYPa) family. ese markers are also likely to be tractable for immunohistochemistry and 
have been previously reported to be downregulated in the livers of Gdf knockout mice 
(Truksa et al. ; Breitkopf-Heinlein et al. ). e CYPa genes may link Gdf 
deficiency to protection against liver damage, since their ablation has been reported to protect 
against inflammation and damage, whilst overexpression predisposes to it (Zhang et al. ; 
Ip et al. ). Circulating levels of inflammatory cytokines, ALP, AST, ALT and albumin 
could be monitored to check liver health in in mice and humans administered BMP. 
More work is needed to elucidate which physiological/pathophysiological 
circumstances, such as infection, diet or toxins lead to downregulation of Gdf in the liver, 
other than the very severe models used currently. Secondly, if liver expression can be altered 
in response to certain stimuli, the effect this has on pulmonary vascular signalling could be 
measured, since there may be compensation. Finally, haemodynamics and histology could be 
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assessed to see whether this predisposes to pulmonary hypertension. Hence, low BMP levels 
could be established as a causal link between liver disease and pulmonary hypertension. 
 e lung itself may be a source of BMP, which may mean it maintains signalling 
independently of plasma BMP levels. I have prepared perfusion fixed samples from wildtype 
and Gdf knockout mice to carry out RNA-in situ hybridisations to assess which cells are 
expressing Gdf. Counterstains could include von Willebrand factor and smooth-muscle 
actin to show whether BMP acts as an autocrine in pulmonary vessel walls. Tissue-specific 
(liver, lung, right-atria) conditional knockouts of Gdf and Bmp would be the definitive 
way to establish from where the activity in different compartments originates, although 
producing them would be laborious. 
Many reports focus on one or other of Gdf or Bmp, but they may have correlated 
expression levels, circulate together and have similar signalling activity. Unfortunately, we do 
not have a validated BMP ELISA for mouse samples, and BMP plasma neutralisations are 
reported to be unsuccessful, which makes analysis difficult. However, the expression and 
levels of BMP should be assessed in tissues of the inducible Bmp knockout mouse. e 
plasma activity and pulmonary signalling of Gdf knockout, Bmp knockout and double 
knockout mice could be compared to see which ligand is most important for quiescing the 
pulmonary vasculature. 
 In conclusion, reproducible genetic in silico and in vitro evidence now shows GDF 
deficiency causes PAH in some patients. In vivo evidence suggests BMP administration is 
likely to be beneficial, and perhaps specifically stimulate protective effects in the lung. GDF 
deficiency is also likely to disrupt liver metabolism, especially fatty-acid synthesis and 
oxidative metabolism, although the phenotypic implications of this are unclear. More work is 
needed to understand the link between BMP and BMP and whether BMP also has roles 
in PAH and hepatic metabolism. e circulating dynamics of endogenous BMP and BMP, 
and how their activity on different tissues is regulated, may be more complex than is 
appreciated in the current literature. ere is much still to discover regarding the physiology 
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